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Summary 
Comprehensive integration site analysis in clinical gene therapy has shown that 
therapeutic vector integrations can lead to clonal selection and even malignant 
transformation by transcriptional activation of cellular proto-oncogenes. Assessing the clonal 
dynamics of gene corrected cells revealed an expansion of hematopoiesis marked with 
unique retroviral insertion sites mainly in the loci of MDS1/EVI1, PRDM16 and SETBP1 in two 
patients treated for correction of chronic granulomatous disease (CGD) 5 months after gene 
therapy. This cell population remained stable for additional 1.5 years. At later time points, 
both individuals developed a myelodysplastic syndrome (MDS) driven by gene-corrected cell 
clones carrying integrations in the MDS1/EVI1 locus. 
In this thesis, large scale integration site mapping using non-restrictive and highly 
sensitive linear amplification mediated polymerase chain reaction (LAM-PCR) focused on the 
gamma-retroviral integration monitoring within the two gene loci MDS1/EVI1 and PRDM16 
in Wiskott - Aldrich syndrome (WAS) clinical gene therapy. Both WAS patients experienced 
substantial improvement in their clinical conditions, showing a polyclonal repopulation of 
the hematopoietic system after reinfusion of autologous ex vivo transduced hematopoietic 
progenitor cells. Although MDS1/EVI1 and PRDM16 were scored as common integration 
sites (CIS), and MDS1/EVI1 and PRDM16 containing clones were mostly restricted to the 
myeloid compartment of reconstituted hematopoiesis, no signs of clonal expansion related 
to these two genes were observed in both patients at 2 years follow up. 
We hypothesized that a concerted sustained or transient overexpression of MDS1/EVI1 
and PRDM16 as pro-myelocytic key regulating transcription factors might be used to 
substantially influence proliferating and differentiation capacity of hematopoietic stem and 
progenitor cells. Therefore, murine Mds1/Evi1 and Prdm16 were cloned and expressed 
either by integration-proficient (LV) or integration-deficient lentiviral vectors (IDLV). Long-
term Mds1/Evi1 and Prdm16 expression in hematopoietic progenitors driven by LV was 
achieved, as well transient expression by IDLV. However, no significant clonal expansion was 
observed after experimental overexpression of Mds1/Evi1 and Prdm16, as transduced cells 
became apoptotic after expression.  
To further assess the biosafety of IDLVs for clinical gene therapy we performed genome 
wide large-scale IDLV integration analysis in vitro, using conventional and non-restrictive 
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XIX 
 
LAM-PCR, as well as newly established two-directional LAM-PCR. This first ever large scale 
IDLV integration analyses yielded more than 800 unique, mappable IDLV ISs in vitro. Our 
data revealed a genome-wide close to random integration pattern without any preference 
for gene coding regions. The results also provided direct molecular evidence that the 
background integration of D64V mutant IDLVs is not mediated by residual catalytic activity 
of the mutant integrase. The risk of insertional mutagenesis events mediated by IDLV is 
highly minimized compared to their integration proficient counterparts and it provides one 
of the potentially safest tools for efficient gene delivery for clinical applications. The 
utilization of IDLVs for transient overexpressing is versatile, but warrants careful evaluation 
of potential toxic effects, as Mds1/EvI1 and Prdm16 as chosen transgenes to expand 
hematopoietic progenitors have shown. 
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Zusammenfassung 
Die umfassende Analyse von Integrationsstellen gentherapeutischer Vektoren in 
klinischen Studien zeigte, dass die Integration des therapeutischen Vektors zu einer klonalen 
Selektion bis hin zu einer malignen Transformation durch transkriptionelle Aktivierung von 
Protoonkogenen führen kann. Untersuchungen zur klonalen Dynamik genkorrigierter Zellen 
in zwei Patienten im Rahmen der klinischen Gentherapiestudie zur Behandlung septischer 
Granulomatose (CGD) zeigte 5 Monate nach Therapie eine Expansion der Hämatopoese, die 
hauptsächlich von Zellklonen mit Vektorintegrationsstellen innerhalb oder in der Nähe der 
Gene MDS1/EVI1, PRDM16 und SETBP1 angetrieben wurde. Diese Zellpopulation blieb für 
weitere 1.5 Jahre stabil. Im späteren Verlauf entwickelten beide Pateinten ein 
myelodysplastisches Syndrom (MDS), ausgelöst durch genkorrigierte Zellen, welche 
Integrationen in dem MDS1-EVI1 Lokus aufwiesen. 
Für die Charakterisierung retroviraler Vektorintegrationsstellen im Rahmen der 
klinischen Studie zur Behandlung des Wiskott-Aldrich-Syndroms (WAS) mit Fokus auf die 
beiden genomischen Bereiche MDS1/EVI1 und PRDM16 wurde in dieser Arbeit die nicht-
restriktive und die hochsensitive lineare amplifikations-mediierte Polymerasekettenreaktion 
(LAM-PCR) verwendet. In beiden WAS Patienten führte die Behandlung zu einer 
grundlegenden Verbesserung der klinischen Situation. Es zeigte sich eine polyklonale 
Repopulation des hämatopoetischen Systems nach Reinfusion ex vivo transduzierter 
autologer hämatopoetischer Vorläuferzellen. Obgleich sich sowohl bei MDS1/EVI1 als auch 
bei PRDM16 eine auffällige Häufung der Vektorintegrationsstellen zeigte („common 
integration sites“, CIS) und diese vorwiegend auf das myeloide System beschränkt waren, 
wurden in beiden Patienten bis zwei Jahre nach Therapie keine Anzeichen einer klonalen 
Expansion in Verbindung mit diesen beiden Genloki beobachtet.  
Wir stellten die Hypothese auf, dass eine gemeinsame fortwährende oder transiente 
Überexpression von MDS1/EVI1 und PRDM16, die beide wichtige Transkriptionsfaktoren im 
myeloiden System darstellen, verwendet werden könnte, um die Proliferations- und 
Differenzierungskapazität von hämatopoetischen Stamm- und Vorläuferzellen zu 
beeinflussen. Daher wurden die murinen Genloki MDS1/EVI1 und PRDM16 kloniert und 
mithilfe von Integrations-profizienten (LV) und Integartions-defizienten lentiviralen Vektoren 
(IDLV) exprimiert. In hämatopoetischen Vorläuferzellen konnte eine Langzeitexpression von 
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MDS1/EVI1 und PRDM16 durch LV sowie eine transiente Expression durch IDLV erreicht 
werden. Es konnte jedoch keine signifikante klonale Selektion beobachtet werden, da die 
experimentelle Überexpression in den transduzierten Zellen Apoptose auslöste. 
Für die klinische Anwendung von IDLV wurde deren biologische Sicherheit weitergehend  
durch eine umfassende genomweite in vitro Integrationsstellenanalyse unter Verwendung 
der konventionellen und der nicht-restriktiven LAM-PCR, sowie einer neu entwickelten 
bidirektionalen LAM-PCR, untersucht. Diese im Hochdurchsatz angelegte Studie konnte 
erstmals mehr als 800 unterschiedliche, dem Genom eindeutig zuordenbare IDLV Integrate 
in vitro identifizieren und charakterisieren. Unsere Daten zeigten eine genomweite beinahe 
zufällige Verteilung von Integrationsstellen, ohne Präferenz für genkodierende Bereiche. 
Weiterhin erbrachten diese Daten erstmals den molekularen Beweis, dass die Hintergrund-
Integration der D64V IDLV-Mutante nicht durch die residuale katalytische Aktivität der 
Integrase vermittelt ist. Das Risiko der insertionellen Mutagenese ausgelöst durch IDLV ist im 
Vergleich zu entsprechenden Integrations-profizienten Vektoren stark minimiert und somit 
könnte die Verwendung von IDLVs eines der potentiell sichersten Werkzeuge für einen 
effizienten Gentransfer in der klinische Anwendung darstellen.  
Die Verwendung von IDLV zur transienten Überexpression ist vielfältig, bedarf aber einer 
genauen Abwägung des potentiell toxischen Effekts, wie die beiden zur Untersuchung der 
Expansion hämatopoetischer Progenitoren ausgewählten Transgene MDS1/EVI1 und 
PRDM16 zeigten. 
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1. Introduction 
1.1  Hematopoietic stem cells and hematopoiesis  
 Human and mouse hematopoietic stem cells and hematopoiesis 1.1.1
Stem cells are single cells that are capable of both self-renewal and 
differentiation (Weissman, 2000). The essential meaning of self-renewal is that these 
cells can undergo division symmetrically or asymmetrically but remain 
undifferentiated, and they possess properties that allow large numbers of self-
renewing cell divisions to occur in a regulated fashion over the life span of a host. 
The stem cells could be divided into three categories based on their differentiation 
potential: totipotent, pluripotent and multipotent. Totipotent stem cells like 
fertilized eggs and each cell of the embryo up to the four-cell stage can form an 
entire organism including all embryonic, extra-embryonic and adult cell types in a 
suitable environment. Pluripotent cells can self-renew and differentiate into any cell 
type of the body, but lack the capacity to independently form a placenta, or to 
organize the formation of proper primitive streak. Multipotent stem cells are single 
cells which are found in the tissues of adult body or in the cord blood, like the 
hematopoietic stem cells (HSCs), which have a restricted differentiation potential, 
can only self-renew and differentiate into more than one cell type in a particular 
tissue lineage.  
The cellular biology of hematopoiesis encompasses three components: the 
hematopoietic stem cells and its progeny, the environment in which they reside, and 
the signal and cytokines that regulate their fate. In adults, hematopoiesis occurs in 
the bone marrow (BM), which supports the lifelong maintenance of stem cells and 
their regulated differentiation. The term hematopoiesis (from Greek ‘haima’ for 
blood and ‘poiein’, to make) refers to the formation and development of the blood 
system. Hematopoiesis is a dynamic and complex developmental process by which 
immature precursor cells develop into mature blood cells.  Per day, hematopoiesis 
yields approximately 175 billion red cells, 70 billion granulocytes (neutrophils, 
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eosinophils, basophils), and 175 billion platelets. If needed, production can be 
increased 5-10 fold (Orkin, 1995, 1996).  
In mice, it has been shown that an early intra-embryonic site of hematopoiesis is 
found in the paraaortic splanchnopleura and in a structure termed aorta-gonad-
mesonephros region (AGM) (Nishikawa et al., 2001). The establishment of blood 
islands in the extra-embryonic yolk sac marks the onset of hematopoiesis and 
vasculogenesis in the developing embryo. Subsequently, hematopoietic cells are 
found within the embryo proper in the gonad-mesonephros region, from where 
HSCs migrate to the fetal liver and later to the BM. In humans, this process begins in 
the yolk sac in the first weeks of embryonic development. By the third month of 
gestation, stem cells migrate to the fetal liver and then to the spleen. Next, the BM 
becomes the major hematopoietic organ and hematopoiesis ceases in the liver and 
spleen.  
HSCs are by far the most well-characterized adult stem cell population both in 
terms of markers for purification and assays to access functional potential. In 1950s, 
researchers demonstrated that just-lethal doses of whole body irradiation caused 
death by hematopoietic failure, and that hematopoietic failure could be averted 
either by shielding hematopoietic organs or by transplantation of unirradiated BM 
(Jacobson et al., 1950; Jacobson et al., 1951; Lorenz et al., 1951). The critical study 
that set the stage for the concept of HSCs was the demonstration that the injected 
BM reconstituted the hematopoietic system rather than provided radiation repair 
factors (Ford et al., 1956; Nowell et al., 1956). The seminal study in HSC field began 
with the observation that transplantation of limiting numbers of BM cells into 
lethally irradiated mice gave rise to colonies in the spleen that contained all 
elements of the myeloerythroid (but not lymphoid) lineages, and that the number of 
colonies was proportional to the number of BM cells injected (Till and Mc, 1961). 
Followed these observations, finding of a clonogenic precursor and lymphocytic 
potential of spleen colony-forming cells (CFCs) likely demonstrated that there existed 
in the BM single cells capable of self-renewal and full differentiation to all 
hematopoietic fates (Becker et al., 1963; Siminovitch et al., 1963; Wu et al., 1968). 
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Subsequently, it was demonstrated that at least two classes of spleen colony-
forming cells existed: those that peaked at days 8-10 and were the progeny, mainly, 
of non-stem cell oligopotent progenitors; and those that peaked in size at days 12-14, 
which included much more primitive progenitors and stem cells (Magli et al., 1982; 
Visser and Van Bekkum, 1990). Recently, following the isolation of both stem and 
progenitor cells, it became clear that most of the day 8-10 spleen colonies are 
derived from committed myeloid progenitors, whereas the day 12-14 colonies are 
derived from HSCs, multipotent but self-renewing progenitors, and some late-
peaking committed myeloid progenitors (Morrison et al., 1997; Morrison and 
Weissman, 1994; Na Nakorn et al., 2002; Spangrude et al., 1988).  
The study of HSCs has been greatly facilitated in the last 20 years with the 
discovery of monoclonal antibodies and the development of high-speed 
multiparameter fluorescence-activated cell sorters. The eventual isolation of HSCs 
required not only these innovations, but also the development of in vitro and in vivo 
assays for the identification and quantification of clonogenic precursors of the all the 
hematopoietic cell lineages. The identification and purification of HSCs relies on the 
unique cell surface molecule expression found on these cells compared with the 
remainder of BM cells including closely related hematopoietic progenitor cell 
counterparts. Although there does not appear to be any single marker that 
segregates HSCs from other hematopoietic cell types, HSCs can be readily identified 
using multiparameter flow cytometry. However, several different antibody 
combination schemes have been developed by different laboratories to achieve this, 
although all have the ultimate goal of producing the highest yield of long-term, 
multilineage reconstituting HSCs. Almost all HSC purification strategies revolve 
around the cell surface phenotype of positive selection for the markers c-Kit and Sca-
1 and negative selection for markers of mature hematopoietic cell lineages (typically 
B220, CD4, CD8, Gr-1, Mac-1, and Ter-119). Although this c-Kit+Lin-Sca-1+ (KLS) 
phenotype greatly enriches for hematopoietic reconstituting activity, this BM 
compartment contains progenitor cells in addition to long-term HSCs. In fact only 
10% of KLS cells are bona fide long-term HSCs, and as such the KLS compartment 
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should be regarded as merely enriched for HSCs. A variety of strategies have been 
used to further enrich BM for HSCs, with or without the KLS as a foundation. These 
strategies include identification of HSCs as KLS-CD34-Flk-2-, KLS-CD150+CD48- cells, 
the Hoechst-effluxing side population (SP), and associated variations on that theme 
(e.g., CD45midLin- HoechstlowRhodaminelow or SP-EPCR). A summary of murine cell 
surface phenotypes and the murine hematopoietic cell types they enrich for is 
presented in Table 1-1. 
Marker Phenotype Cell Types Reference 
KLS Hematopoietic stem and 
progenitor cells 
(Okada et al., 1992) 
SPKLS LT-HSCs (Adolfsson et al., 2001) 
CD150+CD48-CD41-KLS LT-HSCs (Goodell et al., 1996) 
CD45midLin-
RhodaminelowSP 
LT-HSCs (Dykstra et al., 2006) 
Flk-2-CD34-KLS LT-HSCs (Yang et al., 2005) 
Flk-2+CD34+KLS ST-HSCs and MPPs (Yang et al., 2005) 
Lin-Il7rα+c-Kit+Sca-1+ Common lymphoid progenitors 
(CLP) 
(Kondo et al., 1997) 
Lin-Il7rα-c-Kit+Sca-1- Myeloid progenitors (Akashi et al., 2000) 
Lin-Il7rα-c-Kit+Sca-1-
CD34+CD16/32- 
Common myeloid progenitor 
(CMP) 
(Akashi et al., 2000) 
Lin-Il7rα-c-Kit+Sca-1-CD34-
CD16/32- 
Megakaryocyte-erythrocyte (MEP) (Akashi et al., 2000) 
Lin-Il7rα-c-Kit+Sca-1-
CD34+CD16/32+ 
Granulocyte-macrophage 
progenitors (GMP) 
(Akashi et al., 2000) 
Table 1-1 Cell surface phenotypes of various murine hematopoietic stem and progenitor cell populations. 
The advent of antibody technology, culture capability, transplantation, and finally 
genetic engineering of mice has enabled a detailed understanding of processes 
involved in the commitment and differentiation of HSCs into progenitor cells and 
ultimately mature blood cells. Combining antibody-based subselection of cells with 
transplantation has made possible the identification of progenitors and HSCs. A 
range of different methods for characterizing stem and progenitor cell populations 
are now available for use in hematopoietic cell research. In vivo, long-term, 
multilineage reconstitution is the gold standard for detection of HSCs. In a mouse 
model, test donor cells are retrospectively inferred to have contained one or more 
HSCs when their transplantation into lethally irradiated mice results in long-term 
multilineage reconstitution. Competitive repopulation is a modified version of 
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transplantation that ensures the survival of lethally irradiated recipient mice and 
permits the quantitative evaluation of repopulation levels. In experimental 
transplantation, test donor cells and competitor cells are distinguished by certain 
genetic markers. Common used are CD45.1 and CD45.2. CD45 is the leukocyte 
common antigen expressed on all leukocytes and their progenitor cells, including 
adult HSCs, but not on red blood cells, platelets, and their committed progenitors. 
When multilineage reconstitution takes place 4 months after transplantation, this is 
conceivably due to self-renewal and differentiation potentials in HSCs. The HSC 
compartment has been shown to be heterogeneous, comprising a hierarchy of HSCs 
that can be identified by their functional capacity. The most immature HSC in this 
hierarchy is capable of sustaining hematopoiesis throughout serial transplantation. 
In this assay, the source of HSCs is transplanted into sequential serial transplant 
recipients, and the ability of this population to sustain hematopoiesis by 
presumptive self-renewing division is determined.  
In vitro and short term in vivo assays are also often used for measuring HSC and 
progenitor cell content but are generally a reflection of the more mature progenitor 
cells as opposed to the immature HSCs. Hematopoietic progenitor cells can grow in 
semisolid media such as agar and methylcellulose supplemented with growth factors, 
finally forming colonies. The majority of colony-forming cell (CFC) consist of lineage-
restricted colonies: erythroid-restricted burst-forming units-erythroid (BFU-E), which 
are more immature than the colony-forming units-erythroid (CFU-E); 
megakaryocyte-restricted CFU-Mk; colony-forming units-granulocytes (CFU-G); and 
colony-forming-units-granulocytes/macrophages (CFU-GM). The most immature 
(multipotent) CFC measurable contains granulocytes, erythrocytes, macrophages, 
and often megakaryocytes (CFU-GEMM) and is usually measured at day 12 after 
culture initiation. In addition to colony-forming cell assays, short-term in vivo assays 
are also useful for analysis of HSCs and progenitor cells. As previous descript (Till and 
Mc, 1961), Colony-forming unit-spleen (CFU-S) cells are cells that, once injected into 
an irradiated recipient, home to the spleen and form macroscopic colonies that 
provide very short-term in vivo repopulation of the mouse. The CFU-S are therefore 
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early engrafting cells, providing radioprotection to the mouse and allowing it to 
survive more readily in the first 2-3 weeks post transplantation. These progenitors 
are more immature than CFCs but are more mature than HSCs. 
 Hematopoietic stem cells self-renewal and differentiation 1.1.2
HSCs have several unique features, among the core features are the ability to 
choose between self-renewal and differentiation. In addition, HSCs migrate in 
regulated fashion and are subject to regulation by apoptosis. The balance between 
these activities determines the number of stem cells that are present in the body. 
 
Figure 1-1 The hierarchy of hematopoietic cells. LT-HSC, long-term repopulating HSC; ST-HSC, short-term 
repopulating HSC; MPP, multipotent progenitor; CMP, common myeloid progenitor; CLP, common lymphoid 
progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte−macrophage progenitor. The encircled 
pluripotent population, LT-HSC, ST-HSC and MPP are Lin-, Sca-1+, c-kit+ as shown (Larsson and Karlsson, 2005). 
In the HSCs pool (Figure 1-1), multipotent long-term HSCs (LT-HSCs) reside in the 
BM and through a process of asymmetric cell division, can self-renew to sustain the 
stem cell pool or differentiate into short-term HSCs (ST-HSCs) or lineage-restricted 
progenitors that undergo extensive proliferation and differentiation to produce 
terminally differentiated, functional hematopoietic cells. ST-HSCs or multipotent 
progenitors (MPPs) are only able to sustain hematopoiesis in the short term, 
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whereas the LT-HSCs must persist for the lifespan of the organism to perpetually 
replenish the hematopoietic system. In the normal steady state, about 1.5% and up 
to 8% of LT-HSCs randomly enter the cell cycle each day, whereas higher percentages 
of ST-HSCs and MPPs are in the cell cycle at any time. 
Like other stem cell types, one essential feature of HSCs is the ability to make 
copies with the same or very similar potential, so called self-renew. This is a single 
distinguished characteristic between LT-HSCs and the rest of the multipotent and 
oligopotent progenitors in the hematopoietic system. While it has not been 
established that adult HSCs can self-renew indefinitely, it is clear from serial 
transplantation experiments that they can produce enough cells to last several (at 
least four to five) lifetimes in mice. It is still unclear which key signals allow self-
renewal, based on the research of embryonic stem (ES) cells, the genome of stem 
cells must be protected from DNA damage or mutation. Therefore DNA repair and 
maintenance of sufficient telomere length are necessary to support a number of self-
renewal divisions in HSCs (Allsopp et al., 2003a; Allsopp et al., 2003b; Nijnik et al., 
2007; Rossi et al., 2007). Expression of telomerase is associated with self-renewal 
activity. However, while absence of telomerase reduces the self-renewal capacity of 
mouse HSCs, forced expression is not sufficient to enable HSCs to be transplanted 
indefinitely; other barriers must exist. 
It has proven surprisingly difficult to grow HSCs in culture despite their ability to 
self-renew, although expansion in culture is routine with many other stem cells, 
including ES cells and neural stem cells. The lack of this capacity for HSCs severely 
limits their application, because the number of HSCs that can be isolated from 
mobilized blood, umbilical cord blood, or BM restricts the full application of HSC 
transplantation in human. Engraftment periods of 50 days or more were standard 
when limited numbers of BM or umbilical cord blood cells were used in a transplant 
setting, reflecting the low level of HSCs found in these native tissues. Attempts to 
expand HSCs in tissue culture with known stem-cell stimulators, such as the 
cytokines stem cell factor (SCF), thrombopoietin (TPO), interleukins 1, 3, 6, 11 plus or 
minus the myeloerythroid cytokines GM-CSF, G-CSF, M-CSF, and erythropoietin have 
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never resulted in a significant expansion of HSCs (Reya et al., 2003). Rather, these 
compounds induce many HSCs into cell divisions that are always accompanied by 
cellular differentiation. Many experiments demonstrate that the transplantation of a 
single or few HSCs into an animal results in a 100,000-fold or greater expansion in 
the numbers of HSCs at the steady state while simultaneously generating daughter 
cells that permitted the regeneration of full blood-forming system (Iscove and Nawa, 
1997; Morrison et al., 1997; Smith et al., 1991; Wagers et al., 2002). By investigating 
genes transcribed in purified mouse LT-HSCs, investigators have found that these 
cells contain expressed elements of the Wnt/fzd/beta-catenin signaling pathway, 
which enables mouse HSCs to undergo self-renewing cell divisions (Reya et al., 2003). 
Overexpression of several other proteins, including HoxB4 (Antonchuk et al., 2002; 
Sauvageau et al., 1995) and HoxA9 (Lawrence et al., 2005; Thorsteinsdottir et al., 
2002) has also been reported to achieve this. Other signaling pathways are under 
investigation such as Notch and Sonic hedgehog (Reya, 2003). Among the 
intracellular proteins thought to be essential for maintaining the stemness state are 
Polycomb group genes, for instance Bmi-1 (Iwama et al., 2004). Other genes, such as 
c-Myc (Wilson et al., 2004) and JunB (Passegue et al., 2004) have also been shown to 
play a role in this process. The identification of bone morphogenetic protein (BMP) 
pathway (Zhang et al., 2003), parathyroid hormone (PTH) pathway (Calvi et al., 2003), 
as well as Angiopoietin-1/Tie2 pathway (Arai et al., 2004) in osteoblast cells, which 
offer the microenvironment as the niche for the HSCs, have been recently suggested 
to regulate HSCs numbers and quiescence. It is critical to discover which pathways 
operate in the expansion of human HSCs to take advantage of them to improve 
clinical hematopoietic transplantation. 
Differentiation into progenitors and mature cells that fulfill the functions 
performed by the hematopoietic system is not a unique HSC property, but, together 
with the option to self-renew, defines the core functions of HSCs. Differentiation is 
driven and guided by an intricate network of growth factors and cytokines. 
Differentiation seems to be the default outcome for HSCs when stimulated by many 
of the factors to which they have been shown to respond. It appears that, once they 
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commit to differentiation, HSCs cannot revert to a self-renewing state. Thus, specific 
signals, provided by specific factors, seem to be needed to maintain HSCs. This strict 
regulation may reflect the proliferative potential present in HSCs, deregulation of 
which could easily result in malignant diseases such as leukemia or lymphoma. 
 Hematopoietic stem cells expansion and transplantation 1.1.3
Hematopoietic stem cell transplantation (HSCT) is a well-established and widely 
performed strategy as therapy for hematologic malignancies as well as many 
nonmalignant disorders. HSCs are routinely available in sufficient numbers from a 
variety of sources, including BM and mobilized peripheral blood. However, there are 
instances when the number of available HSCs is insufficient for engraftment of the 
host, in particular when cord blood is used as the source of HSCs for transplantation 
or in the case of gene therapy, where the frequency of genetic modified cells is very 
low. One potential solution to this problem of low stem cell numbers is ex vivo 
proliferation of the cells prior to transplantation. Extensive research has been done 
to define the optimal conditions for ex vivo expansion of HSCs, and various 
expansion techniques have been development for this purpose (Sauvageau et al., 
2004; Sorrentino, 2004).  
In murine studies, it has been shown that transplantation of single, limit dilution 
or small numbers of LT-HSCs results in both HSC expansion and lifelong self-renewal, 
through at least four or five serial transplant generations (Allsopp et al., 2001). 
Transplantation of downstream short-term, self-renewing ST-HSCs or MPPs results in 
robust but transient multilineage reconstitution after which residual HSCs recover 
(Christensen and Weissman, 2001). In preclinical studies, xenogeneic transplant 
models have been developed in which human hematopoietic cells can engraft in 
immunodeficient mice and then be serially passaged in vivo (Glimm et al., 2001; 
Holyoake et al., 1999).  Growth factor and stroma-induced HSCs expansion 
experiments suggest that HSCs and HSC progeny retain the ability to engraft 
recipients after several transplantations, but may actually be more differentiated 
with less proliferative capacity, thus, cell with HSC properties may themselves be 
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heterogeneous, and their self-renewal capacity man depend in the source from 
which they are derived, with cord blood HSCs having greater self-renewal capacity 
then mobilized peripheral blood HSCs (Glimm and Eaves, 1999; Glimm et al., 2001; 
Glimm et al., 2002; von Kalle et al., 1998; Zavidij et al., 2010). Overall, preclinical 
studies of human HSCs expansion assayed based on cytokine-induced conditions and 
repopulating ability in xenogeneic transplant models suggest the potential for 
enhancement of ST- or LT- repopulating activity, only a few cell division at most have 
been observed. Thus, current efforts are now focused on identifying and exploiting 
other extrinsic and intrinsic regulators of stem cell fate. 
Retroviral mediated overexpression of Hox transcription factors, in particular 
Hoxa9 and HoxB4, has led to extensive ex vivo HSC expansion in vitro and in vivo 
without loss of lymphomyeloid repopulating ability (Antonchuk et al., 2002; 
Sauvageau et al., 1995; Thorsteinsdottir et al., 2002). The self-renewal induced by 
HoxB4 has been explained by exploration of extrinsic regulators of cell fate involved 
in embryonic development, such as BMP-4, a member of the TGF-ß superfamily, and 
Sonic Hedgehog family of proteins, both have been implicated in early 
hematopoietic development. In ex vivo expansion of human cord blood, human 
BMP-4 has been shown to increase the survival of repopulating blood cells (Bhatia et 
al., 1999), while Sonic Hedgehog protein has been shown to induce an increase in 
repopulating cells via downstream BMP signals (Bhardwaj et al., 2001). Proteins of 
Wnt pathways, which are involved in the growth and differentiation of a variety of 
primitive tissues, have also been implicated in the regulation of hematopoiesis, 
possibly exerting their effects through stromal cells (Yamane et al., 2001), and have 
been shown to stimulate the proliferation of hematopoietic precursor cells (Reya et 
al., 2003). Interaction between various signaling pathways has also been reported 
for HSCs expansion regulation. For instance, Notch-1 receptors have been shown to 
be upregulated in response to Wnt signaling in HSCs (Reya et al., 2003); manipulating 
of Notch signaling pathway, along with cytokine-induced signaling pathways can 
enhance stem cell self-renewal ex vivo and thereby increase HSCs numbers for 
transplantation (Varnum-Finney et al., 2003; Varnum-Finney et al., 2000).  
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Clinically, ex vivo expansions studies of primitive cells from BM, peripheral blood 
cells and cord blood cells have demonstrated the feasibility of ex vivo expansion. But 
cytokine-induced effects on HSC self-renewal and expansion are limited, clinically 
significant expansion has not been achieved and optimal conditions for expanding 
HSCs remain undefined. Continued development of methods using novel stem cell 
regulators that are shown to expand HSCs in preclinical studies is necessary, and 
current trials are underway to assess the safety and efficacy of these approaches, 
which hold promise for the further of expanding HSCs ex vivo and efficient 
transplantation. 
1.2  Somatic gene therapy 
Genes are the basic physical and functional units of heredity. Genes are specific 
sequences of bases that encode instructions on how to make proteins. When genes 
are altered so that the encoded proteins are unable to carry out their normal 
functions, genetic disorders can result. The aim of gene therapy is to modify the 
genetic material of living cells for therapeutic purposes (Amado and Chen, 1999). 
Gene therapy involves the insertion of a functional gene or another molecular that 
contains information sequence into a cell to achieve a therapeutic effect. There are 
two types of gene therapy: somatic cell and germ line. In germ line gene therapy 
concept, a health gene is inserted into the fertilized egg of an animal; every cell that 
develops from this egg will have the corrected gene. Because of the serious social 
and ethical considerations with this type of gene therapy, somatic cell gene therapy 
is the only technique performed so far (Anderson, 1998). The purpose of the 
procedure is to eliminate the clinical consequences of a disease and the inserted 
gene is not passed on to the patient’s offspring. Gene therapy provides modern 
medicine with new perspectives that were unthinkable two decades ago. Progress in 
molecular biology and, especially, molecular medicine is now changing the basics of 
clinical medicine. 
 Gene delivery approaches 1.2.1
Introduction  Wei Wang 
12 
 
Long-term correction of genetic diseases requires permanent integration of 
therapeutic genes into chromosomes of affected cells and continuous expression at 
therapeutic levels. There are various non-viral and viral methods to allow the 
insertion of the therapeutic gene in various cell types, tissues and organs by ex vivo 
and in vivo strategies. The introduction of a therapeutic gene by non-viral methods is 
known as transfection, or via a viral carrier as transduction.  
Gene delivery using non-viral carriers can be divided into three broad categories: 
physical, chemical, and biological approaches. Ultrasound-mediated transfection 
(Taniyama et al., 2002), laser beam transduction technology (Zeira et al., 2003), DNA-
coated gold particle bombardment technology (Yang et al., 1990), 
superparamagnetic nanoparticles, also called magnetofection (Kren et al., 2009; 
Scherer et al., 2002), direct microinjection (Capecchi, 1980) or electroporation (Baum 
et al., 1994; Bloquel et al., 2004; Potter et al., 1984) are among the physical 
approach. The chemical method includes Calciumphosphate Coprecipitation 
(Graham and van der Eb, 1973), Lipofection (Felgner et al., 1987), Polycations, 
Cationic Polymers such as Polyethylenimin, in which the negatively charged nucleic 
acid associates with the carrier. Biological transfection is carried out by DNA-protein 
conjugates (Kern et al., 1999; Wagner et al., 1990) which are taken up by the target 
cell via receptor-mediated endocytosis. Although, non-viral vectors are particularly 
suitable with respect to simplicity of use, ease of large-scale production, lack of 
toxicity, and lack of specific immune response, there are some drawbacks with each 
of these non-viral vectors, including their lower efficiency, compared with viral 
vectors, in gene transfer and their transient gene expression.  
Among the viral-based vectors, manifold different recombinant replication-
defective vector systems for the therapeutic gene delivery in clinical trials have been 
described and over the recent years. These viruses are capable of transducing their 
target cells and delivering their viral payload, but then fail to continue either the 
budding or lytic pathway. However, they all have their individual advantages but also 
their individual limitations and must be judged on a careful risk/benefit analysis. In 
vector systems derived from Adenovirus, Herpes simplex virus, Ebstein-Barr virus, 
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vaccinia virus, poliovirus, alphaviruses (e.g. Semiliki-Forest Virus (SFV), Sindbis virus 
(SIN)), hepatitis viruses, SV40 viruses, or minus-strand RNA viruse (e.g. influenza 
viruses, Ebola virus), the viral DNA does not integrate into the host genome and is 
not replicated during cell division since these vectors remain as episome in the 
nucleus of a target cell (Cooper et al., 1997; Ehrhardt et al., 2008). In contrast to the 
non-integrating, episomal vectors, recombinant adeno-associated vectors can persist 
as episomes or alternatively integrate into the cellular genome (Duan et al., 1998; 
Kay et al., 2001; Miao et al., 1998; Nakai et al., 1999). Integrating vector systems 
derived from the viral family Retroviridae (Gammaretro-, Lenti- or Spumaviruses) 
have the ability to deliver genetic material to a target cell with high efficiency 
enabling long-term expression of an encoded transgene (Ehrhardt et al., 2008; Kay 
and High, 1999; von Kalle et al., 1994). Although gene delivery with viral vectors is 
more efficient than non-viral vector systems, the main disadvantage of integrating 
vector systems is their potential risk of causing insertional mutagenesis. They 
currently represent the most effective means of gene delivery in clinical gene 
therapy trials 
 Gene transfer into hematopoietic stem cells 1.2.2
Over the past dozen years, it has been demonstrated that the transfer of genes 
into hematopoietic stem cells (HSCs) could be a tool for the treatment of genetic 
diseases as well as a number of acquired diseases, including cancer, AIDS and 
autoimmune and neurodegenerative disorders. With the clinical application of gene 
therapy progressing in parallel with a better understanding of stem cell biology, the 
number different target cells, tissues and organs used in gene therapy has increased 
dramatically. However, HSCs remain the main cellular target for genetic intervention 
in a number of clinical settings of primary medical and scientific relevance, especially, 
but not only, those that aim to correct or modulate the immune system.  
Nearly all viral and synthetic vectors developed for different gene therapy 
models have been tested for their ability to transducer HSCs. The majority of clinical 
gene therapy trials and pre-clinical research have been focused on the viral vectors, 
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predominantly murine onco-retroviruses (Kay et al., 2001). These vectors 
permanently integrate the transferred gene into the genome of the host cell, which 
should maintain transgene expression during proliferation, differentiation and 
maturation in all the cell lineages. However, target cell division is required for gene 
transduction with these vectors, whereas immature HSCs are naturally quiescent. To 
overcome this formidable obstacle, many efforts were focused on inducing cell 
division while preserving the self-renewal ability of stem cells and their potential to 
expand and differentiate into all blood lineages. Strategies involved the use of 
different hematopoietic growth factors in various combinations, with or without the 
additional use of BM stromal cell layers (Emmons et al., 1997; Xu et al., 1995) and 
human recombinant fibronectin fragments (Moritz et al., 1996; Williams, 1999). 
Combinations of stem cell factor (SCF), interleukin 3 and 6 (IL-3, IL-6), Flt-3 ligand 
(Flt-3L) and thrombopoeitin (Tpo) have been used to have beneficial effects on HSCs 
survival, expansion and retroviral transduction efficiency (Ailles et al., 2002; 
Conneally et al., 1998; von Kalle et al., 1998). The abilities of these strategies to 
favour gene transfer efficiency while preserving the “stem cell potential” of the 
transduced population were explored. Significant progress in the development of 
animal models of HSC gene transfer, as well as a small number of clinical settings, 
including severe-combined immunodeficiencies (SCIDs) and several gene-marking 
studies in the context of BM transplantation were achieved in last few years.  
The discovery and development of new vectors derived from HIV sharply 
accelerated progress in the field of HSC gene transfer. This family of lentiviral vectors 
can transduce dividing and nondividing cells from different lineages, tissues and 
organs, including HSCs, with great efficiency (Naldini et al., 1996a; Naldini et al., 
1996b). Lentiviral vectors efficiently transduce nondividing cells after direct in vivo 
injection, thus making genetic engineering easier and more suitable for large-scale 
medical application. 
In some cases in vivo gene transfer requires that expression of the transferred 
genes be confined to the lineage of interest. Targeted transduction could 
theoretically be achieved by manipulating the vector envelope, so that binding and 
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infection is confined to a specific cell lineage. Another approach, the insertion of 
regulatory sequences into the vectors to control transcription and confine 
expression of the transgene to a specific lineage after cell differentiation already 
showed promising results (Lois et al., 2002; Miller and Whelan, 1997). This strategy, 
called transcriptional targeting, and related approaches have been already used 
successfully in preclinical models to confine globin expression to the erythroid 
lineage after HSC transduction (May et al., 2000).  
 Family of retroviridae and gene therapy vectors 1.2.3
Retroviridae is a family of medium-sized (about 100nm diameter) enveloped 
viruses with an icosahedral capsid enclosing the single-strand RNA genome which is 
diploid, i.e. two copies per virion. There are three subfamilies: Oncornavirinae, which 
includes avian, bovine, feline and murine leukemia/sarcoma viruses; Lentivirinae, 
which includes maedi/visna virus of sheep, caprine arthritis encephalitis and equine 
infectious anemia viruses and human immunodeficiency virus 1 and 2; Spumavirinae, 
which includes nonpathogenic viruses of monkey, cattle and cats, recognized only in 
cell culture where they produce syncytia (bovine and feline syncytia-forming viruses) 
which have a vacuolated cytoplasm, hence also called foamy viruses. The virions of a 
retroviridae interact between a virally-encoded enveloped protein and a cellular 
receptor and then enter the host cells. The enzyme reverse transcriptase which is 
present in the virion transcribed viral RNA into DNA copy. The viral DNA copy merges 
and becomes a permanent part in the host genome. Provirus is referred to this 
merged DNA. The viral genes are being expressed using the host cell’s transcriptional 
and translational machinery. To create new viral RNA, the provirus is being 
transcribed by the host RNA polymerase II. Other cellular processes then transported 
this new viral RNA out of the nucleus. Some of the new RNAs are being divided to 
enable the expression of some genes, and those undivided new RNAs are left as full-
lengths RNA. The host cell’s translational machinery combines the viral proteins. The 
viral proteins then gather and sprout from the host cell (Figure 1-2). All members of 
the retroviridae go through this reproduction cycle except for spumaviruses. The 
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reverse transcription is completed by the spumaviruses in the virus-producing cells, 
instead of the infected target cells.  
 
Figure 1-2 Retroviral Life Cycle. Entry of a retrovirus into a cell is initiated by interaction of its envelope proteins 
with cellular receptors followed by internalization through membrane fusion or phagocytosis. The vector core is 
released and the RNA serve as a template for reverse transcription and formation of the preintegration complex 
(PIC). The PIC gains access to chromatin during mitosis or, in the case of lentiviruses, by ingress through the 
nuclear membrane. Following integration into host cell DNA, the retroviral genome is expressed in RNA 
molecules which are transported to the cytoplasm to serve as a template for synthesis of new viral protein and, 
in the case of unspliced RNA species, as a substrate for formation of new viral particles. (De Clercq, 2002). 
1.2.3.1 Retroviral vectors 
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Retroviruses are named for their ability to transcribe RNA into DNA. They have 
two identical single-stranded RNA molecules in the nucleocapsid. The two single 
stranded RNA molecules have a 5’cap and 3’polyA tail and from a weak dimer linkage 
structure at several sites along the strands. All retroviruses contain three coding 
domains: gag, pol and env. The gag domain encodes the matrix-, capsid- and 
nucleoproteins; the pol domain encodes the viral protease (pro) together with the 
reverse transcriptase (RT) and integrase, while the env domain encodes the envelope 
glycoprotein. When the virus particles infect the target cells, the viral RNA genome 
enters the cytoplasm as part of a nucleoprotein complex. The process of reverse 
transcription mediated by viral RT begins, which generates a linear DNA duplex via 
an intricate series of steps in the cytoplasm (Figure 1-2). This DNA is collinear with its 
RNA template, but it contains terminal duplication known as the long terminal 
repeats (LTRs) that are not present in viral RNA. LTR regions of provirus, which 
include promoter/enhancer regions & sequences, are required for integration and 
for production of virus RNA. 
The basic principle behind vector development is to replace the coding region 
(gag-pol-env) with the transgene of interest. The cis elements required for the RNA 
encapsidation, reverse transcription and transcription need to be retained in the 
transfer vector. These include the packaging signal (Ψ), the viral LTR, primer binding 
site (PBS) and the polypurine tract (PPT). Additional proteins necessary for vector 
production are supplemented in trans, in packaging constructs. Retroviral vectors 
(RVs) are most frequently based upon the Moloney murine leukaemia virus (Mo-
MLV), which is an amphotrophic virus, capable of infecting both mouse cells and 
human cells, enabling vector development in mouse models and human treatment. 
The viral genes (gag, pol & env) are replaced with the transgene of interest & 
expressed on plasmids in the packaging cell line. Transgene expression can either be 
driven by the promoter/enhancer region in the 5' LTR, or by alternative viral (e.g. 
cytomegalovirus, Rous sarcoma virus) or cellular (e.g. beta actin, tyrosine) promoters. 
The tropisms of RVs can be extended by replacing the env gene with that of another 
virus, in a technique called pseudotyping. Vesicular stomatitis virus G protein has 
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been introduced in Mo-MLV derived vectors (Burns et al., 1994), which are also more 
stable when purified by ultracentrifugation. 
A requirement for retroviral integration & expression of viral genes is that the 
target cells should be dividing. This limits gene therapy to proliferating cells in vivo or 
ex vivo, whereby cells are removed from the body, treated to stimulate replication & 
then transduced with RV, before being returned to the patient. When treating 
cancers in vivo, tumor cells are preferentially targeted (Roth et al., 1996). However, 
ex vivo cells can be more efficiently transduced when exposure to higher virus titers 
& growth factors (Glimm et al., 1998; Glimm et al., 1997). 
Though retroviral mediated transgene expression is usually adequate in vitro & 
initially in vivo, prolonged expression is difficult to obtain. Retroviruses are 
inactivated by c1 complement protein & an anti-alpha galactosyl epitope antibody, 
both present in human sera (Rollins et al., 1996; Rother et al., 1995). Transgene 
expression is also reduced by inflammatory interferons, specifically IFN-alpha & IFN-
gamma acting on viral LTRs (Ghazizadeh et al., 1997). Complete transcriptional 
inactivation observed shortly after retroviral integration is the most dramatic type of 
silencing and is common in embryonic stem cells (Cherry et al., 2000). Some recent 
studies indicate that retroviral vectors are affected by silencing through multiple 
epigenetic pathways including DNA methylation and histone modifications (Ellis, 
2005).  
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Figure 1-3 Process of reverse transcription of the retroviral genome. (Black line) RNA; (light color) minus-strand 
DNAs; (dark color) plus-strand DNA. Reverse transcription is initiated by the binding of specific tRNA(s) from the 
host cell to the virus RNA primer binding site (PBS) where DNA synthesis extends from the tRNA (acting as a 
primer) to the 5′ end of the virus RNA template, thus copying the U5 and R region at that end. This creates a 
short DNA minus-strand that still contains the tRNA at its 5′ end. This process is closely associated with 
degradation of the part of the template RNA that has just been copied (RT also has RNase H activity) except for 
the PBS region, which is protected by the tRNA binding. The R region of the newly synthesized DNA minus-strand 
is then free to align with the complementary 3′ R region of the partially degraded RNA template. This alignment 
may be aided by the affinity of the RT for the 3′ end of the RNA template as well as other factors. Synthesis of the 
DNA minus-strand then proceeds through the PBS region. As before, the reverse transcription is accompanied by 
degradation of the remaining RNA template, except for an RNase-resistant polypurine tract (PPT) that will serve 
as the primer for synthesis of the plus-strand DNA through its PBS region. The tRNA is cleaved from the minus-
strand during the synthesis of the plus-strand PBS region. The next step involves the noncovalent circularization 
of the DNA minus-strand mediated by the complementary pairing of the PBS regions of both strands, which 
includes the loss of the PPT at the 5′ end of the plus-strand.This now allows DNA synthesis of both strands to go 
Introduction  Wei Wang 
20 
 
to completion. Extension of the minus-strand from its 3′ end displaces its own 5′ region from the plus-strand, 
thus allowing this region of the minus-strand to become the complement for completion of synthesis of the plus-
strand.The final result of this complex synthesis is a double-stranded DNA pre-integration complex with identical 
terminally redundant LTR elements (U3-R-U5) on both ends. This form of the virus has the capacity to insert into 
the cellular genomic DNA where it becomes a stably integrated provirus capable of producing virus RNA copies. 
The integrated provirus form has the structure: U3-R-U5-PBS-ψ-gag-pol-env-PPT-U3-R-U5 (Coffin, 1997). 
1.2.3.2 Lentiviral vectors 
Lentiviruses are a family of complex retroviruses inducing chronic and 
progressive disease typically associated with infection of human helper T cells and 
other macrophages. Replication incompetent vector particles derived from 
lentiviruses have been shown to mediate transfer and expression of transgene into a 
variety of cells. Dissimilar to other RVs, in particular those derived from 
gammaretroviruses, lentiviral vectors (LV) can mediate gene transfer into non-
dividing cells, e.g. stem cells, lymphocytes, dendritic and nerve cells. Thus, in 
addition to use in ex vivo cell transduction LV could be useful for gene delivery in 
vivo. In addition, LV may allow for long-term transgene expression, as the transcript 
silencing observed with RVs is less frequent with LV and as such may provide the 
means for long-term in vivo clinical management of chronic diseases. However, in 
common with gammaretroviral vectors, LV suffer a number of drawbacks as gene 
transfer vectors, including limited insert size (8kb) of the transgene and regulatory 
sequences; difficulty in producing high titers of stable vector particles, and 
probability of activating or inactivating an endogenous DNA sequence through 
insertional mutagenesis. Additionally, lentiviral genomes are more complex than 
those of the gammaretroviruses making design of LV a greater challenge. 
Currently, in comparison with gammaretroviral vectors, LVs appear to raise 
greater quality, efficacy and safety concerns, especially since one of the main foci for 
development of LV has been their derivation from HIV, a severe human pathogen. 
Major concerns regarding LV manufacture and clinical use are: the potential 
generation of replication competent lentiviruses (RCL) during LV production; in vivo 
recombination with lentiviral polynucleotide sequences and insertional addition of 
proviral DNA in or close to active genes, which may trigger tumor initiation or 
promotion. Overall, the biohazards associated with the contamination of the LV with 
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a RCL during production might be considered similar for all types of LV whilst the 
strategies for minimizing such contamination would be similar to those already in 
place for gammaretroviral vectors. 
1.2.3.3 Integrase deficient lentiviral vectors 
Recent gene therapy trials employing retroviral vector and lentiviral vector-
mediated gene transfer showed improve treatment for various genetic, malignant, 
and infectious diseases, as well as benefit of clinical outcome. The efficient gene 
correction achieved by using integrating vector is contributed by their ability to 
integrate into the host genome and stable transgene expression. However, adverse 
events described in few gene therapy trials were imputed to vector insertional 
mutagenesis, for instance, insertion of transgenes in the vicinity of oncogenes or in 
the tumor suppressor gene, caused malignant transformation as well as leukemia 
(Hacein-Bey-Abina et al., 2003a; Hacein-Bey-Abina et al., 2003b). 
The retroviral integrase (IN) protein encoded by the 3’ end of the viral pol gene, 
along with the virus-specific sequences attachment sites (att), which located at each 
end of viral LTR, are the only viral factors known required essentially for integration 
of the retroviral genome into the host DNA. Retroviral integration is an essential 
process for viral replication in the viral life cycle. After retroviruses enter the host 
cells, reverse transcription of the viral genome is taken place, resulting in a DNA copy 
of the viral genome located within a viral nucleoprotein (preintegration) complex. 
The viral DNA in the preintegration complex were modified in cytoplasm by IN 
mediates cleavage of the 3’ end of each strand immediately beyond a conserved 
subterminal CA dinucleotide, leaving a hydroxyl group at the 3’ end of each strand of 
viral DNA. After the preintegration complex migrates to the nucleus, a concerted 
strand transfer mediated by IN through a nucleophilic attack involving the viral 3’ 
hydroxyl residue and the phosphate backbone of the target DNA. The coordinated 
strand transfer occurs into the major groove of the target DNA, and the two viral 
ends attack the target DNA in a staggered fashion that determines the length of the 
virus specific direct repeats characteristically flanking each provirus (Figure 1-4). 
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Figure 1-4 The principal steps in retroviral DNA integration. (Coffin, 1997) 
In vitro assays using wild-type and mutant HIV-I IN have showed that classical I 
mutations in highly conserved D,D-35-E motif of the IN catalytic core domain have 
no apparent defect in 3’ processing and strand transfer of viral life cycle (Engelman 
et al., 1995), but prevent the proviral integration (Gaur and Leavitt, 1998; Leavitt et 
al., 1996), resulting in enhanced levels of viral extrachromosomal DNA, which consist 
of late-linear viral DNA and circular forms (1-LTR and 2-LTR forms) in the nucleus of 
infected cells, and 103- to 104- fold reduction of integrated events in comparison to 
wild-type IN mediated transduction (Nightingale et al., 2006). Several studies have 
reported efficient gene expression in vitro and in vivo using integrase defective 
lentiviral vectors (IDLVs). IDLVs are also proficient vehicles for homologous 
recombination, site-specific integration and transposition (Lombardo et al., 2007; 
Vink et al., 2009), and can be converted into stable, replicating episomes (Vargas et 
al., 2004). These properties, combined with their highly reduced risk of causing 
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insertional mutagenesis, have led to a renewed interest on IDLVs for genetic analysis 
and gene therapy (Yanez-Munoz et al., 2006).  
1.2.3.4 Novel development of clinical gene transfer vectors 
The majority of clinical gene therapy trials for inherited genetic diseases and 
cancer therapy have been performed using murine onco-retrovirus as the gene 
delivery vector over the past dozen years. The earliest systems used were relatively 
inefficient in both the rates of transduction and expression of the transgene. 
Formidable obstacles, including low rates of transduction, low protein expression, 
silencing of expression from the integrated vector, risk from insertional mutagenesis 
and in the case of HSC the numerical disadvantage of the engrafting transduced cells, 
limited the efficacy of gene therapy for many target diseases. Developments in novel 
viral mediated gene transfer that are in progress have begun to overcome these 
obstacles.  
To design a viral vector, it is crucial to separate cis-acting sequences, required for 
the transfer of the viral genome to target cells from the trans-acting sequences 
encoding the viral proteins. Thus the biosafety and the efficacy of vector primarily 
depend on the level to which segregation of cis- and trans-acting functions of the 
viral genome is obtained (Kay et al., 2001). Typically, these viral constructs are then 
introduced in to a producer cells that would generate infectious but replication 
deficient viral particles, as these particles can only encapsidate, which results in 
single round of infection, a process known as transduction. In the last several years, 
different variations in vectors design have been introduced, such as self-inactivating 
vectors and vectors which have additional safety features or designing the 
integrating vectors in such a way so that it can integrate into pre-existing transgenic 
loci within the genome. Furthermore, improvements in safety may be also gained by 
using tissue-specific promoters to drive transgene expression, as it would not only be 
more tightly regulated expression, but also it would minimize the potential of 
insertional oncogenesis that are often associated with over expression strategies 
(Brenner and Malech, 2003).  
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The replication deficient LVs have been demonstrated to mediate stable and 
long-term transgene expression in various non-dividing and other difficult to 
transduce cells such as stem cells, nerve cells lymphocytes, and dendritic cell.  Long-
term transgene expression potential is of particular important for in vivo clinical 
management of chronic disease. In addition, the LVs can be pseudotyped with 
specific viral envelopes that highly affect the vector tropism and enhanced biosafety 
and transduction efficiency. However though LVs are designed to be replication-
defective, there are constant concerns about the possible generation of wild type or 
novel human pathogens, while using these vectors following clinical administration. 
Therefore significant modifications have been made in the LVs since the initial 
findings by Naldini and co-workers (Dull et al., 1998; Naldini et al., 1996b). Continual 
efforts are ongoing in recent years that have attempted to further delete wild-type 
HIV sequences in the lentiviral transfer (integrating) and packaging vector to 
enhance vector titer and transgene expression. The newer generation LVs 
technology has many in-built safety features that include separation of critical 
components of the viral genome onto distinct plasmids (split genome approach) that 
allows the safe production of one-round infectious viral particles. Besides, to 
delineate the mechanism by which a specific gene contributes to cell growth and 
viability, inducible and/or conditional systems were explored. Conditional gene 
expression is an absolute requirement in certain cases to have a tight regulation over 
transgene expression, for e.g. generation of a transgenic line may become 
problematic if the presence of the transgene leads to conditions which are toxic, 
lethal to cell growth or probably responsible for causing cell differentiations. 
Tetracycline-dependent regulatory systems (Tet based systems) have been 
successfully employed during enormous biological studies, including transgenic 
mouse modeling and Induced pluripotent stem cell (iPSc) generations (Brambrink et 
al., 2008; Stieger et al., 2009).  
To minimize the possibilities of insertional mutagenesis, two major strategies are 
being used: first, directing LVs insertion into specific sites within the host genome 
(Du et al., 2009; Pfeifer et al., 2001); and secondly by exploring on integration 
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deficient LVs to install therapeutic transgenes. A variety of IDLVs by introducing 
point mutations into the catalytic site, chromosome binding site, and viral DNA 
binding site of the viral integrase (Leavitt et al., 1996) have been developed. 
Mutating or deleting the attachment (att) sites at the ends of viral genome, involved 
in recognition by IN and cut by it, has also been shown to hamper provirus formation 
(Masuda et al., 1998) but no further reduction of integration frequencies when used 
in conjunction with IN mutations in IDLVs (Apolonia et al., 2007; Nightingale et al., 
2006) .  
Modifications in the transfer plasmid include self-inactivation (SIN). SIN vectors 
are produced through the targeted elimination of the promoter sequences from the 
3’-LTR U3 region, making transgene expression necessarily reliant on an internal 
promoter. SIN vectors have reduced risks of host gene transactivation, RCR 
generation, and mobilization upon superinfection with wild-type virus (Dull et al., 
1998; Miyoshi et al., 1998; Zufferey et al., 1998). In addition, boundary elements 
such as the insulator from the chicken beta globin cluster, which has both enhancer 
blocking and chromatin boundary forming activity, can be added to the 3’ LTR during 
vector assembly leading so that the transgene is flanked by insulator elements 
following vector integration (Evans-Galea et al., 2007).To further increase the safety, 
polyadenylation enhancers, internal promoters without enhancer capacity or 
regulatable and tissue specific promoters could be introduced into SIN vectors 
(Matrai et al., 2010). 
 Clinical gene therapy 1.2.4
1.2.4.1 Human primary immunodeficiency syndrome 
The primary immunodeficiencies (PID) represent a class of disorders in which 
there is an intrinsic defect in the human immune systems (rather than immune 
disorders that are secondary to infection, chemotherapy, or some other external 
agent). They result from inherited mutations in genes required for the production, 
function or survival of specific leukocytes (e.g. T, B or NK lymphocytes, neutrophils 
and antigen-presenting cells). The bodies of people with primary immunodeficiency 
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can’t get rid of germs or protect themselves from new germs as well as they should.  
The World Health Organization has identified more than 80 kinds of primary 
immunodeficiency diseases.  But, the general category includes more than 100 
diseases caused by an immune system that doesn’t function properly. 
Because these leukocytes are produced from the pluripotent HSCs in the BM, 
allogeneic BM transplantation (BMT) from a healthy donor into a patient with a PID 
can lead to immune restoration. BMT was first reported for the treatment of 
patients with severe combined immune deficiency (SCID) and Wiskott-Aldrich 
syndrome (WAS) in 1968 (Bach et al., 1968; Gatti et al., 1968). Since that time, 
hematopoietic stem cell transplantation (HSCT), including BM, mobilized peripheral 
blood and umbilical cord blood, has been performed for many of the life-threatening 
PID, including SCID, WAS, chronic granulomatous disease (CGD), leukocyte adhesion 
deficiency (LAD), and others. 
While allogeneic HSCT may lead to essentially normal immune function and 
excellent quality of life for patients with severe PID, there are significant risks, both 
from the conditioning regimen, as well as from the immunologic consequences such 
as graft-vs-host disease (GVHD) wherein donor lymphocytes transplanted with the 
HSC source react against the recipient’s tissues.  
The concepts underlying gene therapy for PID is that gene correction and re-
transplantation of the patient’s own HSC could lead to the same clinical benefits as 
allogeneic HSCT, but without the immunologic complications. Many efforts have 
been taken and many stirring results have been achieved from the treatment of PIDs. 
New approaches using safer integrating vectors or direct correction of the defective 
gene underlying the PID are being developed and may lead to safer and effective 
gene therapy for PID. 
1.2.4.1.1 X-linked Chronic Granulomatous Disease 
X-linked chronic granulomatous disease (X-CGD) is a rare primary 
immunodeficiency, resulting from mutations in the gene encoding for gp91phox 
which, together with p22phox, forms the membrane-bound flavocytochrome b558 
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complex, the redox center of the phagocyte nicotinamide adenine dinucleotide 
phosphate (NADPH)-oxidase complex (Ryser et al., 2007). NADPH oxidase catalyzes 
the formation of superoxide which is then dismutated to hydrogen peroxides (H2O2) 
and subsequently transformed by myeloperoxidase into reactive oxygen species 
(ROS). ROS can directly kill bacteria through their oxidizing activity. More recently it 
has been shown that production of superoxide anion triggers the influx of H+ and K+ 
in the phagocytic vacuole, activating neutral proteases that are responsible for 
destruction of phagocytosed microorganisms (Segal, 2005). Phagocytes from X-CGD 
patients are consequently unable to mount a characteristic respiratory burst that 
accompanies phagocytosis, resulting in inefficient bacterial and fungal killing, and 
affected individuals suffer from recurrent life-threatening infections (Babior, 2004). 
Conventional treatment of X-CGD includes prophylactic drugs, such as antibiotics 
and antifungals, which are given regularly to patients. Recombinant IFN-γ therapy 
also appears beneficial in some patients. Until recently the only cure for X-CGD was 
allogeneic HSC transplantation; offered only to chronically ill patients due to the high 
morbidity and mortality associated with this procedure as a result of the 
myeloablative conditioning regimen and graft-versus-host disease (GvHD). However, 
improved outcomes following this procedure have been reported for patients free 
from infections at the time of transplant (Horwitz et al., 2001; Seger et al., 2002).  
As only low fractions of the patients’ hematopoietic cells have to be corrected to 
convert the phenotype to a healthy individual, and as even 1% of long-term fully 
corrected cells can be expected to be highly beneficial, CGD is a promising candidate 
disease for gene therapy. In vitro and in vivo preclinical studies using retroviral-
vector mediated overexpression of one of the oxidase subunits results in high levels 
of oxidase production in transduced CD34+ cells (Weil et al., 1997), long-term high-
level reconstitution of NADPH oxidase activity in rodent animal models (Dinauer et 
al., 1999; Mardiney et al., 1997; Sadat et al., 2003) as well as  a moderate levels of 
gp91-phox stable expression about 8 months post-transplant in two rhesus 
macaques(Brenner et al., 2006).  
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In the mid-late 1990s, the first two gene therapy for CGD in trials performed at 
the National Institutes of Health and Indiana University School of Medicine. They 
used ex vivo gene transfer with gamma-retroviral vectors to peripheral blood stem 
cells (PBSC) mobilized by granulocyte-colony stimulating factor (G-CSF), which were 
reinfused without prior treatment with chemotherapeutic agents. Low frequencies 
of corrected granulocytes were seen in the peripheral blood for the first months in a 
few of the subjects, but no long-lasting effects were seen (Malech et al., 1997). 
Subsequently, a trial was performed in Germany in which a moderate dosage of 
busulfan (8 mg/kg) was given prior to reinfusion of the transduced PBSC (Ott et al., 
2006). The two young men treated had severe infections that had persisted despite 
intensive medical therapy. These infections resolved after the gene therapy 
procedure, as the patients made neutrophils with functional oxidase activity. 
Relatively high levels of corrected leukocytes were seen in peripheral blood (∼20%) 
in the first months after the gene therapy procedure and this rose to as high as 80% 
over the first year. The vector integration sites were studied in the CGD patients and 
revealed a highly restricted pattern, with the majority of vector integrants in the 
engrafted stem cells being near one of a few genes known to be involved in myeloid 
cell proliferation (MDS1/EVI1, PRDM16 or SETBP1). Both patients subsequently 
developed myelodysplasia with monosomy 7 and first one died 2.5 years after gene 
therapy as a result of a sepsis. The second patient has undergone successful 
allogeneic transplant (ESGT, 2006; Stein et al., 2010). The underlying mechanisms for 
the oligoclonal expansion and progression to myelodysplasia are not fully elucidated, 
but the retroviral vector used had an LTR with potent enhancer activity in myeloid 
progenitor cells and this may have led to trans-activation of genes that promote 
myeloid cell proliferation.  
1.2.4.1.2 Wiskott-Aldrich Syndrome 
Wiskott-Aldrich syndrome (WAS) is a rare X-linked hereditary disorder associated 
with combined immunodeficiency, thrombocytopenia, small platelets, eczema, and 
increased susceptibility to autoimmune disorders and cancers. (Thrasher and Kinnon, 
2000). It caused by mutations in the gene for the Wiskott-Aldrich syndrome protein 
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(WASP), located at Xp11.22-p11.23 (Derry et al., 1994; Devriendt et al., 2001). WASP 
and several related proteins are involved in the reorganization of the actin 
cytoskeleton by activating the actin-related protein 2/3 complex that mediates actin 
polymerization in all cells of the hematopoietic system (Thrasher, 2002). As WASP is 
exclusively expressed in the hematopoietic cells, the complex biologic features of 
this disease result from multiple dysfunction in different subgroups of leukocytes, 
including defective function of T and B cells, disturbed formation of natural killer (NK) 
cell immunologic synapse, and impaired migratory responses in all leukocyte 
subgroups (Bosticardo et al., 2009; Thrasher and Burns, 2010). The patients bearing 
the WAS mutation suffering from recurrent pyogenic, viral and fungal infections as 
well as bleeding diathesis and an increased incidence of Epstein-Barr virus (EBV)-
associated lymphoproliferative disease, severe WAS leads to an early death (Imai et 
al., 2004).  
Currently, the only curative treatment approach for WAS consists of allogeneic 
hematopoietic stem cell transplantation (HSCT). However, HSCT is associated with 
significant mortality and morbidity resulting from infection, graft-versus-host disease, 
non-engraftment and post-transplant lymphoproliferative syndrome (Derry et al., 
1994). In light of the less satisfactory results from HSCT fro WAS treatment, in 
particular regarding those patients for whom an HLA-matched donor is unavailable, 
several groups have embarked on the development of gene therapy as a more 
specific and potentially less toxic therapeutic option. Various in vitro studies as well 
as in vivo mouse model studies have demonstrated that retroviral gene transfer can 
reconstitute the cellular phenotype in WASP-deficient cells and mouse, the 
functional correction of gene modified cells restore the defective actin 
polymerization and immune protecting functions (Klein et al., 2003).  
The first clinical trial of WASP gene therapy is being conducted at the Hannover 
Medical School in Germany, 9 out of 10 children were treated in this trial. The vector 
system used in this trial is a gammaonco-retroviral virus-based, LTR-driven construct 
encoding human WASP cDNA, which has been extensively assessed in preclinical 
experiments using mouse model and human CD34+ derived from WAS patients 
Introduction  Wei Wang 
30 
 
(Devriendt et al., 2001; Dewey et al., 2006). This study shows that gene therapy for 
the WAS is feasible and no adverse treatment related events up to 3 years after gene 
therapy (Boztug et al., 2010).  
1.2.4.2 Integration site preference of retroviral and lentiviral vectors 
Unbiased, high-throughput studies are important to identify integration hot 
spots and provide insights into mechanisms governing integration site selection of 
viral vectors used in clinical settings. Historically, the integration events of 
retroviruses were believed to be random, and the chance of accidentally disrupting 
or activating a gene was considered remote. Early retroviral integration studies 
proposed that condensed chromatin from inactive DNA regions disfavored retroviral 
integration, thereby concentrating the integration in more open active chromatin 
areas of the host genome (Panet and Cedar, 1977; Rohdewohld et al., 1987; Vijaya et 
al., 1986). The availability of the human genome sequence and the development of 
methodology to define DNA sequence at the site of retroviral integration have 
shown that integration is far from random. The murine gamma-retroviral vectors 
used in gene therapy trails to integrate favor the transcription start sites of actively 
transcribed genes in the target cell population (Wu et al., 2003), whereas lentiviral 
vectors favor active genes with more uniform distribution within transcriptional units 
(Schroder et al., 2002). This is suggests that lentiviral vectors are less prone to 
transactivate a downstream oncogene by transcriptional reading through. 
Integration into or near genes involved in cell-cycle progression or cell survival has 
the potential to alter the biologic properties of cells which, in the context of 
engraftment, can result in preferential engraftment and expansion and even clonal 
dominance. In the first case, a mouse leukemia developed as a consequence of the 
aberrant expression of the Evi1 proto-oncogene caused by a nearby integrated 
proviral genome (Li et al., 2002). Side by side comparisons in valid models of 
oncogenic transformation have shown the impact of integration site selection 
between different vector designs. Study with gene trap vectors performed in primary 
hematopoietic cells confirmed a stronger bias of MLV vectors to insert in promoter-
proximal windows, as compared with similarly designed HIV-derived vectors (De 
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Palma et al., 2005). Moreover, in mice engrafted with cdkn2a-/- BM, a gamma-
retroviral vector was found to accelerate tumorigenesis, whereas a lentiviral vector, 
present at higher copy number, did not have such a detrimental effect (Montini et al., 
2006). Studies on transduced BM and CD34+ cells have further revealed that vector 
integration events are undeniably non-random, frequently clustered and potentially 
able to induce immortalization in vitro, conversion of immortalized cells to growth 
factor independence, clonal dominance in vivo, or even contribution to 
leukemogenesis in vivo (Du et al., 2005; Kustikova et al., 2005; Modlich et al., 2006; 
Modlich et al., 2009).  
1.2.4.3 Risk and side effects of retroviral gene transfer in clinical trials  
Integration of the retroviral provirus in the host genome can lead to stable 
transgene expression, one of the outstanding features of retroviral vectors. 
Unfortunately, it is also their demerit, because integration can cause insertional 
mutagenesis and cellular transformation, whose undesired effects may lead to 
cancer in a worst-case scenario. In a clinical gene therapy trial for X-linked severe 
combined immunodeficiency using retroviral vectors expressing common γ chain of 
the interleukin-2 receptor (γc), integration of the retroviral vector in the LMO2 
proto-oncogene resulted in insertional mutagenesis and development of T-cell 
leukemia in 4 children of Paris trial and 1 child of London trial (Hacein-Bey-Abina et 
al., 2008; Hacein-Bey-Abina et al., 2003b; Howe et al., 2008),  this theoretical risk has 
unfortunately materialized. 
The discovery of common integration sites (CISs), namely the nonrandom 
insertional clustering of integration sites into the same genetic locus in 2 or more 
cells in a population, is thought to reflect the biases toward integration into actively 
transcribed genes in the target cells. Retroviral integration analysis has been 
reported in detail for X-SCID and the Adenosine deaminase (ADA)-SCID trial in Italy 
(Aiuti et al., 2007; Deichmann et al., 2007; Howe et al., 2008; Schwarzwaelder et al., 
2007). The distribution of integration sites favoring transcription start sites and CpG 
islands and the predilection for actively transcribed genes were similar to that 
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reported for cell lines and animal models. CISs were defined in patients in the Paris 
trial for X-SCID with 5 insertions within LMO2, 8 within ZNF217, and 9 within or near 
CCND2, a gene involved in cell-cycle progression. CCND2 and LMO2 also emerged as 
CISs in the patients in the Italian ADA trail as well as in the London X-SCID trail. 
Vector insertion induced upregulation of LMO2 has triggered abnormal T cell 
proliferation, potentially enhanced by the constitutive expression of the Interleukin-
2 receptor gamma chain transgene transduced in X-SCID trials. Further observation 
showed that insertional side effects are not restricted to lymphopoiesis. Large-scale 
mapping of retroviral integration sites in the first successful gene therapy trial of 
chronic granulomatous disease (CGD) revealed that activating insertions in the zinc 
finger transcription factor homologs MDS1/EVI1, PRDM16, or in SETBP1 have 
expanded gene-corrected long term myelopoiesis 3- to 5- fold in both patients, 
providing direct evidence that these genes influence regulation of normal 
hematopoiesis (Ott et al., 2006). In both patients treated in CGD trial, progressive 
decline in blood counts has been reported, including platelets, red blood cells and 
neutrophils, at 15 and 28 months after gene therapy, respectively. BM examination 
showed myelodysplasia, a preleukemic clonal marrow failure syndrome 
characterized by ineffective and disordered myeloid maturation. Despite the 
persistent high frequency of vector-corrected neutrophils, expression of NADPH 
oxidase dropped precipitously in both subjects over time, occurred through 
progressive CpG methylation of the promoter contained in the LTR of the vector. 
Cytopenias and loss of oxidase function in one of the patients resulted in a series of 
infections that led to his death. The second patient was referred for unrelated donor 
stem cell transplantation while still infection free (Stein et al., 2010). 
Despite the negative finding described above, the majority of the patients 
benefited from gene therapy trials. For example, in 17 out of 20 X-SCID patients, T-
cell counts reached normal levels and became functionally competent, as 
demonstrated by normal response to mitogens and specific antigens. Ten years of 
follow-up available for patients who were first to be treated have provided evidence 
for still active thymopoiesis, with broadly diversified TCR repertoire (Hacein-Bey-
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Abina et al., 2008). Gene therapy continues to have enormous potential for the 
treatment of disorders of the hematopoietic system, cancer and other diseases. The 
occurrence of these severe adverse events led to the development of a new area of 
research focused on virus-mediated oncogenesis and significantly contributed to 
improving safety standards for gene therapy vectors. 
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2. Projects aims 
Human gene therapy trials using insertional vector systems have achieved 
unprecedented levels of efficiency, but unfortunately also side effects. It has been 
recently shown that insertional mutagenesis in preclinical and clinical gene therapy 
may frequently lead to gene activation in hematopoiesis, producing insertion-
activated expansion of cell clones.  
Thereby, intense attention was focused on the MDS1/EVI1 and PRDM16 gene 
complexes as recurrent targets for gamma-retroviral vector integration. In the first 
clinical gene therapy trial for chronic granulomatous disease, both patients showed 
significant clinical improvement and clearance of chronic infections. Surprisingly, ~3-
4 months after gene therapy, the frequency of genetically modified CD15+ 
neutrophils began to rise, peaking at around 60% in both patients, resulting in the 
formation of a myelodysplastic syndrome ~2 years later. Analysis of vector 
integration of this two patients revealed that the expansion of marked cells 
accounted for vector-containing clones with insertions in three gene complexes: 
MDS1/EVI1, PRDM16 and SETBP1. Malignant transformation was related to cell 
clones harboring MDS1/EVI1 insertions. 
Similar to the findings in the human CGD trial, vector insertions in the MDS1/EVI1 
and PRDM16 loci were highly overrepresented in in vitro and in preclinical in vivo 
animal models, leading to over-expression of Evi1 and Prdm16, and 
myelomonocyctic leukemia in mice.  
In contrast to full LTR driven gamma-retroviral vectors, self-inactivating (SIN) LTR 
containing lentiviral promise immensely for sustainable and long-term mediated 
clinical gene therapy. Even integrase deficient lentiviral vectors (IDLV) demonstrated 
a high applicability for stable, though transient gene delivery, rendering them 
interesting for therapeutic applications. However, little is known about the existing 
residual integration events of IDLV, and comprehensive characterization of IDLV 
integration profiles in mammalian genomes is still missing. 
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Towards a precise characterization of the role of MDS1/EVI1 and PRDM16 in 
human hematopoiesis, and to determine the biological properties of IDLVs as well as 
to develop potentially innovative utilization in combination with transient expression 
of MDS1/EVI1 and/or PRDM16 in hematopoietic stem cells, we specifically aim: 
1. To analyze long-term effects of MDS1/EVI1 and PRDM16 loci as gamma-
retrovirus integration sites in hematopoietic stem cells after WAS gene 
therapy. 
2. To develop a lentiviral vector expression system for investigating the impact 
of Mds1/Evi1, Prdm16 and their truncated forms on more defined 
hematopoietic stem cells. 
3. To test whether transient expression of Mds1/Evi1 or Prdm16 by integrase 
deficient lentiviral vectors (IDLVs) is sufficient to influence long-term 
repopulating cells, and to study integration properties and safety aspects of 
IDLVs. 
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3. Materials and Methods 
3.1 Materials 
 Mice 3.1.1
C57BL/6J (CD45.2) and B6.SJL-Ptprca Pep3b/BoyJ (CD45.1) mice (6-12 weeks age) 
were purchased from Charles River Laboratories and were bred at the animal facility 
of German Cancer Research Center. All animals were maintained under specific-
pathogen-free conditions. All animal experiments were conducted in accordance 
with local and institutional guidelines and were approved by the 
Regierungspräsidium Karlsruhe. 
 Cell lines 3.1.2
Name Organism Description Source 
293T 
Homo 
sapiens 
Derivative of human embryonic kidney 
293 cells, contains the large T-antigen 
of SV40 
Luigi Naldini’s 
laboratory in Milan, 
Italy 
HeLa 
Homo 
sapiens 
Human cervical carcinoma cell line Laboratory stock 
C1498 
Mus 
musculus 
Mouse acute myeloid leukemia cell 
line 
ATCC TIB-49 
SC-1 
Mus 
musculus 
Mouse embryonic fibroblast cell line 
Adrian Thrasher’s 
laboratory in London, 
England 
 Cell culture media and additives 3.1.3
Name Manufacturer 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco, Invitrogen 
Iscove’s Modified Dulbecco’s Medium (IMDM) Gibco, Invitrogen 
StemSpan Serum-Free Medium (SFM) StemCell Technologies 
Opti-MEM® I Reduced Serum Medium (MEM) Gibco, Invitrogen 
Fetal Bovine Serum (FBS) Biosera 
Fetal Calf Serum (FCS) StemCell Technologies 
L-Glutamine (Glu) Gibco, Invitrogen 
Penicillin/Streptomycin (Pen/Strep) Gibco, Invitrogen 
 General buffers chemicals and kits for cell culture 3.1.4
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Name Manufacturer 
Dulbecco’s Phosphate-Buffered Saline (PBS) Gibco, Invitrogen 
Typsin-EDTA 0.05% Gibco, Invitrogen 
Cell Dissociation Buffer, enzyme free, Hanks’-based Gibco, Invitrogen 
20% FBS in PBS Laboratory stock 
Türk’s solution Merck Chemicals 
Typan-blue solution Gibco, Invitrogen 
70% Alcohol Laboratory stock 
Freezing medium (15% DMSO, 30% FBS in cell culture 
medium) 
Laboratory stock 
Thawing medium (50% FBS in cell culture medium) Laboratory stock 
Dimethyl sulfoxide (DMSO) Karl-Roth 
2x HEPES balanced saline (281 mM NaCl, 1.5 mM Na2HPO4, 
100 mM HEPES) 
Laboratory stock 
0.1x TE/H2O (1 mM Tris-HCl, 0.1mM EDTA) Laboratory stock 
Calcium Chloride (2.5 M) Laboratory stock 
Polybrene (hexadimethrine bromide, 8 mg/ml)  Sigma-Aldrich 
Polyethyleneimine (PEI) Sigma-Aldrich 
Magnetofection ViroMag L OZ Biosciences 
 Medium and kits for primary cell culture 3.1.5
Name Manufacturer 
Mouse hematopoietic progenitor enrichment kit StemCell Technologies 
MethoCult methylcellulose-based media M3434 StemCell Technologies 
MethoCult methylcellulose-based media M3630 StemCell Technologies 
 Cytokines for primary cell culture 3.1.6
Name Manufacturer 
Recombinant mouse-Interleukin 6 (rm-IL6) R&D Systems 
Recombinant mouse-Interleukin 3 (rm-IL3) R&D Systems 
Recombinant mouse-Stem Cell Factor (rm-SCF) R&D Systems 
Recombinant mouse-FLT-3 Ligand (rm-FLT-3L) R&D Systems 
Recombinant mouse-Thrombopoietin (rm-TPO) R&D Systems 
 General buffers and antibodies for flow cytometry 3.1.7
Name Manufacturer 
Hanks Balanced Salt Solution (HBSS) Sigma-Aldrich 
2% FBS in HBSS (HF) Laboratory stock 
Red Blood Cells Lysis Buffer (RBC) Laboratory stock 
Prooidium Iodide (PI) Sigma-Aldrich 
7-Amino-actinomycin D (7-AAD) Sigma-Aldrich 
APC-H7 Rat anti-Mouse CD117 (c-kit) BD Pharmingen 
PE-Cy7 Rat anti-Mouse Ly-6A/E (Sca-1) BD Pharmingen 
PE Rat anti-Mouse CD115 (Flk-2/Flt3) BD Pharmingen 
APC Mouse Lineage Antibody Cocktail BD Pharmingen 
Materials and Methods  Wei Wang 
38 
 
PE-Cy7 Rat anti-Mouse CD11b (Mac-1) BD Pharmingen 
PE Rat anti-Mouse Ly-6G/C (Gr-1) BD Pharmingen 
APC Rat anti-Mouse Ly-76 (Ter-119) BD Pharmingen 
PE Rat anti-Mouse CD117 BD Pharmingen 
APC Rat anti-Mouse CD19 BD Pharmingen 
PE Rat anti-Mouse CD3 BD Pharmingen 
FITC Rat anti-Mouse CD34 eBiosciences 
Purified Rat anti-Mouse CD16/CD32  BD Pharmingen 
APC Rat anti-Mouse CD45 BD Pharmingen 
PE Rat anti-Mouse CD45 BD Pharmingen 
PE-Cy7 Rat anti-Mouse CD45 BD Pharmingen 
FITC Rat anti-Mouse CD45 BD Pharmingen 
PE-Cy7 Rat IgG2a, κ Isotype Control BD Pharmingen 
PE-Cy7 Rat IgG2b, κ Isotype Control BD Pharmingen 
PE Rat IgG2a, κ Isotype Control BD Pharmingen 
PE Rat IgG2b, κ Isotype Control BD Pharmingen 
APC Rat IgG2a, κ Isotype Control BD Pharmingen 
APC Rat IgG2b, κ Isotype Control BD Pharmingen 
APC-H7 Rat IgG2b, κ Isotype Control BD Pharmingen 
FITC Rat IgG2b, κ Isotype Control eBiosciences 
 Bacteria 3.1.8
Name Genotype Manufacturer 
TOP10 Chemically 
Competent E. coli 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
NEB 5-alpha 
Competent E. coli 
(High Efficiency) 
fhuA2Δ(argF-lacZ)U169 phoA glnV44 Φ80 
Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
New England 
BioLabs 
dam-/dcm- 
Competent E. coli 
ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 galK2 
galT22 mcrA dcm-6 hisG4 rfbD1 
R(zgb210::Tn10) TetS endA1 rspL136 (StrR) 
dam13::Tn9 (CamR) xylA-5 mtl-1 thi-1 mcrB1 
hsdR2 
New England 
BioLabs 
 Antibiotics for bacteria culture 3.1.9
Name Stock Concentration 
Working 
Concentration 
Manufacturer 
Ampicillin 100 mg/ml 100 µg/ml Sigma-Aldrich 
Kanamycin 100 mg/ml 50 µg/ml Sigma-Aldrich 
Chloramphenicol 25 mg/ml 25 µl/ml Sigma-Aldrich 
 General media for bacteria culture 3.1.10
Name Formulation Final concentration 
Luria-Broth (LB) SELECT Peptone 140  10 g (1%) 
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Media SELECT Yeast Extract 
Sodium Chloride 
Add AquaBidest to 1L 
pH 7.5 Autoclaved 
10 g (1%) 
5 g (0.5%) 
LB-Agar SELECT Peptone 140  
SELECT Yeast Extract 
Sodium Chloride 
Bacto-agar 
Add AquaBidest to 1L 
pH 7.5 Autoclaved 
10 g (1%) 
10 g (1%) 
5 g (0.5%) 
5 g (0.5%) 
S.O.C Media Bacto-tryptone 
Bacto-yeast extract 
Sodium Chloride 
Potassium Chloride 
Magnesium Chloride 
Magnesium Sulfate 
Glucose 
Add AquaBidest to 1L 
pH 7.5 Autoclaved 
20 g (2%) 
5 g (0.5%) 
0.584 g (10mM) 
0.186 g (2.5mM) 
0.952 g (10mM) 
1.204 g (10mM) 
3.603 g (20mM) 
Glycerol Solution 100% Glycerol 
filtered with 0.22µm filter 
50% 
 Plasmids 3.1.11
3.1.11.1 Lentiviral vectors 
Name Description 
pMDLgag/pol RRE 
This 3rd generation LV packaging plasmid encodes 
the HIV-1 Gag and Pol proteins driven by CMV 
promoter, and a Rev protein regulatory element 
(RRE) in pMDL backbone.  
pMDLgag/pol RREintD64V 
Similar to pMDLgag/pol RRE, but contains a single 
amino acid D64V mutation in HIV-1 integrase 
sequences , which results defective provirus 
integration 
pRSV-REV 
Part of 3rd generation LV packaging system, which 
encodes the HIV-1 Rev protein under the 
transcriptional control of RSV U3 promoter 
pMD2-VSVG 
Part of 3rd generation LV packaging system, which 
encodes the VSV G envelope protein 
pRRL pptCMV-GFP-PRE 
3rd generation LV transfer vector contains a Tat-
independent chimeric 3’LTR in which the HIV 
promoter is replaced by RSV promoter and enhancer 
sequences, central polypurine tract (cppt) as well as 
posttranscriptional regulatory element (PRE) in its 
backbone. It encodes enhanced green fluoresces 
protein (GFP) driven by internal CMV promoter upon 
provirus integration. 
pCCL pptPGK-GFP-PRE Similar to the vector above, which Tat-independent 
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chimeric 5’LTR in which the HIV promoter is replaced 
by CMVpromoter and enhancer sequences, and its 
GFP expression is driven by human PGK promoter 
pCCL pptPGK-IRES-GFP-PRE 
Similar to the vector above, which contains a IRES-
GFP expression cassette, allows for translation 
initiation in the middle of a mRNA sequence as part 
of the protein synthesis. 
pCCL pptSFFV-GFP-PRE 
Similar to the pCCL pptPGK-GFP-PRE, which GFP 
expression is driven by SFFV promoter 
pCCL pptSFFV-IRES-GFP-PRE 
Similar to the vector above, contains IRES-eGFP 
expression cassette 
pCCL pptEF1a-GFP-PRE 
Similar to the pCCL pptPGK-GFP-PRE, which GFP 
expression is driven by human EF1a promoter 
3.1.11.2 Cloning vectors 
Name Manufacturer 
pCMV-Sport6 
Invitrogen, 4396bp, CMV promoter, Ampicillin 
resistance 
pYX-Asc RZPD, 1691bp, Ampicillin resistance 
pBluescriptR Stratagene, 2998bp, Ampicillin resistance 
pPCR-Script Stratagene, 2961bp, Ampicillin resistance 
pCR2.1-TOPO 
Invitrogen, 3931bp, Ampicillin and Kanamycin 
resistance 
 Restriction enzymes 3.1.12
Restriction enzymes were purchased from New England Biolabs if there are no 
specific descriptions. The names of restriction enzymes were not list here. All the 
enzymes are stored and worked under the conditions by manufacturer’s 
recommendation. 
 Regents, chemicals and buffers for nucleic acid analysis 3.1.13
3.1.13.1 Oligonucleotides 
HPLC (High Pressure Liquid Chromatography) purified and lyophilized 
oligonucleotides were obtained from MWG Biotech Germany. Oligonucleotides used 
for analysis were partly labeled at the 5‘end with biotin (B). In case of the single-
stranded Linker used in the non-restrictive LAM-PCR (LC1rev), this oligonucleotide is 
phosphorylated at the 5’end and tagged with a di-desoxynucleotid at the 3’ end. 
Sequences of all the oligonucleotides are listed below. 
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Standard PCR Primer Name Sequence (5‘-3‘) 
GAPDH-PCR GAPDH-Hs-Fwd 5‘-GAAGGTGAAGGTCGGAGT-3‘ 
 GAPDH-Hs-Rev 5‘-GAAGATGGTGATGGGATTTC-3‘ 
GAPDH-PCR GAPDH-Mm-Fwd 5‘-ATATTGGAAAATGTGGAAGTGAAAGG-3‘ 
 GAPDH-Mm-Rev 5‘-TCGCCAGAGCCATCTTTTG-3‘ 
HPRT-PCR HPRT down 5‘-GCTGGTGAAAAGGACCTCT-3‘ 
 HPRT middle rev 5‘-CCAACAACAAACTTGTCTGG-3‘ 
GFP-PCR GFP-Fwd 5‘-TGAGCAAGGGCGAGGAGCTGTT-3‘ 
 GFP-Rev 5‘-GCCGGTGGTGCAGATGAACT-3‘ 
WPRE-PCR WPRE-Fwd 5‘-GAGGAGTTGTGGCCCGTTGT-3‘ 
 WPRE-Rev 5‘-TGACAGGTGGTGGCAATGCC-3‘ 
Mds1/Evi1-PCR ME-Mm-PR-Fwd 5‘-CAAGGAAACTGGCCACAAGT-3‘ 
 ME-Mm-PR-Rev 5‘-AGGAGAGCATGGCTCTTGAA-3‘ 
Evi1-PCR cME-Mm-Fwd 5‘-ACCAGCCCCTGGATCTAAGT-3‘ 
 cME-Mm-Rev 5‘-AGCTTCAAGCGGGTCAGTTA-3‘ 
Prdm16-PCR cPrdm16-Fwd 5‘-GCGGCCGTCCCCACTTCTGTT-3‘ 
 cPrdm16-Rev 5‘-GCGCCCTCGTGTTCGTGCTTCT-3‘ 
sPrdm16-PCR Prdm16-PR-Fwd-3 5‘-TGGGAGATGCTGACGGATAC-3‘ 
 Prdm16-PR-Rev-3 5‘-TCACAGGAACACGCTACAC-3‘ 
Cloning PCR Name Sequence (5‘-3‘) 
Prdm16/sPrdm16 Prdm16-388-C 5‘-GCCGACTTTGGATGGGAGATGCTGACGGATACAGAG-3‘ 
 E1S1Prdm16-A 5‘-GGAATTCCTGCAGGACCATGCGATCCAAGGCGAGG-3‘ 
 H3K1Prdm16-741D 5‘-CCCAAGCTTATTAGGCGCCTCAGGTCCAG-3‘ 
 Prdm16-388-B 5‘-CTCTGTATCCGTCAGCATCTCCCATCCAAAGTCGGC-3‘ 
 EIAI-Prdm16-C-F 5‘-GGAATTCCGACCGGTCATTCAGCATCTC-3‘ 
 XIAI-Prdm16-C-R 5‘-GCTCTAGAGCGATCGCTCAGAGGTGGTTGATGGG-3‘ 
 EISI-Prdm16S-N-F 5‘-GGAATTCCTGCAGGACCATGTGTCAGATCAACG-3‘ 
Setbp1 EISI-Setbp1-N-F 5‘-GGAATTCCTGCAGGACCATGGAGCCAGAGG-3‘ 
 XIKI-Setbp1-N-R 5‘-GCTCTAGAGCGGTACCACACTTCCCAAG-3‘ 
 EIKI-Setbp1-C-F 5‘-GGAATTCCACATGGCTCGGGAGG-3‘ 
 XIAI-Setbp1-C-R 
5‘-GCTCTAGAGCGATCGCCTAGGGAAGGACATCACTCTC-
3‘ 
Mds1/Evi1 EIBI-Evi1-N-F 5‘-GGAATTCCGGGATCCATGGCGCCTGACATCCA-3‘ 
 MINI-Evi1-N-R 5‘-CGACGCGTCTGCAATCAGCATG-3‘ 
LTR PCR Name Sequence (5‘-3‘) 
LTR-Test (LV) SK LTR 1 bio (B) 5‘-GAGCTCTCTGGCTAACTAGG-3‘ 
 SK LTR 9 rev 5‘-GCTAGAGATTTTCCACACTG-3‘ 
 SK LTR 2 bio (B) 5‘-GAACCCACTGCTTAAGCCTCA-3‘ 
 SK LTR 8 rev 5‘-CTAAAAGGGTCTGAGGGATC-3‘ 
LAM-PCR Name Sequence (5‘-3‘) 
3’-LAM; LV SK LTR 1bio (B) 5‘-GAGCTCTCTGGCTAACTAGG-3‘ 
 SK LTR 2bio (B) 5‘-GAACCCACTGCTTAAGCCTCA-3‘ 
 SK LTR 3bio (B) 5‘-AGCTTGCCTTGAGTGCTTCA-3‘ 
 SK LTR 4bio (B) 5‘-AGTAGTGTGTGCCCGTCTGT-3‘ 
 SK LTR 5 5‘-GTGTGACTCTGGTAACTAGAG-3‘ 
 SK LTR 5 1/2 5‘-GATCCCTCAGACCCTTTTAGTC-3‘ 
5’-LAM; LV  U3_Lenti_Bio_4 (B) 5‘-AGGCTTAAGCAGTGGGTTCC-3‘ 
 U3_Lenti_Bio_5 (B) 5‘-TTAGCCAGAGAGCTCCCAGG-3‘ 
 U3_Lenti_Bio_6 (B) 5‘-GATCTGGTCTAACCAGAGAG-3‘ 
 U3_Lenti_7 5‘-CCCAGTACAAGCAAAAAGCAG-3‘ 
Materials and Methods  Wei Wang 
42 
 
5’-LAM; MLV RV LTRa bio (B) 5‘-TGCTTACCACAGATATCCTG-3‘ 
 LTRb bio (B) 5‘-ATCCTGTTTGGCCCATATTC-3‘ 
 LTR II bio (B) 5‘-GACCTTGATCTGAACTTCTC-3‘ 
 LTR III 5‘-TTCCATGCCTTGCAAAATGGC-3‘ 
3’-LAM; MLV RV U5Ivbio (B) 5‘-TCCGATTGACTGAGTCGC-3‘ 
 U5Vbio (B) 5‘-GGTACCCGTGTATCCAATA-3‘ 
 U5VI bio (B) 5‘-TCTTGCAGTTGCATCCGACT-3‘ 
 LTR25 5‘-GTGGTCTCGCTGTTCCTT-3‘ 
5’-internal LAM Lenti 1 bio (B) 5‘-GATAGTAGGAGGCTTGGTAG-3‘ 
 Lenti 2 bio (B) 5‘-AGTGAATAGAGTTAGGCAGG-3‘ 
 Lenti 4 bio (B) 5‘-CACCATTATCGTTTCAGACCC-3‘ 
 Lenti 5 5‘-GGCCCGAAGGAATAGAAGAA-3‘ 
 GFP1-Bio (B) 5‘-AAACGGCCACAAGTTCAGCG-3‘ 
 GFP2-Bio (B) 5‘-GATGCCACCTACGGCAAGCT-3‘ 
 GFP3-Bio (B) 5‘-TACGGCGTGCAGTGCTTCAG-3‘ 
 GFP4-Bio (B) 5‘-AAGGGCATCGACTTCAAGGA-3‘ 
 GFP6-Bio (B) 5‘-ACTACCTGAGCACCCAGTCC-3‘ 
 GFP7-Bio (B) 5‘-GCCCTGAGCAAAGACCCCAA-3‘ 
 GFP8-Bio (B) 5‘-GATCACATGGTCCTGCTGGA-3‘ 
 GFP9-Bio (B) 5‘-TGACCGCCGCCGGGATCACT-3‘ 
3’-internal LAM Lenti-Rev1-Bio (B) 5‘-TTCTATTCCTTCGGGCCTGT-3‘ 
 Lenti-Rev2-Bio (B) 5‘-GGAGGTGGGTCTGAAACGAT-3‘ 
 Lenti-Rev3-Bio (B) 5‘-TGGTGAATATCCCTGCCTAA-3‘ 
 Lenti-Rev4 5‘-TTCTTAAACCTACCAAGCCTCCT-3‘ 
 GFP-Rev1-Bio (B) 5‘-GAACTCCAGCAGGACCATGT-3‘ 
 GFP-Rev2-Bio (B) 5‘-GCTTCTCGTTGGGGTCTTTG-3‘ 
 GFP-Rev3-Bio (B) 5‘-ACTGGGTGCTCAGGTAGTGG-3‘ 
 GFP-Rev4-Bio (B) 5‘-ATGGGGGTGTTCTGCTGGTA-3‘ 
 GFP-Rev5-Bio (B) 5‘-AAGTCGATGCCCTTCAGCTC-3‘ 
 GFP-Rev6-Bio (B) 5‘-GGTCTTGTAGTTGCCGTCGT-3‘ 
 GFP-Rev7-Bio (B) 5‘-AGTCGTGCTGCTTCATGTGG-3‘ 
 GFP-Rev8-Bio (B) 5‘-GAACTTCAGGGTCAGCTTGC-3‘ 
Expo-PCR LCI 5‘-GACCCGGGAGATCTGAATTC-3‘ 
 LCII  5‘-GATCTGAATTCAGTGGCACAG-3‘ 
Linker Cassette Name Sequence (5‘-3‘) 
Linker cassette 
for LAM-PCR 
LC1 
5‘-ACCCGGGAGATCTGAATTCAGTGGCACAGCAGTTAGG-
3‘ 
 LC3 (AATT) 5‘-AATTCCTAACTGCTGTGCCACTGAATTCAGATC-3‘ 
 LC3 (TA) 5‘-TACCTAACTGCTGTGCCACTGAAATCAGATC-3‘ 
 LC3 (CATG) 5‘-CATGCCTAACTGCTGTGCCACTGAATTCAGATC-3‘ 
 LC3 (CG) 5‘-CGCCTAACTGCTGTGCCACTGAATTCAGAT-3‘ 
Linker cassette 
for nrLAM-PCR 
LC1rev 
(P)5´-
CCTAACTGCTGTGCCACTGAATTCAGATCTCCCGGGTC-3´ 
3.1.13.2 Regents and kits molecular biological experiments 
Reagents and Chemicals Manufacturer 
100bp DNA ladder Invitrogen 
1Kb plus DNA ladder Invitrogen 
Absolute ethanol VWR 
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Acetic acid Applichem 
Agarose Sigma-Aldrich 
Agencourt AMPure XP PCR Purification Beads Beckman Coulter 
Aqua ad iniectabilia Braun 
Bovine Serum Albumine (BSA) Sigma-Aldrich 
Bromphenolblue Sigma-Aldrich 
Calf intestinal alkaline phosphatase (CIAP) Invitrogen 
Dimethylformamid (DMF) Sigma-Aldrich 
dNTPs Sets Genaxxon 
Dynabeads M-280 Streptavidin Dynal, Invitrogen 
EndoFree Plasmid Maxi Kit Qiagen 
Ethidium bromide Applichem 
Ethylenediaminetetraacetic acid (EDTA) Applichem 
Fast-Link DNA Ligation Kit Epicentre Biotechologies 
FastStart High Fidelity PCR System Roche 
Glycerol Sigma-Aldrich 
Guanidin hydrochloride Applichem 
Hexamin-CoCl2 Fluka 
Hexanucleotide mixture Roche 
High Pure PCR Product Purification Kit Roche 
High Pure PCR Template Preparation Kit Roche 
Human Genomic DNA Roche 
Klenow polymerase Roche 
Licium chloride Sigma-Aldrich 
LightCycler 480 SYBR Green I Master Roche 
LightCyler Uracil-DNA Glycosylase Roche 
Loading Buffer 5x Elchrom Scientific 
Magnesium chloride  Sigma-Aldrich 
Microcon-30, -50 Millipore 
Mid-Range PCR System PeqLab 
MS2 RNA (0.8µg) Roche 
Nonidet P-40 10% Sigma-Aldrich 
PCR SuperMix with Taq DNA polymerase Invitrogen 
PEG 8000 Genaxxon 
Phosphate Buffered Saline (PBS, pH 7.5) Gibco, Invitrogen 
Platinum Pfx DNA polymerase Invitrogen 
ProofStart PCR System Qiagen 
Proteinase K Roche 
QIAGEN LongRange 2Step RT PCR System Qiagen 
QIAGEN Plasmid High-Speed Maxi Kit Qiagen 
QIAprep Spin Miniprep Kit Qiagen 
QIAquick Gel extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
QIAshredder Qiagen 
Quickchange II XL site-directed mutagenesis kit Statagene 
RNAlater RNA stabilization reagent Qiagen 
RnaseZap Ambion 
Rneasy Mini Kit Qiagen 
Sodium Acetate Sigma-Aldrich 
Sodium Dodecyl Sulfate (SDS) Applichem 
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Sodium hydroxide Fluka 
Spreadex EL1200 gel mini/midi Elchrom Scientific 
SuperScript III First-Strand Synthesis SuperMix Invitrogen 
SuperScript III First-Strand Synthesis System for RT-PCR Invitrogen 
SuperScript III One-Step RT-PCR System with Platinum Taq 
DNA Polymerase 
Invitrogen 
T4 DNA-Ligase and 10x reaction buffer New England Biolabs 
T4 RNA-Ligase and 10x reaction buffer New England Biolabs 
Taq DNA polymerase and 10x PCR buffer Genaxxon/ Qiagen 
TOPO-TA cloning kit with pCR2.1 TOPO vector Invitrogen 
Tris-Acetat-EDTA (TAE) Buffer 40x Elchrom Scientific 
Tris-Borat-EDTA (TBE) Buffer 10x  Amresco 
Tris-HCl (pH 7.5) Applichem 
TURBO DNA-free Ambion 
Tween-20 Sigma-Aldrich 
Venor GeM Mycoplasma Detection Kit  Minerva Biolabs 
X-gal Applichem 
β-Mercaptoethanol Sigma-Aldrich 
3.1.13.3 Buffers for LAM-PCR and PCR 
Name Chemicals Final concentration 
5x Blue run loading buffer Tris-HCl (pH 7) 
EDTA (pH 8) 
Bromphenol-Blue 
Glycerol 
25mM 
150mM 
0.5% (v/v) 
25% (v/v) 
Direct lysis buffer 10x PCR buffer  
Tween-20 
Nonidet P-40 
Proteinase K 
1x 
0.5% 
0.5% 
0.91mg/ml 
Alkaline denaturation solution NaOH (1M) 0.1M 
Magnetic bead washing solution PBS (pH 7,4) 
BSA 
 
0.1%(v/v) 
Magnetic bead 3M LiCl washing  
and binding buffer 
Tris-HCl (pH 7,5) 
EDTA 
LiCl 
10mM 
1mM 
3M 
Magnetic bead 6M LiCl washing  
and binding buffer 
Tris-HCl (pH 7,5) 
EDTA 
LiCl 
10mM 
1mM 
6M 
3.1.13.4 Buffers and kits for southern blotting 
Name Manufacturer 
PCR DIG Probe Synthesis Kit Roche 
Expand High Fidelity Plus PCR System Roche 
DNA Molecular Weight Marker VII, DIG-labeled Roche 
High Pure PCR Product Purification Kit Roche 
Positively charged Nylon Membranes Roche 
DIG Wash and Block Buffer Set Roche 
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Anti-Digoxigenin-AP Roche 
CSPD, ready-to-use Roche 
DIG Easy Hyb Roche 
DIG Nucleic Acid Detection Kit Roche 
DNA depurination buffer (250mM HCl) Laboratory stock 
DNA denaturation solution (0.5M NaOH, 1.5M NaCl) Laboratory stock 
DNA neutralization solution (0.5M Tris-HCl, pH 7,5, 1.5M 
NaCl) 
Laboratory stock 
20x SSC buffer Roche 
2x SSC buffer  Laboratory stock 
Salmon Sperm DNA (10mg/ml) Roche 
Low stringency buffer (2xSSC, 0.1%SDS) Laboratory stock 
High stringency buffer (0.5xSSC, 0,1%SDS) Laboratory stock 
 Regents, chemicals and buffers for protein analysis 3.1.14
3.1.14.1 Buffers reagents and kits for western blotting 
Name Manufacturer 
RIPA buffer (50mM Tris-HCl pH7.4, 0.1% NP-40, 0.5% Na-
deoxycholate, 150mM NaCl, 0.1%SDS) 
Laboratory stock 
Protease inhibitor cocktail tablet Roche 
Ponceau S staining Solution Sigma-Aldrich 
Blocking Buffer (3% fat-free milk powder in wash buffer A) Laboratory stock 
Wash buffer A (0.9% NaCl, 10mM Tris-HCl, 0.05% Tween-20, 
pH 7.5) 
Laboratory stock 
Primary antibody dilution buffer (same to blocking buffer) Laboratory stock 
Secondary antibody dilution buffer (5% fat-free milk powder 
or BSA in wash buffer A) 
Laboratory stock 
Blot stripping buffer (0.2M Glycine, pH 2.5) Invitrogen 
Novex Tris-Glycine SDS Sample Buffer 2x Invitrogen 
Novex Tris-Glycine SDS Running Buffer (10X) Invitrogen 
Novex Tris-Glycine Transfer Buffer (25X) Invitrogen 
Novex Tris-Glycine Gel, 10 wells, 15 wells Invitrogen 
PageRuler unstained protein ladder Fermentas 
PageRuler prestained protein ladder plus Fermentas 
Novex sharp protein standard Invitrogen 
BCA Protein Assay kit Thermo Fisher 
SuperSigna WestPico chemiluminescent substrate Thermo Fisher 
Whatman 3 mm paper Whatman GmbH 
Immobilon-P Membrane (PVDF) Millipore 
3.1.14.2 Antibodies for western blotting 
Name Manufacturer 
Mouse anti Mds1/Evi1 (N-terminus) Abgent 
Rabbit anti Evi1 (C-terminus) Santa cruz biotechology 
Rabbit anti GFP Invitrogen 
Rabbit anti GAPDH Imgenex 
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Rabbit anti Prdm16 (N-terminus, 1446, 1447) Biogenes GmbH 
Rabbit anti Prdm16 (middle, 1448, 1449)) Biogenes GmbH 
Rabbit anti Setbp1 (N-terminus, 1450, 1451) Biogenes GmbH 
Rabbit anti mouse IgG-HRP Abcam 
Rabbit anti goat IgG-HRP Abcam 
Goat anti rabbit IgG-HRP Abcam 
3.1.14.3 ELISA assay for HIV-p24 quantification 
Name Manufacturer 
HIV-1 p24 ELISA kit Perkin Elmer 
 Laboratory instruments and disposables 3.1.15
Name Manufacturer 
Balances Sartorius 
BD FACSAria cell sorter Becton Dickinson 
BD LSRII flow cytometer Becton Dickinson 
Cell culture dishes (3.5cm/6cm/10 cm/15cm)  Greiner-Bio-One 
Cell culture flasks(25cm2/75cm2/150cm2)  Nunc 
Cell culture hood Heraeus 
Cell culture incubator  Heraeus  
Cell culture plates (6wells/12wells/24wells/48wells/96wells) Greiner-Bio-One 
Cell scrapers  Corning 
Centrifuge Tube 6ml Becton Dickinson 
Cryogenic Vials Nalgene 
Electrophoresis Power Supply Elchrom Scientific  
Eppendorf tubes 0.5ml, 1.5ml and 2ml Eppendorf 
Falcon 15ml and 50ml Becton Dickson 
Filter System 0.2 µm (250 ml/500 ml) Millipore 
Fluoresces microscope Zeiss 
Freezer -20°C Liebherr 
Freezer -80°C Sanyo 
Fridge 4°C Liebherr 
Gel documentation system Peqlab 
Gel electrophoresis apparatus Peqlab 
Gel electrophoresis comb (20, 24) Peqlab 
Gel electrophoresis Power Pac Supply 300 BioRad 
Glasses and coverslips Neolab 
Heating block Thermo-mixer Comfort Eppendorf 
Heraeus Benchtop Multifuge 3SR Plus Thermo Scientific 
Horizontal shaker KS 260 basic IKA 
Ice machine Ziegra 
Incubator 37°C Heraeus 
LAM 96-well plate Greiner-Bio-One 
LAM 96-well plate sealing foil ABgene 
Latex Exam Gloves Kimberly-Clark 
LightCycler 96-well plate Roche 
LightCycler 96-well plate sealing foil Roche 
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LightCycler480 system   Roche 
Magnetic particle concentrator MPC 96 Dynal, Invitrogen 
Magnetic particle concentrator MPC-E1 Dynal, Invitrogen 
Microscope Zeiss 
Microwave  Siemens 
Nanodrop ND-1000 spectrophotometer Thermo Fisher 
Needle and syringe Becton Dickinson 
Neubauer Hemacytometer Hausser Scientific 
Nitrogen tank Thaylor-Wharton 
PCR soft tubes 0.2ml Biozym 
pH-Meter Knick  
Picofuge centrifuge Neolab 
Pipetboy Integra Bioscience 
Pipettes (P2, P10, P100, P200, P1000) Eppendorf 
Polystyrene Round Bottom Nalgene 
Printer paper VM 65 H Mitsubishi 
Scales Sartorius 
Scalpels Feather 
Serological Pipette 2, 5, 10, 25, 50 ml Corning 
Submerged gel electrophoresis apparatus SEA 2000 Elchrom Scientific 
Syringe Filter 0.2 µm and 0.45 µm Millipore 
Tabletop centrifuge (Microcentrifuge) Eppendorf 
Thermo cycler programmed with desired protocols Biometra 
TipOne Filter tips (10µl, 20µl, 100µl, 200µl, 1000µl) Starlab 
TipOne RPT tips (10µl, 20µl, 100µl, 200µl) Starlab 
Ultracentrifuge Beckman Coulter 
Video printer Mitsubishi 
Vortexer (MS1) IKA  
Water-bath Thermo Fisher  
Microplate Reader SpectraMax plus 384 Molecular Devices 
 Computer Programs and Data Bases 3.1.16
Name Manufacturer 
Adobe Acrobat 9 Professional Adobe 
Adobe Illustrator CS4 Adobe 
Adobe Photoshop CS4 Adobe 
BLAST Search www.ncbi.nlm.nih.gov/blast 
BLAT Search genome.ucsc.edu/ 
Ingenuity Pathway Analysis Software Ingenuity Systems 
Lasergene DNA Star 
LightCycler LC480 Software (Version 1.5) Roche 
Office 2007 (World, Excel, PowerPoint) Microsoft 
Primer3 frodo.wi.mit.edu/primer3 
R 2.7.1 cran.r-project.org 
SoftMax Pro Software Molecular Devices 
Vector NTI Invitrogen 
SigmaPlot Systac Software 
Materials and Methods  Wei Wang 
48 
 
3.2 Methods 
 Cell biology methods 3.2.1
3.2.1.1 Cell lines propagation 
The following cell lines were used in this work: 293T, HeLa, SC-1 and C1498. 293T 
cells are a highly transfectable cell line derived from the 293 human embryonic 
kidney cell line that express the SV40 large T antigen. HeLa is an immortal cell line 
which derived from cervical cancer cells taken from Henrietta Lacks. SC-1 is a murine 
embryonic fibroblast cell line which has a normal karotype. C1498 is an atypical 
myeloid leukemia that originated in a C57BL/6 mouse and has been used as a model 
for acute myelogenous leukemia.  
HeLa, SC-1 and C1498 cell lines are maintained in Dulbecco’s modified eagle 
medium (DMEM) supplemented with fetal bovine serum (10% v/v), L-glutamine 
(4mM), penicillin (100µg/ml) and streptomycin (100µg/ml); 293T cells are 
maintained in Iscove’s modified Dulbecco’s medium (IMDM) with the same 
supplements. Cells were cultured in tissue culture treated cell flasks at 37°C, 5% CO2 
and 95% humidity atmosphere. Cells were passaged when confluence reached 90-
95%.  The adherent cell lines were first washed with Dulbecco’s phosphate buffered 
saline (PBS) and then incubated for 2-5min at 37°C with 0.05% trypsin/EDTA, the 
cells were subsequently diluted 1:10 in fresh complete culture media and transferred 
to new tissue culture flasks. For the suspension cell line, cell suspension was 
centrifuged first for 5min at 1200rpm and RT, the cell pellets were then resuspended 
with fresh complete culture media, diluted 1:10 and transferred to new tissue 
culture flasks. 
3.2.1.2 Cryo-conservation of cells 
Cells from a 90% confluent monolayer in a 75cm2 tissue culture flask were 
pelleted by centrifugation for 5min at 1200rpm and RT in a tabletop centrifuge, 
resuspended in 900µl complete culture media, transferred to a 2ml cryovial which 
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contains 900µl freezing medium (30% FBS, 15% DMSO in complete culture media) 
and mixed well. Cells were frozen slowly overnight to -80°C in an isopropanol 
freezing box and then transferred to liquid nitrogen.  
To revive frozen cells, aliquots were thawed rapidly in a 37°C water bath and 
added drop wisely to 50ml thawing medium (50% FBS in complete culture media). 
The cells were pelleted at 1000rpm by centrifugation for 10min to remove the DMSO 
and then resuspended in 10ml complete culture media and transferred to a 75cm2 
tissue culture flask. 
3.2.1.3 Determination of the number of cells 
To determine the number of living cells, the cells were treated with trypsin-EDTA 
as described. An aliquot of cells was stained with Typan-Blue solution and counted in 
a hemocytometer under the microscope. The total number of cells was determined 
from the average number of cells in 4 large squares (each with 16 small squares), the 
factor 104, the dilution factor and the total suspension volume in ml. 
3.2.1.4 Lentiviral vectors production 
Integration proficient and deficient lentiviral vectors (LV) were produced by 
transient co-transfection of packaging plasmid pMDLgag/polRRE (for integration 
proficient LV) or pMDLgag/polintD64VRRE (for integration deficient LV), REV 
expressing plasmid pRSV-REV, envelop plasmid pMD2-VSVG and transgene 
expression vectors on 293T cells. Transfection was mediated by calcium phosphate 
(CaPO4) or polyethylenimine (PEI). The procedure of LV production was performed 
under the biosafety level 2 (S2) conditions. 
3.2.1.5 Calcium phosphate (CaPO4) transfection 
1x107 293T cells were seeded in 15cm cell culture disk one day before 
transfection. 2 hours prior to transfection, 22.5ml fresh growth medium were 
replaced. The DNA premix was prepared by mixing 9µg envelop plasmid, 12.5µg 
packaging plasmid, 6.25µg REV expressing plasmid and 28µg vector plasmid (32µg if 
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the length of transgene greater than 2.8kb) with 1125µl 0.1 x TE/dH2O in a 15ml 
Falcon tube. 125µl 2.5M CaCl2 were added to the DNA premix gently and mixed well. 
After 5min incubation at RT, 1250µl pre-tested 2xHBS with preferred pH value were 
added to DNA premix drop wisely while vortex. The precipitate was added to 293T 
cells immediately. The transfected cells were incubated in 37°C, 5% CO2 and 95% 
humidity conditions. The transfection media were removed and replaced with 16ml 
fresh growth media 12-14 hours post transfection. 24 hours after media change, the 
supernatant were harvested and the cell debris were removed by filtration through a 
0.22µm filter, and then concentrated by ultracentrifugation at 20,000rpm, 20°C for 2 
hours. The virus particles were resuspended by adding 40µl Opti-MEM medium and 
incubated on RT for 20min. 10µl-20µl aliquots were then distributed and stored 
rapidly at -80°C. 
3.2.1.6 Polyethylenimine (PEI) transfection 
The DNA premix of PEI mediated transfection were made by adding the same 
amount of vector DNAs of CaPO4 transfection and 440µl Opti-MEM medium. 180µl 
PEI (PEI:DNA=3:1) were mixed with 320µl Opti-MEM and added to DNA premix, the 
DNA/PEI complexes were incubated at RT for 30min, then added to 293T cells which 
seeded and prepared same to CaPO4 transfection. The following steps remained the 
same to CaPO4 transfection. 
3.2.1.7 Virus titration 
5x104 HeLa cells were seeded in 12-well cell culture plate in IMDM medium 
supplemented with 10% FBS, 4mM L-glutamine, 100µg/ml Pen/Strep one day before. 
A 10-fold dilution series of 2x viral vector stocks were generated at the day of 
titration. Briefly, for concentrated vector stock, 2µl of thawed virus was added to 
1ml IMDM medium (10-3 dilution), further dilutions were achieved by adding 100µl 
of first 10-3 dilution with 900µl IMDM medium, until 10-7 dilution. HeLa cells were 
washed once with PBS and added with 0.5ml IMDM medium with 2x polybrene 
(16µg/ml). After adding 500ml of series dilution of virus stocks to each represent 
wells, HeLa cells were incubated at 37°C, 5% CO2 and 95% humidity for 48 hours (for 
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integration deficient LV) of 72 hours (for integration proficient LV). FACS analyses 
were performed for functional titer using standard protocol for eGFP expression, p24 
ELISA assays were performed for the total particles present in the virus stock. The 
titer of virus stock was calculated using followed formula:  
GFP titer (TU/ml) = (number of cells at the time of vector addition) x (% GFP 
positive cells) x (dilution factor) 
P24 titer (Virus particle/ml) = (pg of P24/0.01) x (dilution factor) 
3.2.1.8 p24 antigen ELISA assay 
The quantity of p24 antigen in lentiviral supernatants was measured using a 
Perkin Elmer HIV-1 p24 antigen assay as per the manufacture’s instruction. 
Supernatants dilutions from 10-5 to 10-7 were added to p24 antibody-coated wells 
together with diluted calibration standards. Samples were lysed, washed and then 
incubated with biotinylated anti-HIV-1. The samples were washed again and 
subsequently incubated with streptavidin-HRPO followed by the addition of 
tetramethybenzidine and stop reagent (4N H2SO4). The absorbance of each plate 
was then read at 490nm and the quantity of p24 reagent calculated from a standard 
curve generated from the diluted calibration standards. 
3.2.1.9 Isolation of hematopoietic progenitors 
Bone marrow was harvested from femurs and tibias of 8-12 week-old C57Bl/6J 
mice sacrificed with cervical dislocation. Hematopoietic progenitors were isolated 
using EasySep Mouse Hematopoietic Progenitor Cell Enrichment Kit of StemCell 
Technologies, according to manufacturer’s recommendation. Briefly, hematopoietic 
stem and progenitor cells from single cell suspensions of bone marrow were isolated 
by negative selection. Unwanted cells are targeted for removal with biotinylated 
antibodies directed against non-hematopoietic stem and progenitor cells (CD5, 
CD11b, CD19, CD45R, 7-4, Ly-6G/C (Gr-1), TER119) and Tetrameric Antibody 
Complexes recognizing biotin and dextran-coated magnetic particles. Labeled cells 
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are separated using an EasySep magnet without the use of columns. Desired cells are 
poured off into a new tube. 
3.2.1.10 Lentiviral transduction in cell lines and primary hematopoietic 
progenitors 
For transduction of cell lines, 1x105 cells were plated in a well of 12-well plate 
with 1ml complete growth medium supplemented with 8µg/ml Polybrene one day 
before. Different MOIs of LV were added into each well the day of transduction. 
Transduction efficiency was monitored by FACS after 72 hours for integration-
proficient lentiviral vectors, and after 48 hours for integration-deficient Lentiviral 
vectors. 
For primary hematopoietic progenitors, 1x105 cells/ml fresh isolated lin- cells was 
seeded in a 96 well-plate with round bottom. The transduction was carried out in 
IMDM medium supplemented with 15% FBS, 100ng/ml rmSCF, 100ng/ml rmFlt3L, 
50ng/ml rmTPO and 4µg/ml Polybrene. MOI of 50 to 100 viruses were loaded into 
each well, and incubated in 37°C, 5% CO2, 95% humidity for 16 to 20 hours.  
3.2.1.11 Hematopoietic progenitors proliferation assay 
After lentiviral transduction, BM cells were then expanded as mass cultures in 
IMDM supplemented with 10% FBS, 100IU/ml penicillin, 100µg/ml streptomycin, 
2mM L-glutamine and 100ng/ml rmSCF, 6ng/ml rmIL-3, 10ng/ml rmIL-6 cytokine 
cocktail. During this time, cell density was adjusted to 5x105 cells/ml every 3 days. 
eGFP positive cells were monitored every week by FACS, and cells number was 
counted after every medium change. 
3.2.1.12 Colony forming cell assay 
For the detection and quantification of mouse hematopoietic progenitors and 
mouse pre-B progenitor cells in BM, 200 and 600 sorted eGFP positive lin- cells after 
lentiviral transduction were plated on 35-mm dishes in a 1.1 ml methylcellulose-
based medium (M3434 for mouse hematopoietic progenitors and M3630 for mouse 
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pre-B progenitors, StemCell Technologies), according to manufacturer’s instruction. 
The plates were then incubated at 37°C, 5% CO2 and 95% humidity for 2 weeks. 
Colonies were counted under inverted light microscope after 14 days. 
 Microbiology methods 3.2.2
3.2.2.1 Growth and maintenance of E.coli 
Escherichia coli (E.coli) were grown in liquid 1 x LB media at 37°C with agitation at 
250rpm or streaked out on solid LB agar plates containing 1.5% bacto agar. E.coli 
transformed with plasmids was grown on the same media supplemented with 
appropriate antibiotics. For long-term storage, bacterial cultures were stored in 25% 
volume for volume (v/v) of glycerol in LB media at -80°C. 
3.2.2.2 Transformation of chemical-competent E.coli 
To transform chemical competent bacteria, chemical competent bacteria were 
slowly thawed on ice and 100pg to 100ng Plasmid DNA were added to each aliquot. 
This mixture was left on ice for thirty minutes. Bacteria were heat shocked for 30sec 
at 42°C and immediately put back on ice for 2min. 250µl of S.O.C medium was added 
and bacteria recovered in a shaking incubator at 37°C for 1 hour. Bacteria were then 
spread on LB agar plates containing the appropriate antibiotics and incubated 
overnight at 37°C. 
 Molecular biology methods 3.2.3
3.2.3.1 Plasmid DNA preparation 
Plasmid DNA samples were prepared using Qiagen Plasmid Purification Kits. 
Small-scale plasmid DNA was extracted from a 4mL bacteria culture grown overnight 
at 37°C using the Qiagen QIAprep Spin Miniprep Kit as per manufacture’s instruction. 
Large-scale plasmid DNA was obtained from 400ml bacteria cultures using a Qiagen 
plasmid high-speed maxi kit or EndoFree plasmid maxi kit, respectively, following the 
manufacture’s instruction.  The procedure is based on alkaline lysis of bacterial cells 
followed by binding of plasmid DNA to the Qiagen Anion-Exchange Resin under low-
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salt and pH conditions. RNA, proteins, dyes, and low-molecular-weight impurities 
were removed by a medium-salt wash. Plasmid DNA was eluted in a high-salt buffer 
and then concentrated and desalted by isopropanol precipitation. The resulting 
plasmid DNA was dissolved in 30µl (Mini prep) or 500μl ddH2O (Maxi prep). 
3.2.3.2 Genomic DNA isolation from cultured cells 
Genomic DNA was isolated from ~ 1x107 cells and purified using High Pure PCR 
Template Preparation Kit (Roche) following the manufacture’s instruction. Cell 
pellets were resuspended in 200µl 1x PBS and lysed with 40µl Proteinase K in 200µl 
Binding Buffer during an incubation period of 10 min at 70°C to directly inactivate all 
nucleases. Following the addition of 100µl isopropanol, the cellular DNA was bound 
to glass fibres pre-packed in the High Pure Purification Filter tube and purified in a 
series of ‘wash and spin’ steps by pipetting either 500µl Inhibitor Removal Buffer and 
500µl Washing Buffer to the upper reservoir of the Filter tube and centrifuge the 
tube for 1min at 8,000 x g to get rid of contaminating cellular components. Finally, 
the purified DNA was recovered by applying three times 50µl ddH2O to the column 
and incubating the ddH2O on the column for 1min at room temperature before 
eluting the DNA by centrifugation for 1 min at 8,000 x g. 
3.2.3.3 RNA preparation 
Total RNA samples were prepared from various cell lines using TRIzol reagent 
following the manufacturer’s instructions. One ml TRIzol was added to 1x107 cells to 
lyse and homogenize the cells. 200µl chloroform were added to the homogenate and 
centrifuged, the upper aqueous phase was transferred to a new tube and total RNA 
was precipitated with 500µl isopropyl alcohol, following one wash with 75% ethanol. 
The RNA pellet was dissolved in Nuclease-free water. RNA was stored at -80°C until 
use. 
3.2.3.4 Spectrophotometric determination of DNA and RNA concentration 
The concentration and quality of DNA and RNA samples were calculated by 
measuring the absorbance of light with a wavelength of 260nm using a NanoDrop 
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ND-1000 spectrophotometer with a 0.2mm path length. Absorbency (optical density) 
of 1.0 of DNA equals a solution containing 50µg of double strand DNA per ml, or 
40ng of RNA, respectively. The ratio of A260/A230 should be arranged between 1.7-
1.9 for DNA samples and 1.9-2.1 for RNA samples.  
3.2.3.5 DNase Treatment of RNA samples 
After RNA preparation, 1/10 volume of the reaction buffer and 0.1U/µl TURBO 
DNase were added to the RNA solution, incubated at 37°C for 30min. Then, 1/10 
volume of DNase remove reagent was pipetted into the reaction mixture, incubated 
for 2min at RT, centrifuged, and the upper aqueous phase which contains pure RNA 
samples was transferred into a new RNase-free tube.  
3.2.3.6 Cloning 
3.2.3.6.1 Restriction enzyme digestion 
Plasmid DNA (typically 1-2μg) was digested in a final volume of 50μl of 1x buffer 
(supplied by the manufacturer) and bovine serum albumin (0.1mg/ml). The amount 
of enzyme used varied depending of the concentration of the enzyme stock and the 
amount of DNA, but never exceeded 10% (v/v) of the total reaction volume. The 
endonuclease reaction was carried out at the manufacturer’s recommended 
temperature for 1 hour and DNA digestion was verified by agarose gel 
electrophoresis. Double or triple digestions were performed either in compatible 
buffers or sequentially, after clean-up of DNA by ethanol precipitation using the 
QIAquick PCR purification kit by following the manufacturer’s protocol. 
3.2.3.6.2 Polymerase Chain Reaction (PCR) 
Invented in 1983 by Mullis and co-workers, PCR is a standard technique for in 
vitro enzymatic amplification of a specific segment of DNA. PCR reaction mixtures 
were set up using disposable tips containing hydrophobic filter with the aim to 
minimize cross-contamination. Per 50μl PCR reaction, template DNA (≤1μg/reaction) 
was pipetted with a master mix consisting of 5μl of 10x PCR buffer (Qiagen), 1μl of 
deoxyribonucleoside triphosphates (dNTPs, 10mM each), 1μl of each forward and 
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reverse primer (10pmol each), and variable amount of ddH2O to give a final volume 
of 50μl mixture. A negative control without template DNA was included. The 
amplification was performed in a PCR thermal cycler using relatively cycling program 
optimized for each target and primer pair. In most cases, the amplification reaction 
was started by an initial denaturation at 95°C for 2min, followed by 25 to 35 cycles of 
denaturation at 95°C for 45sec, annealing at 56°C to 60°C for 45sec and extension at 
72°C for 1min, with a final extension step at 72°C for 4min. PCR products were 
separated by electrophoresis on 0.8-2% agarose gels stained with ethidium bromide. 
3.2.3.6.3 DNA agarose gel electrophoresis 
DNA fragments were resolved by electrophoresis through 0.8-2% agarose gels in 
1 x TAE buffer or TBE buffer. To prepare the gels, agarose was dissolved in 1xTAE 
buffer by boiling in a microwave. After cooling, ethidium bromide was added (to 
obtain a final concentration of 0.5g/ml) for visualization of DNA. DNA samples were 
mixed with DNA loading buffer before loading onto agarose gels. 5µl 1kb plus DNA 
ladder or 100bp DNA ladder was included in each gel to enable size determination of 
DNA fragments. Gels were electrophoresed using a voltage of 100-130V (up to 
150mA) and the separated DNA fragments subsequently visualized by exposure to 
ultra-violet light using PeqLab gel documentation system. 
3.2.3.6.4 Extraction of DNA fragments 
Following electrophoresis, DNA fragments were excised from agarose gels using 
a clean scalpel blade under ultra-violet light. The DNA was then extracted from the 
agarose using a QIAquick gel extraction kit as the manufacturer’s instructions. 
3.2.3.6.5 Ligation of DNA fragments 
When the digested vector DNA ends had compatible termini with the insert DNA, 
the digested plasmid vector DNA was treated with calf intestinal alkaline 
phosphatase (CIAP) to dephosphorylate the DNA ends prior to ligation. 
Dephosphorylation reactions were performed directly in restriction endonuclease 
buffers, immediately following digestion by adding 10 units of CIAP enzyme to the 
reaction mixture and incubating at 37°C for one extra hour. Ligation of DNA 
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fragments were performed using vector to insert ratios of 1:3 (v/v) in a final volume 
of 10μl of 1 x T4 DNA Ligase buffer containing 1 unit of T4 DNA Ligase. The vector 
DNA concentration used was typically 20-50ng of DNA. Ligation reactions were 
incubated overnight at room temperature or 16°C. The ligation reactions were either 
immediately transformed into E.coli or stored at -20°C for later use. 
3.2.3.7 Reverse transcription PCR (RT-PCR) 
3.2.3.7.1 First strand cDNA synthesis for RT-PCR 
First strand cDNA was synthesized using SuperScript III First-Strand Synthesis 
System for RT-PCR. For each reaction, 0.5-1.0μg total RNA were mixed with 1μl of 
100μM oligo(dT)18 primers, 1μl of 10mM dNTP and distilled water to 12μl, 
denatured at 65°C for 5min and then chilled on ice. Then 4μl of 5x First-Strand Buffer, 
2μl of 0.1M DTT, and 1μl of RNase Block were added and mixed well. The mixtures 
were incubated at 42°C for 2min, 1μl of SuperScript III reverse transcriptase was 
added and mixed by pippetting. Mix contents were incubated at 42°C for 50min, 
then enzymes were inactivated at 70°C for 15min and the mixtures were cooled 
down to 4°C. Synthesized cDNAs were stored at -20°C. 
3.2.3.7.2 Two-step RT-PCR 
To verify transgene expression mediated by lentiviral vectors in transduced cell 
lines, 2µl first strand cDNA was used as template for transgene expression detection. 
The samples which synthesized without adding the reverse transcriptase for 
detecting the cross over genomic DNA contamination (here referred to non-RT 
control NRT) and DNase and RNase free H2O were used as negative control (NC), as 
well as the GAPDH primer pairs were used in positive control samples. PCR 
amplification was performed as described in 50µl reaction volume containing primer 
pairs for gene of interested for 25 cycles. 
3.2.3.7.3 One-step RT-PCR 
To avoid the cross over contamination in the two-step RT-PCR, both cDNA 
synthesis and PCR amplification were performed in a single tube using SuperScript III 
One-Step RT-PCR System with Platinum Taq DNA Polymerase. cDNA synthesis was 
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performed by 1 cycle at 50°C for 30min. Amplification was carried out by 
denaturation at 94°C for 15sec (2 min in the first cycle), annealing at 56°C for 30sec, 
and extension at 68°C for 1min (5min in the last cycle) for 25 to 30 cycles. 
3.2.3.8 Site directed mutagenesis 
To repair the mismatched nucleotides in plasmid DNA, Site directed mutagenesis 
was performed using the Quickchange II XL site-directed mutagenesis kit from 
stratagene. The primer design was performed according to the manufacturer 
directions. The PCR reaction was performed in a total volume of 50μl, containing a 
total of 100ng of template DNA, buffer (1x), 10pmol of primer forward and primer 
reverse, 1μl of dNTP mix, 3μL of quick solution reagent and 2.5U of Pfu Turbo DNA 
polymerase. All reactions followed the thermal cycling parameters: 1min at 95°C 
followed by 16 cycles of 30sec at 95°C, 1min at 55°C and 11min at 68°C. After the 
PCR reaction, the parental DNA was digested with Dpn I enzyme for 3 hours. The 
resulting DNA was then transformed in chemical competent bacteria. DNA was 
extracted from single clones and sequenced to confirm correct mutagenesis. 
 Integration site analysis by linear amplification mediated PCR 3.2.4
To characterize the physiology of the gene-modified hematopoietic repopulation 
and the vector-related influences on clonal contribution, the highly sensitive linear 
amplification-mediated polymerase chain reaction (LAM-PCR) was performed as 
previously. Using this method it is possible to amplify vector-genome junctions. The 
initial linear PCR with 5’ biotinylated primers hybridizing to the U3- and/ or U5 region 
of the vector LTR facilitates the pre-amplification of the vector genome junctions. 
Magnetic capture of the amplified biotinylated target DNA on streptavidin-coupled 
paramagnetic beads allows enrichment of the target DNA. The following steps are 
carried out on the semisolid streptavidin phase. After a hexanucleotide primed 
double strand synthesis using the Klenow-Polymerase and a restriction digest, a 
restriction site complementary linker cassette of known sequence is ligated on the 
genomic end of the fragments. Subsequently, the non-biotinylated strands are 
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separated from the biotinylated strands in an alkaline denaturation step and 
amplified in two nested PCR reactions with linker- and vector-specific primers. 
 
Figure 3-1 Schematic outline of LAM-PCR to amplify 5'-LTR retroviral vector-genomic fusion sequences 
(Schmidt et al., 2007). 
3.2.4.1 Linear PCR 
For detection of lentiviral integration sites, DNA was extracted and pre-amplified 
by repeated primer extension using vector-specific 5’ biotinylated primers. 
Depending on the transduction efficiency and the available amount of template DNA, 
between 100ng and 500ng DNA sample were applied in 2 rounds of a 50-cycle linear 
PCR reaction using 5’ biotinylated primers. 1.67nM of a 5’ biotinylated primer is 
applied to the linear amplification reaction, if one vector-specific LTR primer is used, 
whereas 0.83nM of a 5’ biotinylated primer is added in case of two vector-specific 
LTR primers.  The amplification was performed using one initial denaturation cycle of 
95°C for 2min, followed by 50 cycles of 95°C for 45sec, 60°C for 45sec and 72°C for 
1min. After the first 50 cycles of the PCR, 0.5µl (2.5U) Taq polymerase were added 
and a second 50-cycle amplification was carried out using the same PCR program.  
3.2.4.2 Magnetic Capture 
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200µg of magnetic beads per reaction were exposed for 60sec on a magnetic 
particle concentrator (MPC) and the supernatant was discarded. The beads were 
resuspended in 40µl PBS containing 0.1% BSA, exposed to the MPC and the 
supernatant discarded. This step was repeated once. Following a washing step with 
20µl 3M LiCl buffer, the beads were resuspended in 50µl of 6M LiCl buffer. The 
magnetic bead solution was transferred with a ratio of volumes 1:1 (50µl:50µl) to 
the reaction tube containing the linear PCR product. The samples were incubated ON 
at RT on a horizontal shaker at 300rpm to link the biotinylated PCR products to 
streptavidin-coupled beads, which termed as DNA-bead complexes in the following 
chapters. 
3.2.4.3 Hexanucleotide Priming 
After overnight incubation, the DNA-bead complexes were collected on an MPC 
for 60sec, the supernatant discarded and once washed in 100µl ddH2O. The DNA-
bead complexes then were resuspended in 20µl hexanucleotide priming mixture 
containing 1 x hexanucleotide mixture, 200µM dNTPs and 2U klenow enzyme. The 
reaction was incubated at 37°C for exact 1 hour in a thermo cycler to generate 
double strand DNA. 
3.2.4.4 Restriction Digest 
80µl of ddH2O was added to the hexanucleotide priming mixture and once 
washed in 100µl ddH2O. The DNA-bead complexes were resuspended in 20µl 
restriction digest mixture containing 1 x restriction enzyme buffer, 1U restriction 
enzyme and 1 x BSA if needed. The restriction enzyme was chosen in a way that no 
restriction site was located within the known sequence of interest/the amplified part 
of the vector. The restriction digest mixture was incubated at the temperature 
recommended by the manufacturer to achieve maximum enzyme activity for 1 hour 
in a thermo cycler. 
3.2.4.5 Linker Cassette Ligation 
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To ligate a known oligonucleotide sequence to the unknown flanking sequence, 
the DNA-bead complexes were washed and resuspended in 100µl ddH2O, and then 
100pmol of a double-stranded asymmetric linker cassette and Fast-link ligase (2U) 
were applied to the beads and incubate at room temperature for 5min.  
3.2.4.6 Generation of a Linker Cassette 
To generate a unidirectional double-stranded linker cassette, oligonucleotides 
were used which form overhangs after their hybridization complementary to the 
emerging overhangs of the restriction enzyme used in the LAM-PCR. 40µl 
100pmol/µl primer LC1, 40µl 100pmol/µl enzyme depended LC3 primer, 110µl 
250mM Tris-HCl (pH7.5) and 10µl 100mM MgCl2 incubated at 95°C for 5min in a 
heating block and followed by cooling down the reaction mixture overnight in the 
heating block. The next day, 300µl ddH2O were added to the linker cassette 
formation reaction and transferred on a Microcon-30 column. The sample was 
concentrated by centrifugation at 12,600rpm for 12min. To elute the linker cassette, 
10µl ddH2O was applied to the column and the reversed column placed onto a clean 
tube was centrifuged at 3,600rpm for 3min. The volume of the concentrated sample 
was adjusted with ddH2O to a final volume of 80µl and frozen in small aliquots at -
20°C to thaw the linker cassette only once. 
3.2.4.7 Alkaline Denaturation 
After 90µl ddH2O was added to the ligation reaction, the DNA-bead complexes 
were exposed to an MPC and the supernatant was discarded. Following a washing 
step with 100µl of ddH2O, the beads were resuspended in 5µl of fresh 0.1 N NaOH 
and the denaturation reaction was incubated for 10 min at room temperature on a 
horizontal shaker at 300rpm. The DNA-bead complexes were collected using an MPC 
and the supernatant that contained the non-biotinylated ssDNA was transferred to a 
fresh 0.5ml reaction tube. 2µl of the supernatant (ssDNA/ NaOH fraction) were 
applied as template for the 1st exponential PCR reaction. 
3.2.4.8 Exponential PCRs 
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Both exponential PCRs were accomplished with nested vector- and linker 
cassette (LC)-specific primers. In the first exponential amplification of the vector-
genome junctions, a 5’/3’ biotinylated vector-specific LTR primer was used in 
conjunction with the linker cassette primer LCI. After an additional magnetic capture 
purification step, 2% of the 1st PCR product served as template for a 2nd nested 
exponential PCR with the linker cassette primer LCII and a 5’/3’ vector-specific LTR 
primer.  
3.2.4.9 Magnetic Capture after 1st Exponential PCR 
200µg of magnetic beads per reaction were exposed for 60sec on an MPC and 
the supernatant was discarded. The beads were washed twice with 40µl of PBS 
supplemented with 0.1% BSA. Following a washing step with 20µl 3M LiCl buffer, the 
beads were resuspended in 20µl of 6M LiCl buffer. 20µl of the 1st expo PCR product 
was then incubated with 20µl of the magnetic bead solution for 1h at RT on a 
horizontal shaker at 300rpm. 60µl ddH2O was added to the reaction, the DNA-bead 
complexes were collected using an MPC and the supernatant discarded. Following 
two washing step of the DNA-bead complexes with 100µl of ddH2O, the beads were 
resuspended in 10µl of fresh 0.1N NaOH and the denaturation reaction was 
incubated for 10min at RT on a horizontal shaker at 300rpm. The DNA-bead 
complexes were exposed to an MPC and the supernatant containing the non-
biotinylated ssDNA was transferred to a fresh 0.5ml reaction tube. 1µl of the 
supernatant (ssDNA/ NaOH fraction) was applied as template for the 2nd exponential 
PCR reaction. 
 Integration Site Analysis by non-restrictive LAM- PCR 3.2.5
All currently used integration site analysis methods rely on the use of restriction 
enzymes. Dependent on the distance between the vector integration site and 
recognition sequence of the enzyme used, each restriction motif introduces an 
integration site detection bias. Therefore, we developed the non-restrictive (nr) 
LAM-PCR in our group which is capable of covering all accessible integrant locations 
without the use of restriction enzymes. The linear PCR using biotinylated LTR primers 
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allows the initial pre-amplification of the vector-genome junctions. After removal of 
non-target DNA via magnetic selection, an ssDNA linker is ligated to the unknown 
genomic part of the ssPCR product, allowing its subsequent exponential 
amplification by nested PCRs. 
3.2.5.1 Linear PCR (nrLAM-PCR) 
200ng-1µg DNA was amplified using LTR-specific biotinylated primers that are 
identical to those used in the LAM-PCR approach. After the first 50-cycles of linear 
PCR, 0.5µl (2.5U) Taq polymerase were added per sample and a second 50-cycle 
amplification using the same program was carried out.  
3.2.5.2 Magnetic Capture (nrLAM-PCR) 
PCR products were subsequently purified with Microcon YM-50 to remove DNA 
fragments smaller than 125 nucleotides. The volume of each PCR sample was 
adjusted with ddH2O to a final volume of 500µl, transferred on an YM-50 column and 
centrifuged at 12,600rpm for 12min. To elute the concentrated PCR product samples, 
10µl ddH2O was applied to the column, the reversed column placed onto a clean 
tube was centrifuged at 3,600rpm for 3min and ddH2O was added to a final volume 
of 50µl. Selection of the biotinylated extension products was performed with 200µg 
of magnetic beads as described. The DNA-beads complexes were transferred into a 
96-well plate and incubated at room temperature on a horizontal shaker at 300rpm 
for 2 hours. 
3.2.5.3 Ligation of the Single-Stranded Linker Cassette (nrLAM-PCR) 
The DNA-beads complexes were exposed to an MPC, the supernatant discarded 
and washed once with 100µl ddH2O. Following resuspension of the beads in 10µl T4-
RNA-ligase mixture (20U T4 RNA-ligase, 100pmol LC1-rev, 5µl 50% PEG 8000 and 
1mM Hexamin-CoCl2), the reaction mixture was incubated ON at RT on a horizontal 
shaker to allow direct ligation of a single-stranded linker DNA to the unknown 
genomic end of the amplicon. 
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3.2.5.4 Exponential PCRs (nrLAM-PCR) 
The following day, direct amplification of the linker ligated ssDNA was performed. 
First, 90µl ddH2O was added to the DNA-bead complexes and washed once with 
100µl ddH2O. Following resuspension of the DNA-bead complexes in 10µl ddH2O, 2µl 
of this suspension were directly applied to the 1st exponential PCR. After additional 
magnetic capture purification step as described above, 4% (2µl) of the 1st 
exponential PCR product served as template for a 2nd nested exponential PCR. In 
contrast to the 1st exponential PCR, the 2nd exponential PCR was completed with a 
final elongation step at 72°C for 2min. According to standard LAM-PCR, the same 
primers were used to perform the two exponential PCRs  
 Purification and Concentration of PCR Products 3.2.6
The LAM-PCR and nrLAM-PCR amplicons were purified with QIAquick PCR 
Purification Kit (Qiagen) following the manufacturer’s instruction to sequence the 
vector genome junctions by either Sanger or 454 sequencing technology or both. 
Therefore, 5 volumes of Buffer PB were added to 1 volume of the PCR sample (e.g. 
add 200µl PB buffer to 40µl PCR product), mixed thoroughly and transferred to the 
QIAquick column to bind DNA. Following centrifugation at 13,000rpm for 1min, the 
flow-through was discarded and the samples were washed twice with 750µl of a 35% 
guanidine hydrochloride solution (v/v) and once with 750µl Buffer PE. After an 
additional centrifugation step for 1min at 13,000rpm to remove residual ethanol 
from the Buffer PE, the DNA was eluted into a clean 1.5ml tube by applying 30µl 
ddH2O to the center of the QIAquick membrane, letting the column stand for 1min 
before centrifugation for 1min at 13000rpm. 
PCR products were purified with High Pure PCR Product Purification Kit (Roche) 
following the manufacturer’s recommendation to further create the standard curve 
for the LightCycler480 system. After PCR amplification the total volume for each PCR 
sample is adjusted with ddH2O to 100µl. Following addition of 500µl Binding Buffer, 
the sample is transferred to the upper reservoir of the Filter Tube, centrifuged at 
13,000rpm for 1min and the flow-through discarded. The samples were washed 
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twice with 500µl and 200µl Wash Buffer to ensure optimal purity before eluting the 
DNA into a clean 1.5 ml tube with 30µl Elution Buffer. 
To purify and concentrate PCR products, Microcon YM-50 was used. The volume 
of the PCR products was adjusted with ddH2O to a final volume of 500µl, transferred 
on an YM-50 column and centrifuged at 12,600rpm for 12min. To elute the 
concentrated PCR product samples, 10µl ddH2O was applied to the column and the 
reversed column placed onto a clean tube was centrifuged at 3,600rpm for 3min. 
ddH2O was added to a final volume of 15.5µl. 
 Sequencing 3.2.7
Incipiently, LAM-PCR /nr LAM-PCR products were purified, shotgun cloned into 
TOPO TA vector, transformed into competent cells, colonies picked and sequenced 
using the Sanger method. Nowadays, the LAM-PCR amplicons were purified and 
prepared for the 454 pyrosequencing technology which is performed either at GATC 
(Konstanz, Germany) or at the Genomics and Proteomics Core Facility (DKFZ, 
Heidelberg, Germany). 
3.2.7.1 TOPO TA Cloning - Preparation for Sanger Sequencing Method 
Cloning of the purified LAM-PCR/ nrLAM-PCR products was performed using 
TOPO TA Cloning Kit. 4µl of the purified PCR products was added to a mixture 
containing 1µl salt solution, 0.7µl TOPO vector and 0.3µl ddH2O and incubated at RT 
for 4 ½min before stop on ice. For each transformation, one vial (50µl) of One Shot 
TOP10 chemically competent cells were thawed on ice, added to 3µl of the ligation 
reaction and incubated on ice for 30 min. Following heat-shock for 30 s at 42°C, the 
reaction was stopped on ice; 250µl S.O.C medium was added and shaked at 37°C for 
1h at 300rpm. 75µl from each transformation was spread on pre-warmed LB-agar 
plates containing 50µg/µl Kanamycin and 40µl X-gal (40mg/ml) selective LB-plate 
and incubated overnight at 37°C. The next day, white colonies of the Blue/White 
selection system were picked into 96-well plates (one colony per well) which 
contained LB soft-agar and sent for sequencing to GATC (Konstanz, Germany). 
Materials and Methods  Wei Wang 
66 
 
3.2.7.2 Pyrosequencing Using the 454 GS Flx Platform (Roche) 
DNA-sample preparation of the final LAM-PCR and/or nrLAM-PCR amplicons 
were performed as suggested by the manufacturer, consisting of an additional PCR 
amplification reaction with special Fusion Primers. Primer design was done as 
recommended by 454 Life Science (Roche). In brief, the fusion primers (FuP) consist 
of a 20-25bp linker or LTR specific sequence. In addition to a 19bp fixed sequence at 
the 5’ end, the vector-specific LTR primer contains an individual recognition 
sequence (barcode) of 2 to 6 bases at the 3’end. The individual barcodes differ in at 
least 2bp to exclude misinterpretation of the data due to sequencing mistakes. 
Primer FuP-A was fused to a vector-specific LTR primer and primer FuP-B was fused 
to a linker-specific primer. The unique barcodes in the LTR-specific FuP-A allow the 
parallel analysis of various samples in a single sequencing run. Having purified the 
LAM-PCR/ nrLAM-PCR amplicons with the PCR purification Kit according to the 
manufacturer’s description (Qiagen Kit) including a guanidine hydrochloride step, 
40ng DNA were amplified in 12-PCR cycles with the special Fusion primers (linker and 
LTR, 10pmol/µl each). After a second PCR purification, DNA concentration was 
measured photometrical by Nanodrop and then subjected to pyrosequencing as 
implemented by 454 Life Sciences. 454 pyrosequencing was performed either at 
GATC (Konstanz, Germany) or at the Genomics and Proteomics Core Facility (DKFZ, 
Heidelberg, Germany). 
3.2.7.3 Sequence Analysis 
Originally, the sequencing results were trimmed manually by eliminating 
sequences derived from the linker cassette, the viral vector and/ or the plasmid used 
for sequencing (Lasergene software). After the alignment of the trimmed sequences 
(Lasergene software), the genomic consensus sequences were aligned to the mouse 
genome (assembly July 2007, NCBI37/mm9) using University of California, Santa Cruz 
(UCSC) BLAT genome browser  
For a faster and more efficient analysis of huge data volumes, our group 
established a bioinformatics program. This program allows the analysis of 
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untrimmed and trimmed integration site sequences and also allows alignment of the 
genomic sequences of the vector-genome junction to the human genome using BLAT. 
Information as the sequence count (retrieval frequency; frequency of mappable 
integration sites), genomic length, span, identity, chromosome, integration locus, 
vector orientation in the genome, distance to the next RefSeq gene or in the gene to 
the TSS, intron/exon, gene length, RefSeq ID and missing LTR bases is analyzed and 
exported to an excel sheet for further analysis. Integration sites were judged to be 
authentic if the sequences began within 3bp of vector LTR ends, had either a >95% 
sequence match or no more than one base mismatch if the read length was <50bp, 
and had a unique best hit when aligned to the human genome using BLAT.  
 Quantitative real time PCR 3.2.8
Absolute quantitative real-time PCR was performed to detect and quantify the 
copy number of IDLV and LV in transduced samples. 2µg plasmid DNA of pCCL 
pptSFFV-IRES-GFP-PRE vector was linearized by EcoRV digestion and purified using 
High Pure PCR product purification kit. The concentration of purified linearized 
plasmid DNA was determined by Nanodrop spectrophotometer. A series of 10-fold 
dilutions in 20ng/µl MS2 RNA, starting at 2 x 1010 down to 2 x 10-1 copies/ 5µl were 
made for standard curve. PCR product was amplified by the complementary primers 
to WPRE sequence. For negative controls, 5µl H20 and 5µl genomic DNA from 
untransduced cells were used. The amplification was performed using one cycle of 
95°C for 10min, followed by 50 cycles of 95°C for 10sec, 56°C for 5sec and 72°C for 
25sec in Roche Light Cycler 480 with SYBR Green I Master Mix. The average of 
integrated viral vectors number in analyzed was estimated by interpolation the 
WPRE copies form each DNA sample in the standard curve. 
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4. Results 
4.1 MDS1/EVI1 and PRDM16 are preferred gamma-retroviral 
integration loci in Wiskott-Aldrich syndrome clinical gene 
therapy 
In the first gamma-retroviral clinical gene therapy trial for WAS, which was 
conducted and accomplished in Hannover medical school, leading by Prof. Dr. 
Christoph Klein and colleagues, 9 of 10 young patients were successfully treated with 
HSC gene therapy. Unfortunately, 3 patients developed T-cell acute lymphoblastic 
leukemia related to LMO2 integrations. Samples from the first 2 treated patients 
were analyzed and reported in this dissertation. 
Autologous CD34+ HSCs were collected by leukapheresis and then transduced 
with WASP-expressing gamma-retroviral vectors derived from MFG Moloney murine 
leukemia virus (CMMP) and pseudotyped with gibbon ape leukemia virus (GALV) 
envelope protein. The transduced cells were then reinfused 4 days later after 
myeloablation with busulfan conditioning. After gene therapy, sustained expression 
of WAS protein in HSC, lymphoid and myeloid cells, as well as platelets were found. T 
and B cells, nature killer (NK) cells, and monocytes were functionally corrected. After 
treatment, the patients’ clinical condition markedly improved, with resolution of 
hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe 
infection (Boztug et al., 2010). 
 Clonality analysis of gene-modified cells 4.1.1
Almost 2.5 years after gene therapy, there were no morphologic or cytogenetic 
aberrations observed in patients’ BM aspirates. Large-scale analysis of retroviral 
vector insertions sites (RISs) with LAM PCR combined with 454 pyrosequencing was 
performed to monitor the clonal distribution and fate of gene-corrected cells in vivo. 
In both patients, a sustained highly polyclonal reconstitution pattern was 
demonstrated in BM cells, primary blood leukocytes, sorted lymphoid CD3+ T cells, 
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as well as myeloid CD15+ granulocytes (Figure 4-1, A and B). 5709 unique RISs (in 
Patient 1) and 9538 unique RISs (in Patient 2) were retrieved and could be mapped 
to a single position in the human genome. Vector integration occurred preferentially 
in the vicinity of transcription start sites and into gene coding regions of the human 
genome, reflecting a typical gammaretroviral target-site distribution (Boztug et al., 
2010). 
As the LAM-PCR approach relies on the use of restriction enzymes and thus only 
allows the identification of a certain fraction of genomic integration sites, in this 
thesis the patient samples were additionally analyzed by non-restrictive (nr) LAM-
PCR, which was newly developed in our group, for less sensitive but more unbiased 
retrieval of insertion sites.  The nrLAM-PCR allows us to retrieve and identify the 
retroviral integration sites genome-widely in a single reaction, circumventing the 
detection bias accompanied by methods dependent on restriction enzymes (Gabriel 
et al., 2009; Paruzynski et al., 2010). Standard LAM-PCR produces amplicons of a 
defined length for each vector-genome junction, whereas nrLAM-PCR results in a 
variety of amplicon lengths for each insertion, appearing as a ‘smear’ on 
electrophoresis (Figure 4-1, C). 
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Figure 4-1(nr)LAM-PCR analysis of vector integrants. RISs were detected in tranduced hematopoietic cells at 
various days after gene therapy from BM cells and primary blood leukocytes obtained from Patient 1 (A) and 2 (B) 
using conventional LAM-PCR (Boztug et al., 2010) and non-restrictive LAM-PCR (C). CD3 denotes sorted T cells, 
CD15 sorted granulocytes, Ctl: healthy control subject, IC: internal vector control and M 100-bp marker. 
Multiplex Barcoding of LAM-PCR samples together with downstream 
bioinformatical analysis of up to 1 million reads generated in one deep sequencing 
run enables analyzing over hundred thousand RISs in multiple samples at the same 
time (Paruzynski et al., 2010). This technique allows us to semi-quantitatively analyze 
the insertion sites, which represent unique molecular identities of particular marked 
clones in a certain sample, and to monitor clonal progeny and dynamics in 
hematopoiesis. In the WAS study, the abundance of individual gene-corrected cells 
and their clonal progeny in the hematopoietic system was estimated by the retrieval 
frequency of individual RIS sequences generated by deep sequencing. The presence 
of individual gene corrected cells is given as the percentage of all LAM-PCR amplicon 
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sequence reads identified in a particular sample. The 10 most frequently sequenced 
RISs were ranked from 1 to 10 according to retrieval frequency. In both patients, 
several clones appeared repeatedly within the 10 most abundant clones in each 
analyzed time point, including PRDM16, MDS1/EVI1, CCND2,  and LMO2 containing 
clones, indicating that clonal skewing had emerged among active hematopoietic 
gene-corrected clones (Boztug et al., 2010). 
 Distribution of integration events in MDS1/EVI1 and PRDM16 4.1.2
loci in patients over time 
To analyze the long-term impact of MDS1/EVI1 and PRDM16 retroviral 
integration sites in hematopoietic stem cell lineages, MDS1/EVI1 and PRDM16 loci as 
vector genome adjunction are monitored and analyzed by LAM-PCR prospectively 
more than two years after gene therapy. For this, the specific MDS1/EVI1 and 
PRDM16 IS identified by LAM-PCR (Boztug et al., 2010) were further analyzed with 
the nrLAM-PCR data generated in this thesis. In both patients, the same multiple 
vector targeted genes that were previously found to expand clones in gene-
corrected myelopoiesis (MDS1/EVI1, PRDM16, and SETBP1) and lymphopoiesis 
(LMO2, CCND2, and BMI1) were noted. The most active cell clone in Patient 1 
showed a vector integrant upstream of CCND2, and in Patient 2, the site of insertion 
was MDS1/EVI1. Although MDS1/EVI1 and PRDM16 loci were evaluated as common 
insertion sites (CIS) in this study, gene-modified clones containing insertions in 
MDS1/EVI1 and PRDM16 exhibited and remained constantly lower than 7% of the 
whole population (Figure 4-2, A and B)(Boztug et al., 2010). Similar results were 
observed in this thesis with nrLAM-PCR analyzed samples: although MDS1/EVI1 and 
PRDM16 containing clones were overrepresented in those 2 patients over time, 
there was no obvious clonal expansion accounted for these clones. The proportion of 
those MDS1/EVI1 and PRDM16 containing clones in whole BM and PBC samples 
remained constantly below than 8%. These results were different compared to the 
recent X-CGD study, in which patient clones showed in vivo clonal expansion after 
gene therapy. This expansion of vector marked cells was completely accounted for 
vector-containing clones with insertions in three gene complexes: MDS1/EVI1, 
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PRDM16 and SETBP1. No sign of hematopoietic clone expansion related to 
MDS1/EVI1 and PRDM16 containing clones was observed so far in the WAS study.  
 
Figure 4-2 Relative clonal contribution of MDS1/EVI1 and PRDM16 containing clones in bone marrow and 
peripheral blood leukocytes samples of Patient 1 and 2 analyzed by LAM-PCR (A, B) (Boztug et al., 2010) and 
nrLAM-PCR (C, D) over time. 
Further, the contribution of MDS1/EVI1 and PRDM16 containing clones to 
hematopoiesis lineage reconstitution and differentiation, sorted myeloid (CD15+) 
and lymphoid (CD3+) lineages were analyzed by LAM-PCR. MDS1/EVI1 and PRDM16 
containing clones were slightly restricted in the myeloid compartment of 
reconstituted hematopoiesis in both patients (Boztug et al., 2010). In patient 1, 
MDS1/EVI1 and PRDM16 containing clones were exclusively appeared in CD15+ 
myeloid compartment; few MDS1/EVI1 and PRDM16 containing clones could be also 
detected in CD3+ lymphocytes in patient 2. One particular MDS1/EVI1 containing 
clone 169071575 began to increase its frequency of whole CIS in granulocytes 
compartment over time. In contrast, LMO2 and CCND2 containing clones were 
almost exclusively restricted to lymphocytes in both patients (Boztug et al., 2010). 
Retroviral insertion sites that were identical between sorted lymphoid or myeloid 
cell fractions were also retrieved from both patients. This indicated the 
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hematopoietic stem cells or progenitor cells with multilineage capacity were initially 
transduced by retroviral vectors. 
 Short summary of this section  4.1.3
To analyze the long-term impact of MDS1/EVI1 and PRDM16 retroviral 
integration sites in hematopoietic stem cell lineages, MDS1/EVI1 and PRDM16 loci as 
vector genome adjunction are monitored and analyzed by (nr)LAM-PCR 
prospectively more than two years after gene therapy. Vector insertion sites analysis 
of peripheral blood and bone marrow samples demonstrated sustained highly 
polyclonal reconstitution over time, although MDS1/EVI1 and PRDM16 loci were 
evaluated as common insertion site (CIS) in this study. Gene-modified clones 
containing the insertion of MDS1/EVI1 and PRDM16 exhibited only very small 
proportion and remained constantly low level of the whole population. In sorted 
myeloid (CD15+) and lymphoid (CD3+) lineages, MDS1/EVI1 and PRDM16 containing 
clones were slightly restricted in the myeloid compartment of reconstituted 
hematopoiesis in both patients. The vector integration pattern remained highly 
polyclonal and no obvious clonal dominance related to MDS1/EVI1 and PRDM16 
containing clones have been observed after two years of gene therapy. Prospective 
monitoring for signs of clonal dominance in gene-corrected hematopoiesis will 
continue in both patients. 
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4.2 Influences of Mds1/Evi1 and Prdm16 in long-term 
repopulating hematopoietic stem cells 
We have introduced the concept of measuring physiological and aberrant clonal 
contributions of stem and progenitor cells to complex configurations of the 
peripheral blood by using highly sensitive and specific retrovirus integration site (RIS) 
analysis of gene marked cells. This approach has enabled us to decipher clonal 
contributions not only in mouse models, but also in large animals and clinical gene 
transfer studies, providing access to a new quality of clonal contribution data, and 
thereby progress in understanding human hematopoiesis.  
To monitor clonal contribution and to study the hypothesis that biological side 
effects of vector insertion might confer a cells selection advantage to affected cells in 
vivo, we have performed a large-scale mapping of RIS in a clinical trial using HSCs 
directed gene therapy to treat X-linked chronic granulomatous disease (X-CGD, see 
introduction). 5 months after transplantation and recovery of marrow function, we 
observed that RIS distribution became non-random and that vector insertional 
activation of MDS1/EVI1, PRDM16 and SETBP1 triggered a 3- to 5- fold expansion of 
the transduced cell pool, leading to a sustained long-term transgene expression for 
the following 1.5 years, before turning into malignant transformation. Thus, studies 
on the influence of Mds1/Evi1 and Prdm16 gene expression on morphologically 
normal hematopoiesis was followed in this thesis.  
 The MDS1/EVI1 and PRDM16 genomic locus and its gene 4.2.1
products 
The EVI1 genomic locus was initially identified as a retrovirus integration site in 
AKXD murine myeloid tumors (Mucenski et al., 1988). The human homolog was then 
localized to chromosome 3 band q26 (Morishita et al., 1990). The murine and human 
EVI1 complementary DNAs are highly homologous in nucleotide and amino acid 
sequence. The human EVI1 gene spans 60kb and contains 12 exons (Figure 4-3, A), 
capable of generating multiple alternative 5-mRNA variants and several alternatively 
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spliced transcripts (Wieser, 2007). The human MDS1 gene was first identified as a 
component of the AML1-MDS1-EVI1 translocation 3;21 found in some spontaneous 
human myeloid leukemias (Fears et al., 1996). MDS1 spans 500 kb, contains five 
exons, three coding, and is located 3 kb apart to the first exon of EVI1 (Figure 4-3, A). 
Transcripts are produced that contain only EVI1 exons, only MDS1 exons, or an 
alternatively spliced product containing the first two exons of MDS1 fused to exon 2 
and all remaining exons of EVI1 (Figure 4-3, A). This fusion gene product is expressed 
in both normal and leukemic tissues (Fears et al., 1996). Both MDS1/EVI1 transcripts 
and EVI1 transcripts are more abundant than the MDS1 transcripts, and in most 
tissues MDS1/EVI1 and EVI1 transcripts are coordinately regulated (Wimmer et al., 
1998).  
Three different proteins can be produced from the MDS1/EVI1 locus, namely: 
MDS1, EVI1 or MDS1/EVI1. The major EVI1 protein derived from all the alternatively 
spliced variations is 1,051 amino acids in length with a predicted molecular weight of 
118kd. The MDS1/EVI1 protein contains 188 additional amino acids encoded by the 
first two MDS1 exons, and the entire EVI1 exons, thereby producing a so-called “PR” 
domain (PRD1-BF1/BLIMPI1-RIZ homology), a 134 amino acid region with high 
homology to the SET domain, the structural hallmark of histone methytransferases.  
 
Figure 4-3 Schematic representaion of genomic locus of MDS1/EVI1, PRDM16 and their truncated forms. Exons 
are represented as solid boxes with light blue. Dashed lines represent splicing events occuring to produce 
messenger RNA. Proteins are represented as black lines.  
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PR domain containing 16 (PRDM16; also known as MEL1) is involved in rare AML-
associated translocations t(1;3)(p36;q21) and t(1;21)(p36;q15). In both cases, 
expression of PRDM16 is altered, either as consequence of cis juxtaposition to the 
enhance element of RPN1 at 3q21 (Mochizuki et al., 2000; Shimizu et al., 2000) or to 
its fusion with AML1 (AML1/PRDM16) at 21q15 (Sakai et al., 2005). The PRDM16 
locus encodes 2 proteins: PRDM16 and the short isoform, sPRDM16, differ at their 
N-terminal in the presence or absence of the PR domain (Nishikata et al., 2003) 
(Figure 4-3, B).  
The PR-domain negative isoform of MDS1/EVI1 and PRDM16 has the potential to 
be oncogenic (Buonamici et al., 2004; Shing et al., 2007). However, a direct 
comparison of the impact of the 2 PRDM16 and MDS1/EVI1 isoforms in 
hematopoiesis is still missing, and whether transient co-expressing of MDS1/EVI1 
and PRDM16 could influence HSC engraftment and proliferation remains unclear. 
 Lentiviral expression system for Mds1/Evi1, Prdm16 and their 4.2.2
truncated forms 
 
Figure 4-4 Schematic representation of SIN lentiviral vector constructs expressing murine Prdm16, sPrdm16, 
Mds1/Evi1 and Evi1, respectively. Murine Prdm16 and sPrdm16 coding sequences (CDS), as well as Mds1/Evi1 
and Evi1 CDS were cloned into SFFV promoter (spleen focus-forming virus) containing transfer lentiviral vector 
backbone, expressing Green Fluorescence Protein (GFP) or Yellow Fluorescence Protein (YFP) simultaneously, 
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respectively. LTR: long terminal repeat; IRES: internal ribosomal entry site; WPRE: woodchuck hepatitis virus 
post-transcriptional regulatory element; The 3′ ΔU3 comprises the SIN deletion, ΔU3. The R region contains the 
vector polyadenylation signal. 
To construct the lentiviral vectors, endogenous protein coding sequences of 
murine Mds1/Evi1, Prdm16 and their PR domain lacking variants Evi1 and sPrdm16 
were directionally cloned into multi-cloning sites of third generation pCCL pptSFFV-
GFP-PRE SIN lentiviral backbone, which contains either an IRES-eGFP or an IRES-eYFP 
cassette as tracing marker (Figure 4-4). The transgene coding sequences were 
verified by Sanger sequencing. To produce the functional lentiviral vectors, transfer 
vector constructs together with envelope and packaging plasmids were transient co-
transfected into 293T cells mediated by PEI or calcium phosphate. 48 hours after 
transfection, virus particles containing medium were harvested and concentrated by 
ultracentrifugation, resulting into ~100-fold enrichment of functional virus particles 
(Figure 4-5).  
 
Figure 4-5 Schematic representation of the process of lentiviral vector production (modified from 
www.invitrogen.com). I. Transient transfection in 293T cells. II. Harvest pseudoviral particles from supernatant. 
III. Concentration of viral partilcles through ultracentrifugation. 
Functional titers of LVs were determined by serial transduction in HeLa cells. In 
all LV constructs either eGFP or eYFP were present, and the percentage of 
transduced cells could be easily determined by FACS based on fluorescence gene 
expression. To estimate the transduction ability, whole LV particles produced after 
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ultracentrifugation, including partially packaged, empty or destroyed particles were 
also titrated using a HIV-1 specific p24 ELISA kit. Reliable titers in the range from 107 
to 108 TU/ml were achieved for Mds1/Evi1, Prdm16 as well as Evi1 and sPrdm16 
constructs.   
 Lentiviral mediated transgene expression in murine cell lines 4.2.3
To verify the transgene expression mediated by LVs, murine SC-1 cells were 
transduced by the produced LVs in presence of 8µg/ml Polybrene. 48 hours after 
transduction, cells were harvested and mRNA and Protein were isolated as well. To 
verify the transgene expression at the mRNA level, RT-PCR was performed using 
specific primer pairs complementary to the C-terminus of the transgene (full length), 
N-terminus (PR domain specific), eGFP as well as house keeper GAPDH region, 
respectively. All negative controls, non-template controls, as well as non-RT controls 
showed no PCR products after gel electrophoresis, indicated that all the PCR 
products in RT positive samples were derived from transgene expressing LVs. PR 
domain specific PCR demonstrated the PR domain presence or absence in the 
respective expressed isoforms (Figure 4-6, A). 
 
Figure 4-6 Overexpression of Mds1/Evi1 and Prdm16 in lentiviral vector transduced SC-1 cells. (A) RT-PCR 
analysis of transgene expression at mRNA level. cDNAs were synthesized with (RT+) or without reverse 
transcriptase (RT-). GAPDH primer was used as positive control, eGFP primer was used as functional provirus 
control, C-terminus and N-terminus primers were used to detect PR domain present or absent isoforms, 
respectively. (B) Western blot analysis of transgene expression at protein level. GAPDH antibody was used as 
loading control, C-terminal and N-terminal antibodies were used to detect PR domain present or absent isoforms. 
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To confirm the LV mediated transgene expression also at the protein level, 10µg 
whole lysate of transduced cells were loaded into Tris-Glycin SDS PAGE gel. After 
electrophoresis, SDS page gels were blotted on a PVDF membrane and probed with 
N-terminal (PR domain specific) or C-terminal (full length) antibodies against 
Mds1/Evi1 or Prdm16, respectively. Specific expression of PR domain containing or 
lacking isoforms driven by the respective LVs was shown (Figure 4-6, B). The 
expression of Mds1/Evi1 and Prdm16 driven by the produced LVs was also verified in 
the murine C1498 cell line (data not shown). 
 Effects of Prdm16 and sPrdm16 on HSCs and progenitors 4.2.4
To study the direct impact of Prdm16 and sPrdm16 on hematopoietic 
differentiation and proliferation, Prdm16 and sPrdm16 were ectopically expressed 
after lentiviral gene transfer in a murine cell population enriched in HSCs and 
progenitors (lineage-depleted cells “lin-”). 4 days after transduction, FACS analysis 
for eGFP confirmed transgene expression in all transduced lin- cells (Figure 4-7). 
Surprisingly, the initial transduction efficiencies between control vector (LV-109) and 
transgene expressing vectors (LV-Prdm16 and LV-sPrdm16) varied from 64.7% ± 2.6% 
to only 2.2% ± 0.8% and 2.9 ± 1.1%, respectively. At day 7 post transduction, the 
proportion of eGFP positive cells in control vector transduced lin- cells was increased 
to 75% ± 1.4%, but in Prdm16 and sPrdm16 transduced cells, the already low initial 
percentage further decreased to 0.8% ± 0.5% and 1.5% ± 0.7%, respectively. At day 
14 post transduction, the percentages of eGFP positive cells in control, Prdm16 and 
sPrdm16 transduced samples were dropped to 46.3% ± 0.5%, 0.1% ± 0.1% and 0.1% 
± 0.1%, respectively. This finding suggests that transgene expression was probably 
limited by transgene size, methylation of vector promoter or toxicity of ectopic 
transgene expression. Notably, the latter has also been noticed in other groups 
(personal communication Prof. C. Baum, MHH, Hannover) 
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Figure 4-7 Gene transfer efficiency of Prdm16 and sPrdm16 LVs in lin- cells. Lineage depleted bone marrow cells 
were transduced by Prdm16 and sPrdm16 expressing lentiviral vectors with MOI=50, which were titrated in HeLa 
cells. The transduced cells were cultured in vitro for 72 hours in cytokine containing medium. Transduction 
efficiency was measured by FACS based on eGFP expression. 
The effects of Prdm16 and sPrdm16 expression on progenitor life span were 
assessed by serial replating of lin- cells in methylcellulose based cytokines containing 
medium. In the first round of plating, although the frequency of clonogenic 
progenitors detected transduced lin- cells was essentially identical for control and 
Prdm16/sPrdm16 transduced cells, Prdm16/sPrdm16 transduced progenitors 
formed much larger granulocyte, erythroid, macrophage, and megakaryocyte 
colonies (GEMM) at the very beginning time point (Day 1) (39/Prdm16, 59/sPrdm16, 
15/untransduced and 22/mock transduced) (Figure 4-8). When directly comparing 
the cells expressing Prdm16 and sPrdm16, sPrdm16 expressing cells formed larger 
portion of GEMM colonies then those expressing Prdm16 in Day1 and Day 7. Notably, 
overexpressing of Prdm16 and sPrdm16 increased both the number and the size of 
colonies, suggesting that their expression affects both clonogenicity and proliferation 
of progenitors. After the first observation period, no colonies were detected in all 
samples, therefore no serial replating assays were conducted. Together with the 
observation of low gene transfer efficiency, these findings suggest that Prdm16 and 
sPrdm16 expression might block differentiation and extends survival of 
hematopoietic progenitor cells, but further optimization of experimental procedure 
and improvement of transduction efficiency was needed. 
64,7% 2,9%2,2%
eGFP
SS
C
sPrdm16Prdm16109
Results  Wei Wang 
81 
 
 
Figure 4-8 Increased hematopoietic stem/progenitor cells in Prdm16 and sPrdm16 over expressed Lineage 
negative bone marrow (lin- BM) cells. Total number of CFU-Bone marrow derived from 800 FACS-sorted 
unstranduced, mock, Prdm16 or sPrdm16 transduced Lin- BM cells post transduction. E: Colony forming units- 
erythroid; GM: Colony forming units-granulocyte and megakaryocyte; G: Colony forming units-granulocyte; M: 
Colony forming units-megakaryocyte; GEMM: Colony forming units- granulocyte, erythrocyte, monocyte and 
megakaryocyte. 
 Long term persistence of LV transduced clones in hematopoiesis 4.2.5
in vitro  
To investigate the effect of Prdm16 and sPrdm16 expression on HSCs, we used 
the long-term culture assay that assesses the expansion of primitive HSCs in vitro. 
Transduced lin- cells were cultured in medium containing IL-3, IL-6 and SCF for 4 
weeks. In this period, a portion of cells were monitored for eGFP expression by FACS. 
After counting the cell numbers of each transduced cell population at each 
observation time point, only one third of cells were further cultured under the same 
condition to monitor the clonal expansion of the transduced cells. In the first 
experiment, the proportion of untransduced and mock transduced remained 
constant at input level over 2 weeks, while Prdm16 and sPrdm16 transduced cells 
began to expand. 2 weeks later, in contrast to untransduced and mock transduced 
cells, Prdm16 and sPrdm16 transduced cells expanded from input level by nearly 
1100- to 1300- folds. After long-term culture, cell morphology showed a higher 
proportion of immature myeloid cells upon expression of Prdm16 and sPrdm16.  In 
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the second experiment, no significant differences in the proliferation or 
differentiation were observed between Prdm16, sPrdm16 and eGFP transduced cells.  
In both long-term culture experiments, the eGFP expression level in transduced 
cells was decreasing overtime under detection limit. This finding suggests that 
initially transduced committed progenitors terminally differentiate, while low 
frequent HSCs self-renew. To verify the presence of transduced cells in long-term 
cultured samples, LTR test PCR was performed on genomic DNA of transduced cells 1 
and 3 weeks after transduction (Figure 4-9). LTR specific PCR products appeared in 
all three analyzed samples of both time points, indicating the long-term persistence 
of LVs in transduced primary samples. 
 
Figure 4-9 LTR test for long-term cultured Prdm16 and sPrdm16 transduced lin- cells. 7 days and 23 days after 
transduction, genomic DNA of samples were isolated and PCRs were performed using LTR specific PCR. Nested 
PCRs were performed to increase the signal strength. C: control, not transduced lin-cells; G: eGFP expressing 
control LV transduced samples; P: Prdm16 expressing LV transduced samples; sP: sPrdm16 expressing LV 
transduced samples.  
 Optimization of lentiviral vector production 4.2.6
In the context of LV transduction of primary hematopoietic cells, the general 
gene transfer efficiency was contrary to our expectation. This could be explained by 
transgene toxicity, promoter methylation, inadequate LV packaging as well as 
inaccurate LV titration, etc. To improve the titer of LVs, several optimization steps 
were performed.  
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First, the quality of FBS used in LV production as well as downstream 
HSCs/progenitor cell based assays were critically analyzed. 11 FBS batches from 
different vendors were used for LV production, using the control construct and 
compared the respective titers either on p24 or functional GFP assays. As shown in 
Figure 4-10 A, p24 titers demonstrated analogous results to functional GFP titers, 
suggesting the procedure of LV production was reliable and reproducible; both 
titration methods could be further used to estimate the qualities and quantities of 
produced LVs. Sample 8 showed the best p24 titer as well as GFP titer (Figure 4-10, 
A), including minimal effects on HSCs differentiation and proliferation (data not 
shown). Although the infectivity (GFP titer/p24 titer) was not superior, in 
combination with the data of HSCs assays, FBS 8 was selected for further 
experiments. 
To stabilize the virus mRNA transcripts upon LV entry, as well as to improve the 
transgene expression level, Kozak consensus sequence “gccacc” was cloned in front 
of the start codon of each transgene construct. Further optimization steps including 
293T cell numbers, ratio and amount of plasmids used in LV production, condition 
for ultracentrifugation were performed. After extensive optimization works, the 
general functional GFP titers on HeLa cells were successfully increased with 20- to 
100- fold (Figure 4-10, B).  Thus, the usage of higher MOIs in primary cell 
transduction experiments became feasible. 
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Figure 4-10 Significant improvement of lentiviral vector titers after optimization. (A) 11 batches FBS from 
different vendors were tested for LV production. Functional LV titers were measured by FACS based on eGFP 
expression, total LV titers were measured by p24 ELISA assay. LV infectivity of each production was calculated by 
dividing GFP titer with p24 titer. (B) Summary of titer improvement of transgene expressing LVs before 
optimization (blue bar) and after optimization (red bar). 
 Fractionation of the LSK HSC pool into distinct LT-, ST- HSC and 4.2.7
MPPs 
To further improve the LV transduction efficiency in the context of primary cell 
gene transfer, more defined LT-, ST- HSCs and MPPs separated by FACS using cell 
surface marker Sca1, cKit, Flt3 and CD34 were evaluated in this thesis (Figure 4-11). 
Although representing only 0.05% to 0.1% of total adult BM cells, the LSK 
compartment contains all LT-HSCs. Whereas the LSK LT-HSCs population lacks CD34 
and flt3 expression, more than 90% of LSK cells are CD34+ with short-term 
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repopulating stem and progenitor cell activities. However, the potential 
heterogeneity of the LSKCD34+ ST-HSC pool can be further divided into 
LSKCD34+flt3- and LSKCD34+flt3+ after co-staining with anti-CD34 and anti-flt3 
antibodies (Yang et al., 2005). These three distinct LSK populations, LSKCD34-flt3-, 
LSKCD34+flt3- and LSKCD34+flt3+, representing 0.007%, 0.04% and 0.05% of total 
BM cells, exhibit also distinct HSCs properties, reflecting LT-, ST- and MPPs, 
respectively. 
 
Figure 4-11 LT-, ST- HSC and MPPs sub-fractionation of LSK cells based on expression of CD34 and Flt-3. Lin- BM 
cells (left panel) expressing high levels of c-kit and Sca-1 (middle panel) were investigated for expression of CD34 
and flt3 (right panel). Percentages indicate frequencies (mean of 3 independent experiments) within total BM of 
LSKCD34-flt3- (lower left quadrant), LSKCD34+flt3- (lower right quadrant) and LSKCD34+flt3+ (upper right 
quadrant) cells. Boxes denote the sorting strategy used for each of the populations. Cells used in these studies 
were double sorted, always resulting in 98% or higher purity (data not shown). 
 Short summary of this section 4.2.8
Protein coding sequences of murine Mds1/Evi1, Prdm16 and their PR domain 
lacking variants Evi1 and sPrdm16 were cloned and verified by sequencing. Lentiviral 
vectors (LVs) were produced and reliable titers in the range from 107 to 109 TU/ml 
were achieved after optimization for all LVs. Sufficient transgene expression was 
detected for all constructs by Western-Blot and RT-PCR after transduction of murine 
SC-1 cells. To study the direct impact of the Prdm16 and sPrdm16 expression on 
hematopoietic differentiation and proliferation, lineage depleted murine primary 
bone marrow cells were transduced with Prdm16 or sPrdm16 LVs (MOI 50) and 
monitored for 30 days in vitro. Long-term eGFP expression was observed in all three 
transduced cells populations for up to 30 days. No significant differences in the 
proliferation potential or differentiation capacity were observed between Prdm16, 
sPrdm16 and eGFP transduced cells. To improve the transduction efficiency, more 
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defined LT- and ST- HSCs separated by FACS using cell surface marker Sca1, cKit, Flt3 
and CD34 were tested for further studies. 
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4.3 Comprehensive characterization of integration deficient 
lentiviral vector (IDLV) integration profiles in vitro 
The application of IDLV which can persist in the nucleus with surprising 
robustness might address growing concerns about vector and gene therapy biosafety 
issues. Murine leukemia virus based integrase mutant class I deficient vectors have 
shown to persist as circular 1-LTR, 2-LTR and oligomeric episomal vector forms 
(Hagino-Yamagishi et al., 1987).  Residual integration events have been attributed to 
non-homologous recombination, often coupled with the loss of nucleotides at the 
site of integration (Gaur and Leavitt, 1998). One pre-clinical study on the successful 
long-term functional correction of retinal degeneration in two rodent disease models 
have proven the therapeutic potential of these vectors, at least in post-mitotic or 
otherwise quiescent cells (Yanez-Munoz et al., 2006). 
Episomal forms of IDLVs are not able to replicate and are diluted out in rapid 
dividing cells. The resulting transient expression of specific transgenes can represent 
an important biosafety feature. A transient transgene expression should however be 
sufficient to induce critical changes in the cell fate of transduced cells during their 
first few replication cycles, e.g. when trying to modify proliferation and 
differentiation capacities of repopulating HSCs, or iPS cells. The transient presence of 
these nuclear forms further allows the use of IDLVs as a hybrid gene ferry thus to 
combine the non-toxic nucleic acid transfer properties of LV particles with the 
reliable and stable integration of animal transposases (Ivics et al., 1997), I-SceI 
nuclease (Cornu and Cathomen, 2007) and Zin finger nuclease for targeted genome 
modifications (Lombardo et al., 2007). 
The main objectives of this study were I) to study the base line functional 
properties of IDLVs, including residual integration frequency and distribution analysis, 
II) to test whether IDLV derived transient MDS1/EVI1 and PRDM16 expression is 
relevant to influence the fate of long-term hematopoietic repopulating cells. 
 Construction of integration deficient lentiviral vector  4.3.1
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Transgene expression from IDLVs probably depends on both the number and the 
structure of extra-chromosomal viral DNA (Philpott and Thrasher, 2007). Based on 
the previous study, we chose to introduce class I mutation into IN at positions D64 
(Figure 4-12, B), which is part of the DDE catalytic triad and is absolutely essential for 
integration (Leavitt et al., 1996), resulting a mutant D64V gag/pol packaging plasmid. 
The expression of Mds1/Evi1, Prdm16 and their PR domain absence forms are driven 
by internal SFFV promoter, eGFP is co-expressed as a surrogate marker for the 
intracellular presence of vector genomes (Figure 4-12, A).  
 
Figure 4-12 Schematic representation of IDLV constructs expressing murine Prdm16, sPrdm16, Mds1/Evi1 and 
Evi1, respectively. (A) Murine Prdm16 and sPrdm16 Coding sequences (CDS), as well as Mds1/Evi1 and Evi1 CDS 
were cloned into SFFV promoter (spleen focus-forming virus) drived transfer vector backbone expressing Green 
Fluorescence Protein (GFP) simultaneously. LTR: long terminal repeating element; IRES: internal ribosome entry 
site; WPRE: woodchuck hepatitis virus post-transcriptional regulatory element; the 3′ ΔU3 contains the SIN 
deletion ΔU3; the R region contains the vector polyadenylation signal. (B) HIV-1 integrase consists of three 
domains: the N-terminal domain, the C-terminal domain, and a catalytic core domain. Mutation was introduced 
in D64 residue within the catalytic core. 
To confirm that introduction of D64V mutation in IN did not interfere with virus 
production, the concentration of p24 was measured. The p24 enzyme-linked 
immunosorbent assay (ELISA) results in Table 4-1 showed minor variation between 
the WT and D64V vector stocks, indicating that introduction of the class I IN 
mutation did not interfere with virus budding and production. Viral titers were 
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quantified by measuring transducing units in HeLa cells. Albeit IDLVs achieved lower 
titers in comparison to wild type LVs, which might be explained by dilution of 
transduced events during culturing, all stocks showed relative high titers in a range 
between 107 to 109 TU/ml. therefore, the D64V IN mutation allow efficient viral 
genome encapsidation, reverse transcription of RNA genome, nuclear entry of the 
viral complementary DNA, and efficient transcription and translation of the 
transgene.  
 
Table 4-1 Quantification of p24 and eGFP expression levels in vitro. Titer measurements were obtained from 
serial dilutions of at least three separate batches of each vector. Viral stock p24 concentrations were measured 
by performing a p24 ELISA assay using serial dilutions of the vectors. eGFP titer were measured by performing 
transduction of HeLa cells using the same serial dilution of vector stocks used in p24 ELISA assay. FACS was 
performed on the third day after transduction and titers were calculated in transducing units/ml (TU). 
 Transient transgene expression driven by IDLVs 4.3.2
In order to evaluate transgene expression overtime, SC-1 and C1498 cells were 
transduced by LVs and IDLVs expressing eGFP at the MOI of 25, 50 and 100, 
respectively, and eGFP expression was measured by flow cytometry. As shown in 
Figure 4-13, all of the vectors showed a maximal eGFP expression level at the day 2 
after transduction, demonstrated a typical LV-mediated transgene expression kinetic 
described before (Brussel and Sonigo, 2003, 2004; Butler et al., 2001). After 
transduction of both SC-1 and C1498 cell lines with wild type LVs, eGFP expression 
was stable and sustained over time, indicating that stable viral integration into host 
genome and sustained transgene expression. Of note, expression of eGFP from 
Virus Transgene
Viral particles
(pg p24/ml)
eGFP Titer
(TU/ml)
LV 109 4,81E+09 1,10E+09
IDLV 109 4,03E+09 1,30E+08
LV Prdm16 1,71E+09 3,30E+08
IDLV Prdm16 5,59E+09 1,39E+07
LV sPrdm16 4,47E+09 6,30E+08
IDLV sPrdm16 2,24E+10 1,10E+07
LV Mds1/Evi1 1,76E+09 1.70E+07
IDLV Mds1/Evi1 6,84E+08 1,00E+07
LV Evi1 8,08E+09 1,55E+08
IDLV Evi1 2,23E+09 5,00E+07
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transduced C1498 cells was lower as compared with SC-1 cells. This was probably 
attributable to the variation of transduction efficiency in suspension cell line and 
adherent cell line. In contrast, by 14 days after transduction, background levels of 
expression was seen in samples transduced with IDLVs, indicating the episomal 
forms were diluted in the dividing cell population over time, but residual integration 
still occurred. Interestingly, cells transduced by IDLVs with all three MOIs showed 
similar kinetics of transgene expression diminishment, suggested that IDLV 
background integration was not associated with initiate load of vectors. 
 
Figure 4-13 Transgene expression driven by IDLV was transient in dividing cells. (A) SC-1 and (B) C1498 cells 
were transduced with eGFP expressing IDLV and LV vectors with MOIs of 25, 50 and 100, respectively. Data 
represent means ± standard deviation (SD); n=3. 
 Quantification of IDLV background integration 4.3.3
Data obtained from measuring eGFP expression in SC-1 and C1498 cells 
suggested that all IDLVs were integration deficient, the eGFP expression levels were 
diminishing over time. Next, we wanted to quantify more precisely the efficiency of 
residual integration.  IDLV transduced cells were cultured over a period of 4 weeks to 
dilute out the un-integrated episomal forms, e.g. 1-LTR circle, 2-LTR circle and linear 
forms. 
The absolute integration events of IDLV in SC-1 and C1498 cells were shown in 
Figure 4-13, the frequencies of stable eGFP expression ranged between 1.8% and 2.4% 
in C1498 cells and between 2.0% and 4.6% in SC-1 cells, in a dose dependent manner. 
For the relative integration frequency between IDLV and LV, we isolated genomic 
DNA from IDLV transduced and LV transduced samples, performed qPCR using WPRE 
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primer sets, which is specific present in provirus sequences. The level of background 
integration of the IDLVs was calculated by comparison the absolute virus copy 
numbers in the same amount (5ng) of genomic DNA from IDLV and LV transduced 
samples. As shown in Figure 4-14, the level of background integration of the D64V 
mutant was in general 10-2 to 10-3 fold lower than integration of the wild type vector. 
Notably, the residual integration rate of IDLVs in C1498 cells was higher than in SC-1 
cells. It could be explained by tumor genetic background of C1498 cells, which have 
higher genomic arrangement and instability, more IDLVs could be captured by those 
cells through non-homologous end joining mechanism upon vector entry.  
 
Figure 4-14 Quantification of background integration of IDLVs. Difference of integration efficiency was 
calculated by comparing the copy number of provirus in 500ng of genomic DNA of IDLV and LV transduced SC-1 
and C1498 cells with MOI 25, 50 and 100, respectively.  
 Enrichment of residual integrated events 4.3.4
In order to precisely analyze IDLV integration events genome-widely, enhance 
the sensitivity of LAM-PCR, we isolated eGFP positive cells, referred to IDLV 
transduced cells, based on eGFP expression by FACS sorting. As mentioned above, 
the bulk IDLV transduced cells were cultured in vitro for 4 weeks after transduction 
to dilute out the un-integrated forms. 20,000 monoclonal eGFP positive cells were 
sorted by FACSAria in DKFZ flow cytometry core facility.  Sorted cells were cultured 
in vitro for additional 2 week for cell expansion, a portion of cells from each samples 
were analyzed by FACS for sorting purity. As shown in Figure 4-15, all the samples 
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showed relative high eGFP positive cells proportion (≥ 85%). In comparison to wild 
type LV transduced samples, which eGFP positive cells were also over 85% percent in 
whole cell population, direct comparison between sorted IDLV transduced cells and 
LV transduced cells became feasible. 
 
Figure 4-15 Purity of FACS sorted IDLV transduced SC-1 and C1498 cells. 20,000 eGFP positive cells were sorted 
by FACSAria based on eGFP expression; sorted cells were cultured for additional 2 weeks to get enough cells for 
further experiments.  
 Clonality of IDLV transduced samples 4.3.5
To uncover specific features of the IDLV IS distribution in vitro, and gain a 
comprehensive overview of IDLV integration preference and distribution, we 
performed comparative large scale IS analysis on the IDLV and LV transduced SC-1 
and C1498 samples using (nr)LAM-PCR combined with high-throughput 
pyrosequencing (454/Roche). 
The clonality of IDLV or LV transduced samples was determined by 5’ LAM-PCR 
using NlaIII and HpyCH4IV first. 100ng genomic DNA was used as starting material. 
The results from both transduced cell lines showed a polyclonal (Figure 4-16, A, 
HpyCH4IV only, Tsp509I not shown) virus integration pattern. A distinct vector 
related fragment was present - the band for internal control fragment (300bp). The 
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3’LAM-PCR approach using Tsp509I and MseI for the both transduced cell lines 
resembled the result same to 5’LAM-PCR: a polyclonal pattern of IDLV IS (Figure 4-16, 
B, NlaIII only, MseI not shown). A 400bp internal control band could be also detected 
in this procedure. To overcome the obstacle of using restrictive enzymes and obtain 
many IS as possible, nrLAM-PCR for both 5’ and 3’ directions were also performed 
using 500ng genomic DNA as starting material, as mentioned in 4.1.1, nrLAM-PCR 
resulted in a variety of amplicon lengths for each insertion, appearing as a ‘smear’ on 
electrophoresis (data not shown). 
 
Figure 4-16 LAM-PCR analyses of IDLV integrants in the genome of transduced cells. (A) 5’ strand and (B) 3’ 
strand LAM-PCR analysis of FACS-sorted eGFP positive cells 6 weeks post transduction. IC, internal control 
derived from the vector sequences. 
 Distribution analysis of IDLV IS in vitro 4.3.6
LAM-PCR and high-throughput sequencing of integration sites was performed on 
genomic DNA isolated from LV and sorted IDLV transduced SC-1 and C1498 cells with 
MOI of 25, 50 as well as 100, respectively. In total, 905 unique insertion sites were 
retrieved from combined IDLV transduced SC-1 cells with all three virus loads, of 
which 533 IS could be mapped exactly to the mouse genome. Similarly, 437 unique 
insertion sites were retrieved from IDLV transduced C1498 cells, among them 271 
were unique mappable. For LV thansduced cells, much more IS were isolated using 
the same experiment conditions: 2419 of 2788 and 898 of 1062 unique IS could be 
mapped exactly into mouse reference genome for SC-1 and C1498 cells, respectively 
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(Table 4-2). This reflecting the conclusion that IDLV integrate less frequently into 
host genome. The relative high number of retrieved IS of IDLV was resulted by 
enrichment of positive transduced cells using FACS. Of note, this was first time to 
retrieve such many IS of IDLV, allowing us to dissect the preference and distribution 
of IDLV integration genome widely, as well as the safety aspect for IDLVs. 
 
Total IS Unique mappable IS In gene In gene +/-10kb 
SC1 (IDLV) 905 (100) 533 (59) 229 (43) 299 (56) 
C1498 (IDLV) 437 (100) 271 (62) 110 (41) 134 (49) 
SC1 (LV) 2788 (100) 2419 (87) 1802 (74) 1935 (80) 
C1498 (LV) 1062 (100) 898 (85) 557 (62) 613 (68) 
Table 4-2 Large scale integration site analysis of IDLV by LAM-PCR and nrLAM-PCR. Cumulative genomic 
distribution of IS detected in IDLV and LV transduced SC-1 and C1498 cells. LAM-PCR amplicons were sequenced 
by next generation sequencing (Roche 454). IS are shown as absolute number (percent) of the exactly mappable 
sequences for each category. 
The chromosomal distribution of ISs was analyzed to determine the relationships 
among chromosome size, gene density, and insertion frequency. For each of the 
mouse chromosomes, the number of integrations was not related to the size of the 
chromosome, whereas a correlation between gene content and insertion numbers in 
both IDLV transduced samples and LV transduced samples was shown (Figure 4-17, 
A). This suggested that integration of IDLV and LV is dependent on the gene density 
of a chromosome, rather than its size.  
To analyze the positional preferences of IDLV ISs in vitro, we mapped all the 
unique mappable IS on the mouse genome, as shown in Figure 4-17 B, IDLV ISs close 
to randomly distributed of each chromosome, no IS clustering near to centromeric or 
telomeric region was observed.  
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Figure 4-17 Genomic distribution of IDLV integration sites. (A) Distribution of ISs among chromosomes. Values 
for ISs are shown as a percentage of all ISs from the corresponding samples. Light blue bars, IDLV in SC-1 cells; 
dark blue bars, IDLV in C1498 cells; light green bars, LV in SC-1 cells; dark green bars, LV in C1498 cells. (B) 
Positions of IDLV ISs among chromosomes (Generated by Ensembl KaryoView). Each triangle represent a IS in 
responding samples. Red triangle, IDLV in SC-1 cells; Blue triangle; IDLV in C1498 cells.  
 Close to random in vitro IDLV integration frequency in gene 4.3.7
coding regions 
Previous studies revealed that integration sites from MLV and HIV-1 based 
vectors showed distinct differences in respect to annotated features of human 
genome. MLV based vectors showed significant clustering around the transcription 
start sites (TSS) or RefSeq genes and in the proximity to CpG-islands whereas HIV-1 
based vectors disfavored TSS and CpG islands, but showed preferences for 
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integration inside transcribed regions of RefSeq genes (Schroder et al., 2002; Wu et 
al., 2003).  
To dissect the IDLV IS pattern in vitro, IS for each of IDLV and LV transduced 
samples were mapped to the mouse genome, and nearby features were assessed 
(Figure 4-18). Given the number of genes in the mouse genome and assuming 
random integration, 25% of ISs would be expected to fall into or within a 10-kbp 
window around RefSeq genes, which account for approximately one third of the 
mouse genome. As shown in Figure 4-18 C, and Table 4-2, the actual frequency of 
IDLV IS in gene region (42.5% for SC-1 and 40.4% for C1498) and including the 10kb 
window up- and downstream (55.5% for SC-1 and 49.2% for C1498) was significantly 
lower than LV IS pattern, which showed a typical favorable integration pattern inside 
of RefSeq genes as expected (74.5% for SC-1 and 62% for C1498, p<0.0001, chi-
square test). Both IDLV and LV insertion patterns were significantly different from 
the random integrations sites, of which only 32% were within RefSeq genes, a 
percentage identical to the average estimation of the mouse genome content 
(25.5%-37.8%, median 31.5%). 
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Figure 4-18 IDLV integration sites distribution in mouse RefSeq genes and the surrounding 10kb region. (A) The 
percentage of IDLV and LV IS in mouse RefSeq genes and (B) in RefSeq genes including surrounding 10 kbp region 
is shown. (C) Comparison of IDLV and ID IS inside of RefSeq gene region. ISs locations inside genes are expressed 
as the percentage of the overall length of each individual target gene. Light blue bars, IDLV in SC-1 cells; dark blue 
bars, IDLV in C1498 cells; light green bars, LV in SC-1 cells; dark green bars, LV in C1498 cells. TSS, transcription 
start sites.  
We next examined whether specific regions of the transcription units were most 
likely sites of integration than others. We analyzed the distribution of the integration 
events within the transcription unit by dividing the distance of each integration site 
from the transcription start site by the gene length. The resulting ratio, reported as 
the total number of integration events in RefSeq genes for each vector, provides the 
percentage of integrations within ten equal sections of transcription units. While 
both IDLV and LV targets entire transcription unit with no noticeable preference, as 
expected, LV integration pattern exhibited a strong preference for integration near 
transcription start sites (TSS) - 63 of 3317 (2%, SC-1 and C1498) of the LV integration 
sites, as compared 64 of 811 (8%, SC-1 and C1498) for IDLV, are located within 10kb 
upstream of TSS (Figure 4-18 A).  
To further explore IDLV preferential integration in the vicinity of TSS, we 
determined the distance to the nearest 5’ and 3’ ends of a RefSeq gene for each 
integration site. Interestingly, whereas IDLV integration events do not favor locations 
upstream or downstream of transcription units, 64 of 811 (8%, SC-1 and C1498) of 
the total IDLV integration sites landed within a 10-kbp region upstream of a RefSeq 
gene, as compared to 5% expected with the random integration sets (p<0.0001). The 
frequency of insertions within 10kb downstream of the 3’ end is almost identical for 
the IDLV and the in silico-generated random sets (3.6% versus 4.8%, p=0.057). 
We then looked at the proviral integration within a 2kb window on either side of 
transcription start sites. This survey revealed a strong tendency for IDLV vectors to 
integrate close to transcription start sites, with 27 of 539 (5%, SC-1) of the total IDLV 
integration events occurring within 2kb upstream or downstream, as compared to 24 
of 2419 (1%, SC-1) for LV (p<0.0001). Interestingly, this finding was not observed in 
C1498 cell line, where 4 of 272 (1.5%) of the total IDLV IS as compared to 15 of 898 
(1.7%) of the total LV IS located within 2kb window (Figure 4-18 B).  
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Taken together, these data demonstrated a distinct integration pattern between 
IDLV and LV in vitro (p<0.0001, Chi-square test): while the latter appear to integrate 
predominantly within transcription units, IDLV vectors integrate close to randomly 
into genome, when it presents, favor integration within a 10kb window centered on 
transcription start sites. 
 Network analysis using ingenuity pathway analysis  4.3.8
To define and compare specific physiological functions and networks included in 
the IDLV and LV IS datasets, we performed comparative ingenuity pathway analyses 
(IPA). Ingenuity analysis also offers further insights into gene data sets associated 
with specific diseases. In both IDLV and LV transduced samples, IS are mainly found 
in genes involved in genetic disorder and immunological disease. In “genetic 
disorder”, “immunological disease”, “cell death”, “cell cycle” and “caner” related 
gene classes, IDLV transduced samples showed significant lower (p<0.05, student t-
test) overrepresentation as compared to LV transduced samples (Figure 4-19).  
 
Figure 4-19 IPA analysis of LV and IDLV integrations. Genes of IDLV and LV transduced (A) SC-1 and (B) C1498 
cells with an insertion within the gene or in the neighboring 10 kb were classified according to physiological 
function. The y-axis indicates the category to which the analyzed genes contribute. Only the significant categories 
were shown. For each analyzed gene group the statistical significance (student t-test) of overrepresented genes 
in a pathway is given on the x-axis.  
 No proto-oncogenes were found in IDLV IS sets 4.3.9
It is generally recognized that known preferences of gamma-retroviral vectors to 
target regulatory regions of genes increase the risk for genetic alterations of 
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neighboring genes (Baum et al., 2003; Nienhuis et al., 2006). In contrast, it has been 
shown that independent of the integration pattern also vector design and dose 
influence the likelihood of vector induced cellular transformation (Maruggi et al., 
2009; Montini et al., 2009). To address this potential problem for IDLV application in 
clinical gene transfer, we compared the integration site datasets generated in our 
experiment with Retrovirus and Transposon tagged Cancer Gene Database (RTCGD, 
http://variation.osu.edu/rtcgd/index.html), which summarized potential or known 
proto- and oncogenes from multiple high-throughput insertional mutagenesis 
screening projects, using retroviral vectors or transposons as tools to discover potent 
cancer gene in mouse hematopoietic tumors or other tumor types (Akagi et al., 2004; 
Collier et al., 2005; Starr et al., 2009). No match was found in 503 known RTCGD 
genes from 804 unique mappable IDLV integrants, especially the overrepresentated 
MDS1/EVI1 and PRDM16 loci found in other vector. The T-cell acute lymphocytic 
leukemia (T-ALL) oncogenes LMO2, TAL1, TAN1, LCK, LMO1, HOX11, HOX11L2, LYL1, 
TAL2, C-MYC and CCND2 were not present in the IDLV IS data sets.  
 Establishment of Two-directional LAM-PCR 4.3.10
We used (nr)LAM-PCR strategies that could detect LTR- and non-LTR-mediated 
vector integration, which we estimated allowed scanning of 50% to 70% of the 
vector genome for host DNA-vector junctions. But LAM-PCR on genomic DNA of 
these nonclonal samples only analyses one end of the integration events, so no 
conclusions are possible regarding the presence or absence of the flanking 5-bp host 
DNA duplication, LTR sequence deletion, genomic DNA deletion as well as addition . 
To further understanding the mechanism of IDLV integration, we used two strategies 
to overcome this obstacle: First, we performed 5’ and 3’ strand LAM-PCR separately, 
combined the IS we obtained from individual experiment, and then selected the 
unique IS which has both strand vector-genomic DNA junction; Second, we 
established a mixed, so called two-directional LAM-PCR, which both strand LAM-PCR 
could be performed in the same reaction tube. 
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The concept of two-directional LAM-PCT is instead of using only one strand LTR 
primer for linear PCR, by performing the same experiment with both strand LTR 
primer sets. For exponential PCR, we used equal amount of both strand LTR primer 
sets and linker sets instead of one strand sets. To avoid any methodological bias 
introduced by increasing the primer amounts, the same concentration of primer sets 
were used as single strand based LAM-PCR. 
To evaluate the feasibility of this method, we performed both single strand and 
two-directional LAM-PCR on the single HeLa cells single clones transduced with 
lentiviral vector, which their integration sites are known. As shown in Figure 4-20, 5’ 
strand LAM-PCR was performed using MseI as restriction enzyme, resulted an 
internal control band with around 110bp; 3’ strand LAM-PCR was performed using 
MseI as well, resulted an internal control band with around 290bp; when two-
directional LAM-PCR was performed using MseI, both internal control of 110bp and 
290bp were shown, indicating that the combined method is capable to detect both 
direction of vector-genomic DNA junction in the same reaction, no noticeable 
changes of IS pattern and decreases of signal density were seen in the gel 
electrophoresis. Two-directional based nr LAM-PCR was also tested and functional 
(data not shown). 
 
Figure 4-20 Two-directional LAM-PCR. (A) 5’,  (B) 3’ LAM-PCR and (C) two-directional LAM-PCR were performed 
on LV transduced HeLa single cell clone D10, F03, H05 as well as bulk samples transduced with MOI=2. IC: 
internal control 
5’ LTR-LAM PCR 3’ LTR-LAM PCR TD-LAM PCR
IC
IC IC
IC
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To further evaluate the two-directional LAM-PCR, the amplicons generated from 
5’ and 3’ strand LAM-PCR and two-directional LAM-PCR were sequenced by high-
throughput sequencing using 454 platform. As summarized in Figure 4-21, both in 
conventional and nr LAM-PCR, two-directional based LAM-PCR generated less 
sequence counts in comparison to single-directional one, except one sample of HeLa 
clone D10, on the 3’ strand, 9 ISs with 300 sequence counts were retrieved in two-
directional LAM-PCR sample, whereas only 5 ISs with 277 sequence counts were 
retrieved in 3’ strand LAM-PCR sample.  
Of note, the frequency of IS retrieved by different method was different. It was 
not surprisingly in single strand based conventional LAM-PCR because of the usage 
of restriction enzyme and inequipotential distribution of motifs for enzyme cutting 
among the genome. IS retrieved by nr LAM-PCR showed less variant then 
conventional one, but for unknown reasons, in HeLa clone F03 and H05, two-
directional based nr LAM-PCR didn't retrieve any sequence counts in 5’ strand after 
sequencing. Taking account with the less efficiency of nr LAM-PCR, few ISs were 
discovered by nr LAM-PCR in contrast to conventional method.  
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Figure 4-21 Sequencing summary of two-directional LAM-PCR. LV integrants retrieved in (A) HeLa D10, (B) HeLa 
F03 and (C) HeLa H05 were listed and compared between different methods. The percentage of each IS retrieved 
from individual sample and method was calculated by dividing IS with total sequence count. Red represents 10-
100%; orange, 1-10%; yellow, 0.1-1%, respectively. 
 Canonical and noncanonical integration of LV and IDLV 4.3.11
In addition to providing viral-host DNA junction sequences, the two-directional 
LAM-PCR allowed us to determine the sequence of host DNA flanking the integrated 
provirus on both side. HIV-1 provirus are characteristically flanked by a 5-bp direct 
repeat of host cell DNA, the consequence of a 5-bp staggered cleavage of host DNA 
during IN-mediated strand transfer. To distinguish noncanonical integration from 
residual integrase activity-mediated integration, we screened our IDLV and LV 
integration data for the presence of the characteristic 5-bp direct repeat of host DNA 
flanking the proviral terminal CA dinucleotide as a hallmark of integrase activity. For 
IDLVs, we retrieved the 5’- and 3’-vector-host genome junctions in 22 instances from 
the bulk cell populations (statistical considerations make it extremely unlikely that 
such junctions could from two distinct integration events) and in 2 instances from 
single cell-derived clones. 17 of 24 integrants (71%) showed loss of the CA 
dinucleotide at least at one end of the vector. All 24 integrants revealed a partial 
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deletion of LTR and/or genomic sequences, and no 5-bp direct repeat could be 
detected in any of these vector-genome junctions (Figure 4-22, B).  
 
Figure 4-22 Canonical and noncanonical integration of LV and IDLV.  (A) Frequency of LTR deletions in IDLV and 
LV transduced SC-1 and C1498 cells. Light blue: IDLV in SC-1; dark blue: IDLV in C1498; light green: LV inSC-1 and 
dark green: LV in C1498. (B) LTR deletions (swung dash) and genomic deletions (red triangles) identified in IDLV 
and LV integrants from which both the 5’ and 3’ genomic flanking region were identified by LAM-PCR (Matrai et 
al., 2011). The terminal CA dinucleotide (underlined, GT at end of 5’ strand LTR, complementary to CA at end of 3’ 
strand LTR) is shown if exist. The 5-bp direct repeat of host DNA flanking the provirus is delineated with double 
underline if exist. The number of deleted bp in host DNA is indicated (Del). LTR: long terminal repeat. LV: 
lentiviral vector. IDLV: integration deficient lentiviral vector. 
ATATGAGTTCAATAC tggaaggg-----ctctagca AATACCTAGAACCCA
ACTAAAGGAACTTAG tggaaggg-----ctctagca CTTAGGGATAAAAAT
TATTAGGACAGTTTT tggaaggg-----ctctagca GTTTTGTGTCCCAAG
GCATGTAGTGGACAT tggaaggg-----ctctagca GACATCCTTAACAAA
TGTCTGAGAGACTAC tggaaggg-----ctctagca ACTACATAAGTAGGT
TTACAGGTGTGTGCC tggaaggg-----ctctagca GTGCCACCACATAGA
TACGAACGTGTTGGC tggaaggg-----ctctagca TTGGCTTATCACAGT
GACAGGTGGGAGGAG tggaaggg-----ctctagca GAGGAGGAACTGCGA
TGAAACTATACTTCT tggaaggg-----ctctagca CTTCTTCACCATTTT
TGTGAGTGAAGTAGG tggaaggg-----ctctagca GTAGGGTAGTCGCTG
ACACCTCCACGGGAC tggaaggg-----ctctagca GGGACAATGCACTGT
TTTCTTTTTAATTTT ~ggaaggg-----ctctagca ATTTTCTAATCTCAA
TCTANATAAGGAAAC tggaaggg-----ctctagca GAAACTAAGGCAGAC
AGCGCTGTCCCTAGC tggaaggg-----ctctagca CTAGCCACAGCTGCT
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GGGGGTGGGAGTTAG tggaaggg-----ctctagca GTTAGTTAAAGATTC
TTCTATGTGGGTCTC tggaaggg-----ctctagca GTCTCTTTCCATCAT
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AACTACTGCTGCCAC tggaaggg-----~~~~~~~~ GAAAGGGGAGAATCT
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TCTGCACTTGTTTCC tggaaggg-----ctctagca GGCAAACCAAGACTA
TAAGGAAGCATTCCT ~~~aaggg-----ctctagca GTGGTCAGGACATTT
TGTTTTTCAGACAGC tggaaggg-----ctctagca CATTCCCATGGAACT
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In contrast, 18 of 19 LV integrations (94.7%) for which both sequence ends were 
mapped revealed neither CA dinucleotide deletions nor LTR sequence deletions, and 
they harbored  the typical 5-bp direct repeat without genomic deletions (Figure 4-22, 
B).  
To further investigate the nature of the strand transfer reaction, we screened for 
LTR sequence deletions in our complete IS data sets, as well as for target genomic 
DNA deletions in those two directional clones. Surprisingly, one-third of all IDLV 
integrations had a partial loss of the LTR sequence, whereas LTR deletions accounted 
for only approximately 2% of all LV sequences (Figure 4-22, A). Due to the limitation 
of primer sets used in this experiment, up to 18 bps deletion of LTR sequence could 
be detected.  
The 5-bp direct repeat of host DNA normally flanking HIV-1 provirus is due to the 
left and right ends of incoming virus ligating to the host DNA in a 5’-staggered 
fashion. A deletion of target DNA could occur if an integration event involved a 3’-
staggered cleavage of the target DNA, as opposed to the normal 5’-staggered 
cleavage. 21 of 24 two directional clones underwent a deletion during the viral 
integration process, with deletions ranging from 2 to 1808 bps (Figure 4-22, B).  
 Integrated IDLV viral DNA is oligomeric 4.3.12
Gene expression from non-integrated lentiviral DNA can be from linear DNA, 1- 
or 2-LTR circles, or even concatemers of the exogenously acquired DNA formed by 
intermolecular ligation (Perucho et al., 1980). To detect potential existing 
concatemeric integrated IDLV forms, we have used a combination of a nested PCR 
and LAM-PCR for the analysis of sorted IDLV transduced long-term cell lines. In 
theory, if concatemeric IDLV formations exist, 3 types of LTR concatemers could be 
detected: “Tail to Head”; “Head to Head” and “Tail to Tail”. We designed 4 primers 
locate in different LTR region. All three potential concatemer formations could be 
detected using different primer combinations (Figure 4-23, A). We performed nested 
PCR for sorted IDLV transduced SC-1 and C1498 samples with MOI 25, 50 and 100, 
respectively, multiple bands were shown after agarose electrophoresis (Figure 4-23, 
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B). All the amplicons were tagged with LAM-PCR primers and sequenced with high-
throughput pyrosequencing. Interestingly only “Tail to Head” formation could be 
retrieved from all assayed samples, suggesting that GFP expression derived either 
from remaining 2-LTR circles of IDLV or from “Tail to Head” IDLV concatemers.  
Statistically it is very unlikely that only “Tail to Head” concatemers could be detected 
if all three formations exist. The present of “Tail to Head” formation need be further 
evaluated by other experimental approach (such as southern blot) if it exists and the 
mechanism for “Tail to Head” formation remains unclear.  
 
 
Figure 4-23 Integrated IDLV provirus is oligomeric. (A) Strategy to detect potential IDLV concatemers formations: 
“Tail to Head” formation should result a184 bp band; “Tail to Tail” formation should result a 166 bp band; and 
“Head to Head” should result a 202 bp band. LTR: long term repeat element. (B) Detection of concatemers in 
sorted IDLV transduced SC-1 and C1498 cells. M: 100bp marker; Ctl: control; 25: MOI=25; 50: MOI=50; 100: 
MOI=100. 
 Integrated IDLV viral DNA is intact 4.3.13
Some episomal DNA molecular as well as episomal virus, such as Epstein Barr 
Virus (EBV) and human papillomaviruses (HPV), often break anywhere on the 
episome and integrate into host genome through non-LTR-mediated mechanism. To 
address this aspect in IDLV transduced cells, we performed a modified LAM-PCR  , so 
called internal LAM-PCR, using 3 primer pairs covered almost 75% of IDLV backbone 
to screening for the potential episomal breakage flanking host genomic DNA. One 
primer pair locates inside of viral packaging signal to monitor the formation of 
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provirus; the other two primer pairs locate beginning as well as ending of eGFP 
sequences to monitor the functional provirus. A combination of HpaI/FspI/StuI 
restriction enzymes, whose cutting motifs are absent in vector backbone, but often 
present in human genome, was used in this protocol. 
Sorted and bulk unsorted IDLV transduced SC-1 and C1498 with MOI 100 were 
analyzed in this experiment. PCR amplicons were only seen in sorted SC-1 and C1498 
cells assayed with packaging signal and GFP front primers (Figure 4-24). The 
amplicons were analyzed by short-gun cloning following by Sanger sequencing, as 
well as by pyrosequencing with 454 platform, only virus sequences were retrieved 
from both methods. It indicated that no breakage was occurred during residual IDLV 
integration, the provirus of integrated IDLV remains intact. 
 
Figure 4-24 Integrated IDLV provirus is intact. Detection of IDLV breakage in sorted and unsorted IDLV 
trausduced SC-1 and C1498 cells by internal LAM-PCR using packaging signal primer sets (A), GFP front primer 
sets (B) and GFP behind primer sets (C). C: H2O control; S: Sorted sample; U: Unsorted sample; M: 100bp marker 
 
 Target site selection may not be random for IDLV 4.3.14
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While the location of retroviral integration within the host cell genome is not a 
random event, DNA structural characteristics, and not nucleotide sequence, appear 
to be the primary determinants that influence target site selection (Pryciak et al., 
1992; Pryciak and Varmus, 1992). Previous work has shown that a favored 
palindromic sequence can be detected when many HIV integration sites are aligned, 
the inverted repeat structure likely originating from the symmetry of the IN-DNA 
complexes responsible for covalent DNA joining at each end (Berry et al., 2006). We 
asked whether the conserved favored primary sequences characteristic of HIV 
integration sites were present also in IDLV data sets. The primary chromosomal DNA 
sequence immediately flanking each integration site was scanned for base 
composition using the WebLogo sequence logo tool with ± 20bp resolution (Crooks 
et al., 2004).  
For both LV and IDLV transduced SC-1 and C1498 cells, a host ‘G’ residue is 
disproportionately represented immediately flanking each end of the provirus, and 
there is a tendency for a ‘T’ at positions -2 and +2. In LV transduced SC-1 samples, 
324 of 1283 cases (25.3%) for 3’ strand and 242 of 1136 cases (21.3%) for 5’ strand 
host DNA represent a weak favored ‘GT’ sequence selection, respectively. Similar 
results were found in LV transduced C1498 cells,  88 of 344 cases (25.6%) for 3’ 
strand and 119 of 553 cases (21.5%) for 5’ strand host DNA immediately flanking LV 
LTR were demonstrated (Figure 4-25, A and B). IDLV, however, demonstrated a 
striking preference for a ‘GT’ residue immediately adjacent to the conserved viral CA 
dinucleotide at the left viral end (44.7% for SC-1 and 47.8% for C1498, respectively). 
Similarly, a ‘GT’ residue was found immediately adjacent to the right viral end with 
28.7% in SC-1 and 25.7 in C1498 cells (Figure 4-25, C and D).  If we exclude the clones 
with truncated LTR ends, which may integrate via mechanism different than that 
used by clones with intact LTR ends, the percentage of ‘GT’ residue immediately 
adjacent to the left viral end raised to 62.4% for SC-1 and 63.4% for C1498 cells, and 
to 40.5% for SC-1 and 42.4% for the right viral ends. 
The 3’ end of each strand of unprocessed HIV-1 DNA ends in ‘CAGT’. During a 
normal infection, IN-mediated 3’-processing removes the terminal ‘GT’ dinucleotide 
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from the 3’ end of each strand of viral DNA. Each 3’ end of the viral DNA is left with a 
terminal ‘CA’ dinucleotide. If the IN was mutated, the mutant virions failed to 
undergo 3’-processing prior to provirus formation, the so called flanking ‘GT’ residue 
would actually be of viral, not host, origin. These data clearly demonstrated that the 
residual IDLV integration was guided by different mechanism to wile type LV.  
 
Figure 4-25 Primary sequence at integration sites of IDLV and LV in vitro. A sequence logo was generated using 
the WebLogo tool to identify preferred base pair usage at the LV transduced (A) SC-1 and (B) C1498 as well as 
IDLV transduced (C) SC-1 and (D) C1498. Position 0 denotes the first base of flanking LTR sequence 3’ of the 
integration site. That is, the host DNA sequence is adjacent to the top strand of viral DNA on the right but from 
the bottom strand of viral DNA on the left. For sequence to the left of the provirus, host DNA at -1 is immediately 
adjacent to the provirus and -20 is located 20bp from the provirus; for the right side, host DNA at +1 is 
immediately adjacent to the provirus and +20 is located 20bp from the provirus. 
 
 Short summary of this section 4.3.15
Our large-scale IDLV IS data revealed IDLV represent the lacking of representative 
5-bp direct repeat of host DNA flanking the provirus, deletion of host DNA and LTR 
sequences, abnormal 3’-processing and no concatemer integration. IDLV Integration 
pattern demonstrated random distribution of chromosomes, non-clustered around 
TSS sites, and less preference integration into Refseq genes as compare to lentiviral 
vectors (LV) integration pattern. No proto- and oncogenes loci as integration sites 
have been found in IDLV transduced cells. Taken together, the residual integration of 
IDLVs might be mediated by an integrase-independent mechanism, the risk of 
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insertional mutagenesis from IDLV is highly minimized and it provides one of the 
potentially safest tools for efficient gene delivery for clinical applications. 
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5. Discussion 
5.1  Integration “hot spots” in MDS1/EVI1 and PRDM16 in WAS 
gene therapy 
Gamma-retroviral DNA permanently inserts into the genome, usually near 
promoters of active genes. Thus, the major safety concern in gene therapy patients 
is that permanent insertion may occur in or near an oncogene to promote its 
upregulation and to lead to malignant transformation and leukemia. Retroviral 
insertion into the LMO2 locus in children with X-linked severe combined 
immunodeficiency (X-SCID) was associated with development of leukemia after gene 
therapy. Therefore, we performed extensive insertion site analyses in an ongoing 
clinical gene therapy trial with patients suffering from Wiskott-Aldrich syndrome. 
Gamma-retroviral vector insertions in the MDS1/EVI1 and PRDM16 loci were 
founded to be highly overrepresented. To analyze the long-term impact of 
MDS1/EVI1 and PRDM16 retroviral integration sites in hematopoietic stem cell 
lineages, MDS1/EVI1 and PRDM16 loci as vector genome adjunction are monitored 
and analyzed by LAM-PCR and (nr)LAM-PCR prospectively more than two years after 
gene therapy in patient 1 and 2.  
Patient 1 presented with hematoma and petechiae after birth, and within the 
first year of life, hemorrhagic colitis, eczema, and therapy-refractory autoimmune 
hemolytic anemia developed. In addition, he had autoimmune neutropenia and 
recurrent infections (bronchitis, otitis media, and enterocolitis). Patient 2 presented 
with thrombocytopenia and hemorrhagic diathesis soon after birth. He had recurrent 
episodes of upper respiratory tract infection, life-threatening salmonella septicemia, 
and eczema that was not responsive to local and systemic therapy. Molecular studies 
revealed mutations in WAS, no residual protein or somatic chimerism was detectable 
in both patients (Boztug et al., 2010).  
In both patients, vector insertion site analysis of peripheral blood and bone 
marrow samples demonstrated sustained highly polyclonal reconstitution over time, 
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MDS1/EVI1 and PRDM16 loci were evaluated as common insertion sites (CIS) in this 
study. Both conventional and non-restrictive LAM-PCR results revealed that gene-
modified clones containing the insertion of MDS1/EVI1 and PRDM16 exhibited only 
minor contributions to hematopoietic repopulation within the first 2 years after 
treatment and remained constant. In Patient 1, MDS1/EVI1 containing clones were 
first been detected at 7 weeks after gene therapy with a contribution of 0.6% in total 
222 retrieved ISs. The proportion of MDS1/EVI1 containing clones increased slowly 
and peaked at 4 months after gene therapy with 5.7% in total ISs detected. At 33 
months, the last observation time point in this thesis, it remained constant with 5.2% 
in total retrieved ISs. In patient 2, MDS1/EVI1 containing clones remained at very low 
level from undetectable to 1.8% in whole retrieved ISs during the entire observation 
period (up to 30 months). In both patients, Prdm16 containing clones contributed 
minor in whole retrieved ISs, ranged from undetectable to 1.1%, with an exception in 
patient 2 at 2.5 months after gene therapy, which had 6.1% in 44 detected ISs. In 
sorted myeloid (CD15+) and lymphoid (CD3+) lineages, MDS1/EVI1 and PRDM16 
containing clones were mostly restricted in the myeloid compartment of 
reconstituted hematopoiesis in both patients, suggested that MDS1/EVI1 and 
PRDM16 may contribute mainly to myeloid progenitor differentiation and 
proliferation. 
EVI1 has been described as a proto-oncogene since its first discovery in 1988 
(Morishita et al., 1988). Overexpression and aberrant expression of EVI1 has been 
associated with human acute myelogenous leukemia (AML), myelodysplastic 
syndrome (MDS) and chronic myelogenous leukemia (CML), and more recently has 
been shown to represent a poor prognostic indicator (Metais and Dunbar, 2008). All 
of these malignancies involve erratic cellular development and differentiation in the 
bone marrow leading to dramatic alterations in the normal population of blood cells 
(Goyama et al., 2008; Yuasa et al., 2005). EVI1 has also been found to play a role in 
solid ovarian and colon tumors, although it is not yet well characterized (Shackelford 
et al., 2006). It has been hypothesized that it acts as a survival factor in tumor cell 
Discussion  Wei Wang 
112 
 
lines, preventing therapeutic-induced apoptosis and rendering the tumor cells more 
resistant to current treatments (Liu et al., 2006). 
Prdm16 is expressed very selectively in the earliest stem and progenitor 
compartments, and, consistent with this expression pattern, is critical for the 
establishment and maintenance of the HSC pool during development and after 
transplantation (Deneault et al., 2009). Prdm16 deletion enhances apoptosis and 
cycling of HSCs (Aguilo et al., 2011; Chuikov et al., 2010). Expression analysis 
revealed that Prdm16 regulates a remarkable number of genes both enhancing and 
suppressing HSC function, and affecting quiescence, cell cycling, renewal, 
differentiation, and apoptosis to various extents (Aguilo et al., 2011). Elevated 
PRDM16 expression, because of promoter hypomethylation, is frequently observed 
in karyotypically normal AML (Shing et al., 2007). Deletion of the PR domain, which 
shows homology with a SET chromatin remodeling domain and is also present in 
MDS1/EVI1 (Mochizuki et al., 2000), appears important for the leukemogenic 
properties of human PRDM16. Translocations involving PRDM16 invariably delete 
the PR domain, whereas PR-deleted Prdm16 causes AML in p53−/− mice (Shing et al., 
2007). Overexpression of Prdm16 expands HSCs in vitro. However, these expanded 
HSCs cause a myeloproliferative disease after transplantation (Deneault et al., 2009). 
Strikingly, all the models investigating the impact of MLV vector transduction on 
primary hematopoietic cells results strongly suggest that hematopoietic stem and 
progenitor cells with insertional activation of MDS1/EVI1 have a significant 
advantage. First, primary murine bone marrow myeloid progenitor cells are all 
immortalized by vector insertions either directly or indirectly activating the Evi1 or 
the homologous Prdm16 locus (Du et al., 2005). Second, extraordinary 
overrepresentation of MDS1/EVI1 and PRDM16 clones contributing to the myeloid 
lineage were seen over the long term in rhesus macaques (Kim et al., 2009) and 
human CGD patients (Ott et al., 2006), respectively. Third, serial transplantation in 
the mouse model increased the dominance of clones with insertions in Mds1/Evi1 
and Prdm16, as well as a limited number of other genes that encode proteins 
implicated in self-renewal and stem cell survival (Modlich et al., 2009).  
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The vector integration pattern in the analyzed WAS patients remained highly 
polyclonal and no obvious clonal dominance have been observed after two years of 
gene therapy. But this work accentuates the need for safer gene therapy vectors that 
will not activate oncogenes. Ongoing efforts to make gene therapy safer include: 1) 
assuring that the inserted virus does not activate adjacent genes by removing all 
promoter activity except for that which drives expression of the therapeutic gene; 2) 
insulating expression of the transgene from the surrounding genomic DNA; and 3) 
targeting integration to “safe” genomic regions. 
5.2  Effects of Mds1/Evi1 and Prdm16 in hematopoiesis 
The increasing number of gene therapy clinical trials resulting in patient clinical 
benefit highlights the rising use of gene therapy to treat a variety of disease 
conditions. Many trials have used retroviral vectors which are successful as they 
integrate their genetic material into patient chromosomes. This allows therapeutic 
DNA to be passed to daughter cells during mitosis, enabling stable gene expression 
in dividing tissues. However, five cases of acute lymphoblastic leukemia in two SCID-
X1 clinical trials caused by integration of the retroviral genome near proto-
oncogenes including LMO2 have raised concerns about the safety of integrating 
vectors. 
In patients with CGD, rhesus macaques, and mice receiving hematopoietic stem 
and progenitor cells transduced with retrovirus vectors, a highly non-random pattern 
of vector integration has been reported. The most striking finding has been 
overrepresentation of integrations in two specific genomic loci, a complex containing 
the MDS1 and the EVI1 genes, as well as the locus of the PRDM16 gene. Most 
evidence suggests that this overrepresentation is primarily due to a modification of 
primitive myeloid cell behavior by overexpression of MDS1/EVI1, EVI1 or PRDM16, as 
a specific preferential integration site of viral vectors. These phenomena could be 
accounted for via two general underlying mechanisms. Either these loci are 
extraordinary “hot spot” for retroviral integration in hematopoietic stem and 
progenitor cells, or progenitor cells that happen to acquire an insertion in those loci 
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have a unique propensity to engraft, persist, expand and/or contribute to 
hematopoiesis after transplantation. Although components of both mechanisms may 
be operative, the preponderance of evidence suggests that in vitro and in vivo 
selection for survival and hematopoietic output from clones with insertional 
activation of the MDS1/EVI1 complex and PRDM16 gene can account for the findings. 
To test whether non-integrating vectors derived transient expression of 
MDS1/EVI1 and/or PRDM16 is sufficiently stable to influence long-term repopulating 
hematopoietic cells, we established a lentiviral based transient and stable expression 
system for this purpose. Protein coding sequences of murine Mds1/Evi1, Prdm16 
and their PR domain lacking variants Evi1 and sPrdm16 were directionally cloned 
into LV constructs and verified by sequencing. Functional LVs were produced by 
transient co-transfection of 293T cells with envelope, packaging and transfer vector 
constructs. Reliable titers in the range from 107 to 109 TU/ml were achieved after 
optimization. Sufficient transgene expression was detected for all constructs by 
Western-Blot and RT-PCR after transduction of murine SC-1 cells. IDLVs expressing 
Mds1/Evi1, Prdm16 and their PR domain lacking variants Evi1 and sPrdm16 were 
also constructed and produced. 
To study the direct impact of Prdm16 and sPrdm16 expression on hematopoietic 
differentiation and proliferation, lin- murine primary BM cells were transduced with 
Prdm16 or sPrdm16 LVs and cultured for 30 days in vitro. Long-term eGFP expression 
was observed in all three transduced cells populations for up to 30 days. This 
suggested that lentiviral mediated stable transgene expression in hematopoietic 
stem and progenitor cells are feasible. However, no significant differences in the 
proliferation potential or differentiation capacity were observed between Prdm16, 
sPrdm16 and eGFP transduced cells. This could be accounted for the poor gene 
transfer efficiency in primary murine BM cells mediated by LV and the dilution steps 
during the process of the experiment. In each observation time point, only certain 
numbers of transduced cells were kept further in culture due to the volume capacity 
of in vitro medium and space. Hematopoiesis is a highly hierarchy system, the HSCs 
constitute only 1:10.000 of cells in myeloid tissue. In this experiment, although lin- 
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BM cells were assayed, the frequency of HSCs is still below 0.01%. Combined with 
the relative low transduction efficiency of <3%, there was only a small likelihood to 
have ‘true’ stem cells transduced in this setup.  
There are several possible ways of improving gene delivery efficiency to stem 
cells. First, we employed several optimization steps to increase our lentiviral titers. 
Several batches of FBS from different vendors and sources were tested since the FBS 
quality is reported as a crucial factor for LV production.  Kozak consensus sequence 
was cloned in front of the transgene to enhance the translation procedure as well. 
The reliable functional titers increased approximately about 3- to 4- fold after 
optimization. Second, we tried different transduction protocols, including 
spinoculation; magnetic beads based transduction; two-round transduction 
procedure and others. Magnetic beads based transduction was evaluated as the 
most stable and reliable procedure and selected as standard protocol for LV 
transduction in primary cells. Third, protocol to separate more defined MPP, LT- and 
ST- HSCs by FACS using cell surface markers (i.e. CD34, Sca1, cKit and Flt3) was 
established. Taking advantage of the short transduction procedure of LVs, we could 
significantly increase the transduction efficiency in more defined cell types. These 
developments and improvements in gene transfer parameters enabled further 
studies on the impact of transient expression of MDS1/EVI1 and PRDM16 on 
proliferation, engraftment and expansion of HSCs in vitro and in vivo, beyond the 
scope of this thesis. 
5.3  LV and IDLV differ in their integrations characteristics 
Integration deficient lentiviral vectors (IDLV) use the advantages of lentiviral 
based vectors without the potential risk of insertional mutagenesis. As these vectors 
do not integrate into the host chromosomes and lack a replication signal, the viral 
DNA will be diluted out during cell division. Therefore, IDLVs will be particularly 
useful, for example, in post mitotic tissue gene therapy (Wanisch and Yanez-Munoz, 
2009). 
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IDLVs can be produced through the use of integrase mutations that specifically 
prevent proviral integration, resulting in the generation of increased levels of 1- and 
2-LTR circular episomes in transduced cells. Compared to integration proficient 
lentiviral vectors IDLVs have a significantly lower risk of causing insertional 
mutagenesis and a lower risk of generating replication competent retroviruses 
(RCRs).   
Few studies on integration of IDLVs have been published (Gaur and Leavitt, 1998; 
Nightingale et al., 2006). Available data include analyses of residual proviruses and 
host DNA–vector junctions in a very limited data set of integration events, commonly 
not exceeding 10 events, and quantitation of integration frequencies is based on 
using selectable transgenes or eGFP expression. Thus, little is known about the 
existing residual integration events of IDLV, and comprehensive characterization of 
IDLV integration profiles in mammalian genomes is still missing. 
In this large-scale LAM-PCR analysis of integration events from IDLVs, we used a 
high dose (MOI 25, 50 and 100, respectively) vectors carrying integrase D64V 
mutation and expressing eGFP to transduce two murine cell lines, C1498 and SC-1. 
Despite the low level of eGFP expression from all three doses of IDLVs after 4 weeks, 
we did consistently observe low levels (from <0.5%-2.3%) of cells persistently 
expressing eGFP, depending on the type of cell lines and vector dose. We 
hypothesized that inadvertent integration was responsible for the small amount of 
sustained gene expression we observed. Those eGFP expressing cells were then 
cultured for another 4 weeks to dilute out the residual nonintegrated viral episomes, 
sorted by FACS and analyzed for IDLV integration pattern. 
The highly sensitive conventional LAM-PCR technology as well as the newly 
developed non-restricted LAM-PCR has been employed as a powerful and standard 
tool to identify lentiviral integration sites. With minimal amounts of DNA input, LAM-
PCR has the potential to characterize integration site preferences of retroviral and 
lentiviral vectors, and to determine the clonal complexity in gene therapy research. 
We retrieved 905 integrants from IDLV transduced SC-1 cells and 437 integrants 
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from C1498 cells, respectively. Among them, 533 (SC-1) and 271 (C1498) integrants 
could be mapped to a definite position in the mouse genome. In comparison to IDLV, 
much more integrants from LV transduced samples (2788/2419 for SC-1, 1062/898 
for C1498, total/unique mappable) were retrieved. These large IS data sets allowed a 
confident LV and IDLV IS analysis. The chromosomal IS distribution of the 
experimental groups resembled near random in either IDLV or LV. In some cases the 
distribution of IDLV IS showed a significant deviation in two cell lines, also an under- 
or overrepresentation of RefSeq genes at certain chromosomes was found 
(chromosome 2, 4, 8, 10 and X). It might be explained by different integration 
mechanism between the IDLVs and LVs, as well as the different genetic background 
between cell lines. 
Previous studies have found that two thirds of LV IS are commonly located in 
genes, these results were observed consistently in in vitro and ex vivo experimental 
settings with different HIV-1 based LV and SIN-LV in varying cell populations (Beard 
et al., 2007; Felice et al., 2009; Laufs et al., 2006; Lewinski et al., 2005; Mitchell et al., 
2004; Montini et al., 2009; Schroeder et al., 2002; Wang et al., 2009). Only recently, 
our group found that these results cannot be extrapolated to all cell types and 
tissues. Instead, a reduced IS frequency into gene coding regions was noticed in 
postmitotic tissue (eye and brain) after in vivo injection of LVs (Bartholomae et al., 
2011). The reduced IS in gene coding regions went in line with a reduced expression 
of Psip1, which results the LV preintegration complex to specific, gene associated 
genomic loci. Underexpression of the Psip1 and gene associated preference of 
lentiviral vector integration loci could also be found in terminally differentiated 
macrophages and growth arrested cell lines (Barr et al., 2006; Ciuffi et al., 2006). 
Taken together, the discrepancies of lentiviral integration pattern does not seem to 
simply relate to the mitotic active versus quiescent cellular state, but might also 
reflect cell type / tissue specific differences. In our study, Integration pattern of IDLV 
showed significant lower gene associated preference than LV, indicating that the 
residual IDLV integration events are underlying different mechanism to LV.  
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Remarkably, a significantly reduced LV IS frequency was observed for the close 
upstream genomic region of the transcription start site. This was supported by the 
finding that nearly no LV IS were found within a 1kb distance to a CpG island, which 
are typically located at TSS (Saxonov et al., 2006). This was consistent with the 
previous experiments where no LV IS was found within the 1kb distance to a CpG 
island in postmitotic rat eye (Bartholomae et al., 2011). In comparison to LV, IS 
distribution of IDLV is nearly uniform in the genome, including gene and CpG island 
rich regions. Interestingly, the IS pattern of IDLV showed significantly to be more 
clustered around the TSS region compared to LV, suggesting the integration of IDLV 
might more easily occur through opened chromatin structure and might be 
mediated by other mechanism. 
5.4  IDLVs integrate only to background levels 
The peculiarities showed by proviruses from IN mutant HIV-1 and IDLVs, together 
with the lack of effect on residual integration frequencies from adding att mutations 
to IN mutants, have led to the conclusion that integration events from IN mutants 
are unlikely to be IN-mediated (Gaur and Leavitt, 1998; Nightingale et al., 2006). In 
support of this, integration of an IDLV has been observed in a pre-existing DSB in 
human osteosarcoma U-2 OS cells consistent with the known frequent capture of 
extrachromosomal DNA fragments and vector genomes by pre-existing genomic 
DSBs (Cornu and Cathomen, 2007; Lin and Waldman, 2001). However, the lack of IN 
involvement in some of the residual integration events has not been formally 
demonstrated, and it could be argued that residual IN activity could have aberrant 
characteristics and hence the products would not necessarily display all the features 
of wild type proviruses. 
An analysis of relative integration frequencies of replication defective, 
integrating and IN mutant HIV-1 variants encoding a hygromycin resistance gene 
showed that mutations in the catalytic triad led to reductions of 3–4 logs in the 
number of drug-resistant colonies with the latter (Leavitt et al., 1996). Similar results 
have been also obtained in this thesis in the context of SIN IDLVs. Relative 
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integration frequency in C1498 and SC-1 cells have been estimated as about 350- to 
1000- fold lower than wild type for D64V mutant, regardless the cell lines and vector 
doses. 
5.5  Noncanonical integration of IDLVs 
The product of HIV reverse transcription is a linear double stranded DNA 
molecule (with a discontinuous plus strand) (Miller et al., 1995). Linear double 
stranded DNA can be integrated non-specifically in the host genome. When there is a 
double strand break in the host genome, the DNA is repaired either by homologous 
recombination or non-homologous end joining. The last pathway involves the 
ligation of two double stranded DNA molecules, not requiring any homology 
between them. Using this mechanism, the cells may then integrate the viral linear 
DNA produced upon reverse transcription or viral DNA circles that were broken at 
double stranded break points in the genome. In either case it would be reasonable 
to find host DNA–vector junctions involving the ends of the vector LTRs, and assays 
for the analysis of integration junctions are normally biased to detect such LTR-
mediated events.  
The viral locus responsibility for retroviral IN function was originally described in 
1984 landmark papers (Donehower and Varmus, 1984; Panganiban and Temin, 1984). 
One of these studies already analyzed that residually integrated IN mutant MoMLV 
proviruses (Donehower and Varmus, 1984). Only in very rare cases had IN mutant 
proviruses the structures expected from wild-type virus, i.e., two nucleotides lost 
from each end of viral DNA and identical 4-bp (or 5-bp) flanking sequences of host 
origin (Hagino-Yamagishi et al., 1987). For the wild type LVs, we predominantly 
observed the hallmark signature of integrase-mediated integration, in the most 
majority (>98%) perfectly intact LTR sequences at the integration site. Strikingly, 
sequencing of integration junctions isolated by LAM-PCR showed that the integrated 
proviruses from IN mutants did not confirm the canonical characteristics of 
integrated LVs: (i) the 5-bp direct repeat of host DNA was often not maintained; (ii) 
integration often occurred with truncations of vector DNA ends, perhaps due to 
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aberrant 3’-processing; (iii) in some cases integration caused a deletion of host DNA 
at the insertion site; and (iv) target site selection of mutant IN viruses showed 
sequence preferences not observed with wild-type proviruses (Gaur and Leavitt, 
1998). 
Regarding the structure of the integrated IDLV proviruses, a study in human 
colon adenocarcinoma HT-29 cells transduced with HIV-1 vector showed gross 
reorganizations by Southern blot in about 50% of G418-resistant colonies 
(Nightingale et al., 2006). Inverse PCR-based strategies on genomic DNA of 
nongrossly reorganized proviruses from IN mutant vectors, followed by DNA 
sequencing, demonstrated noncanonical patterns including deletions, duplications or 
reorganizations of vector sequence and lack of the characteristic 5-bp duplication of 
flanking host DNA (Gaur and Leavitt, 1998; Nightingale et al., 2006). From large-scale 
data sets of 800 and 3300 unique mappable IS from IDLVs and LVs transduced 
samples, respectively, we retrieved 24 ‘clones’ from IDLVs and 19 ‘clones’ from LVs, 
which showed both 5’- and 3’- vector/genomic junctions (statistical considerations 
makes it extremely unlikely that such junctions could originate from distinct 
integration events). For the LVs, our data demonstrated the hallmark of signature of 
integrase-mediated integration, with perfectly intact LTR-sequences (18/19) and 
duplication of 5 bp of the cellular DNA sequences at the integration sites, no 
genomic junction deletions/additions were observed. In contrast, the IDLV data set 
showed abnormalities of the LTR/genomic structure, including CA dinucleotide 
deletions (24/24), LTR sequences deletions, as well as genomic junction 
deletions/additions. In agreement with these data, screening for LTR sequences in 
our complete IS data sets showed that one-third of all IDLV integrations had a partial 
loss of the LTR sequences, whereas LTR deletions accounted for only approximately 
2% of all LV sequences.  
Circular IDLV episomes may be subjected to DNA damage non-LTR-mediated 
genomic integration. Very few attempts have been made to detect such host DNA–
vector junctions not involving the LTR ends, but the stable detection of 2-LTR HIV-1 
junction in dividing cells is supporting evidence for non-LTR-mediated integration of 
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viral circles (Brussel and Sonigo, 2003). In an effort to elucidate the mechanism 
underlying the rare integration by IDLVs, we analyzed the integrated vectors by LAM-
PCR based internal PCR using 3 sets of primers that covered nearly 75% of the vector 
genome. The amplicons were sequenced per deep sequencing for 5000 raw 
sequencing reads and validated per Sanger sequencing in 96-well plate format. Since 
the sorting procedure particularly enriched the intact form of integrated provirus, 
unsorted samples were also investigated in the same setting. After extensive 
searching either in sorted or unsorted samples, no virus/genomic junctions have 
been identified, suggesting that neither rearrangement in the integrated DNA nor 
random breakage of circular IDLV episomes was present.  
Another hypothesis that IDLVs might integrate into the host genome through 
concatemer formats by homologous integration (Hagino-Yamagishi et al., 1987). To 
address this question, nested PCR on the LTR region was performed based on three 
concatemer hypothetical formats: “Head to Head”, “Tail to Head” and “Tail to Tail”. 
The amplicons of two samples were sequenced by deep sequencing, and analyzed 
for LTR formations. Surprisingly, only “Tail to Head” format has been detected in 
around 2000 reads.  These results are most simply explained by the presence of 2 -
LTR circle in the analyzed samples, although the cells were cultured for 8 weeks post 
transduction. It is very unlikely that only one format but no other formats were 
present in case of existing concatemers. It might also be argued that the nested PCR 
is performed only within LTR sequences; no LTR/genomic junctions could be 
detected. But by combining the data with only intact provirus (disregard LTR 
sequences) presented in the IDLVs transduced samples, we could claim that IDLVs 
integrate into the host genome in a more or less intact and oligomeric formation. 
5.6  Target site selection of IDLV integration 
Target site selection by retroviruses is not random (Scherdin et al., 1990; Shih et 
al., 1988), but structural aspects of the target DNA, and not DNA sequence, appear 
to be most critical for determining if a given stretch of DNA will be the site of 
integration (Pryciak et al., 1992; Pryciak and Varmus, 1992). Both LV and IDLV 
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demonstrated a marked preference for a ‘G’ residue immediately adjacent to the 
conserved ‘CA’ dinucleotide found at the end of each strand of viral DNA, along with 
a tendency for the ‘G’ to be followed by a ‘T’ residue (Figure 4-25). Notably, IDLV 
demonstrated more preference in this phenomenon compared to LV. Regions of 
HIV-1 IN near D64 and E152 have recently been demonstrated to come into close 
contact with viral att sites and the target DNA (Heuer and Brown, 1997). That 
observation makes it intriguing to think that the mutations that we introduced 
directly affected target site selection. Possibly an unknown cellular protein interacts 
with the mutant IN proteins to affect target site selection. Alternatively, the ‘G’ 
preference seen in Figure 4-25 may indicate that IN is so crippled by the mutations 
that very few, if any, of the integration (strand transfer) reactions occurred via IN-
mediated transesterification. In that case, integration sites may be influenced by 
simple base pairing between the viral ends and target DNA, with cellular ligases 
performing the actual integration events. This hypothesis predicts a ‘GT’ sequence 
immediately adjacent to the ‘CA’ dinucleotide at each viral end. Consistent with this, 
we found a favored ‘GT’ residue immediately flanking the virus at both viral ends. If 
this hypothesis is true, it could predict the predominant flanking host nucleotide for 
other retroviruses with similar IN mutations.  
Bi-directional clones sequencing revealed that in some cases has few nucleotides 
to the left and right of the integrated viral DNA that are not of host origin. The extra 
DNA places a ‘GT’ dinucleotide immediately adjacent to the ‘CA’ dinucleotide found 
at the end of each viral DNA strand. While we do not know the exact origin of the 
extra DNA, the ‘GT’ immediately flanking each viral ‘CA’ dinucleotide is most likely 
from a viral genome that did not undergo 3’-processing prior to integration. The 
additional extra nucleotides on the left and right have no obvious source. Others 
have described extra nucleotides at the ends of HIV-1 DNA thought to be due to 
reverse transcriptase-mediated addition of non-template-encoded bases (Miller et 
al., 1997; Patel and Preston, 1994). While this is possible, the extra sequence could 
also be related to the mechanism underlying the recombination event that lead to 
this particular clone. While the target site sequence data strongly suggest that 
Discussion  Wei Wang 
123 
 
mutations to the conserved acidic residues of the D,D(35)E motif produce a bias 
toward integrating at a host ‘G’ residue, they do not allow us to conclude that the G 
residue flanking the provirus is of host origin. We cannot distinguish between (i) the 
integration of 3’-processed viral DNA via a mechanism that retains the host ‘G’ 
residue and (ii) the integration of unprocessed viral DNA via a mechanism that 
deletes the host ‘G’ residue. Consequently, we were unable to address the effects of 
our mutants on 3’-processing during viral infection. 
5.7  In vivo applications of IDLV 
There are only two published analysis of genomic integration of IDLVs in vivo, 
that were performed in our group on genomic DNA from mouse and rat eyecups 
subretinally injected as well as from mouse liver intravenously injected with D64V 
based IDLVs (Matrai et al., 2011; Yanez-Munoz et al., 2006). We used LAM-PCR 
strategies that could detect LTR- and non- LTR-mediated integration, which allowed 
scanning of 30–50% of the vector genome for host DNA–vector junctions. An 
extensive analysis showed a single integration event in a rat eyecup 2.5 months post 
injection, LTR-mediated and with canonical vector sequence. As our LAM-PCR search 
for integration events in these samples only revealed a single case in rat eyecups and 
35 cases in mouse liver samples, we concluded that the high levels of IDLV 2-LTRs 
corresponded to episomal molecules, present at much higher levels than integrated 
vectors.  
In conclusion, D64V based IDLVs have residual integration frequencies 2-4 log 
below those of their wild-type counterparts, at least in cell culture. Initial data sets 
from in vivo experiments are equally encouraging. Estimates of stable integration 
frequency of IDLVs in cultured cells (0.1–2.3%) are within the range described for 
plasmid transfection. Integrated proviruses from IDLVs are frequently noncanonical 
regarding terminal nucleotides, deletions in host cell DNA, and abnormal or missing 
DNA flanking repeats. IDLV integration pattern demonstrated random distribution on 
chromosomes, non-clustering around TSS sites, and less preferred integration into 
RefSeq genes as compared to LV integration pattern. Notably no proto-oncogene loci 
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as integration sites have been found in IDLV transduced cells. The rare but real 
integrations that do occur with IDLVs may also occur with other transient gene 
delivery methods, such as adenoviral vectors and nonviral plasmid-mediated gene 
delivery. Even this minor level of residual integration may be unacceptable in some 
clinical applications, like those involving mitosis-promoting genes, which may require 
non-DNA-based methods to prevent any genomic modification. However, the risk of 
insertional mutagenesis from IDLVs is highly reduced compared to integrating LVs, 
and from a biosafety standpoint IDLVs should be considered highly suitable at least 
for applications involving quiescent tissues. 
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Figure 7-1 Linker cassette design for the LAM-PCR. For the production of linker cassettes oligonucleotides (LC1 + 
one LC3) were chosen, which form overhangs after hybridisation. The overhang from the LC3 oligonucleotide had 
to be complementary to the overhang produced by the used restriction enzyme in the LAM-PCR. Hybridisation of 
the linker cassette oligonucleotides LC1 and LC3 is shown for the enzymes Tsp509I, MseI and HpyCH4IV which 
generate an AATT, TA and GC overhang, respectively. Locations of the linker cassette primers LCI and LCII are 
indicated. These primers were used to amplify the vector-genome junctions. The LCIII primer sequence is the 
linker-specific part of the fusionprimer B-LK (454 pyrosequencing). LC, linker cassette. 
 
Figure 7-2 Location of 5’ LAM-PCR primers for MLV based gamma-retroviral vectors. LTR, long terminal repeat; 
Bio, biotinylated 
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Figure 7-3 Location of 3’ LAM-PCR primers for MLV based gamma-retroviral vectors. LTR, long terminal repeat; 
Bio, biotinylated 
 
Figure 7-4 Locations of 5’ LAM-PCR primers for the SIN lentiviral vectors. . LTR, long terminal repeat; Bio, 
biotinylated 
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Figure 7-5 Locations of 3’ LAM-PCR primers for the SIN lentiviral vectors. . LTR, long terminal repeat; Bio, 
biotinylated 
 
 
Figure 7-6 Locations of the eGFP-LAM-PCR primer in the LV/IDLV vector backbone. Bio, biotinylated 
 
 
